U.S. patent application number 15/355494 was filed with the patent office on 2017-05-25 for heterocyclic compounds as immunomodulators.
The applicant listed for this patent is Incyte Corporation. Invention is credited to Jingwei Li, Liangxing Wu, Wenqing Yao.
Application Number | 20170145025 15/355494 |
Document ID | / |
Family ID | 57472102 |
Filed Date | 2017-05-25 |
United States Patent
Application |
20170145025 |
Kind Code |
A1 |
Li; Jingwei ; et
al. |
May 25, 2017 |
HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
Abstract
Disclosed are compounds of Formula (I'), methods of using the
compounds as immunomodulators, and pharmaceutical compositions
comprising such compounds. The compounds are useful in treating,
preventing or ameliorating diseases or disorders such as cancer or
infections. ##STR00001##
Inventors: |
Li; Jingwei; (Westfield,
NJ) ; Wu; Liangxing; (Wilmington, DE) ; Yao;
Wenqing; (Chadds Ford, PA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Incyte Corporation |
Wilmington |
DE |
US |
|
|
Family ID: |
57472102 |
Appl. No.: |
15/355494 |
Filed: |
November 18, 2016 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
62385099 |
Sep 8, 2016 |
|
|
|
62332632 |
May 6, 2016 |
|
|
|
62257342 |
Nov 19, 2015 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C07D 498/04 20130101;
C07D 413/10 20130101; C07D 491/048 20130101; C07D 413/12 20130101;
C07D 413/14 20130101; A61P 43/00 20180101; C07D 417/10 20130101;
A61P 37/04 20180101; A61P 35/00 20180101; A61P 31/12 20180101; C07D
491/04 20130101; C07D 277/66 20130101; C07D 263/57 20130101 |
International
Class: |
C07D 491/048 20060101
C07D491/048; C07D 263/57 20060101 C07D263/57; C07D 413/12 20060101
C07D413/12; C07D 417/10 20060101 C07D417/10; C07D 277/66 20060101
C07D277/66; C07D 413/10 20060101 C07D413/10; C07D 413/14 20060101
C07D413/14 |
Claims
1. A compound of Formula (I'): ##STR00135## or a pharmaceutically
acceptable salt or a stereoisomer thereof, wherein: one of X.sup.1
and X.sup.2 is O or S and the other of X.sup.1 and X.sup.2 is N,
CR.sup.1 or CR.sup.2; X.sup.3 is N or CR.sup.3; X.sup.4 is N or
CR.sup.4; X.sup.5 is N or CR.sup.5; X.sup.6 is N or CR.sup.6; at
least one of X.sup.1, X.sup.2, X.sup.3, X.sup.4, X.sup.5 and
X.sup.6 is N; Y.sup.1 is N or CR.sup.8a; Y.sup.2 is N or CR.sup.8b;
Y.sup.3 is N or CR.sup.8c; Cy is C.sub.6-10 aryl, C.sub.3-10
cycloalkyl, 5- to 14-membered heteroaryl, or 4- to 10-membered
heterocycloalkyl, each of which is optionally substituted with 1,
2, 3, 4 or 5 independently selected R.sup.7 substituents; R.sup.1,
R.sup.2, R.sup.8a, R.sup.8b and R.sup.8c are each independently
selected from H, C.sub.1-4 alkyl, C.sub.3-6 cycloalkyl, C.sub.3-6
cycloalkyl-C.sub.1-4alkyl-, C.sub.6-10 aryl,
C.sub.6-10aryl-C.sub.1-4alkyl-, 5-10 membered heteroaryl, 4-10
membered heterocycloalkyl, (5-10 membered heteroaryl)-C.sub.1-4
alkyl-, (4-10 membered heterocycloalkyl)-C.sub.1-4 alkyl-,
C.sub.2-4 alkenyl, C.sub.2-4 alkynyl, halo, CN, C.sub.1-4haloalkyl,
C.sub.1-4 haloalkoxy, NH.sub.2, --NHR.sup.10, --NR.sup.10R.sup.10,
NHOR.sup.10, C(O)R.sup.10, C(O)NR.sup.10R.sup.10, C(O)OR.sup.10,
OC(O)R.sup.10, OC(O)NR.sup.10R.sup.10, NR.sup.10C(O)R.sup.10,
NR.sup.10C(O)OR.sup.10, NR.sup.10C(O)NR.sup.10R.sup.10,
C(.dbd.NR.sup.10)R.sup.10, C(.dbd.NR.sup.10)NR.sup.10R.sup.10,
NR.sup.10C(.dbd.NR.sup.10)NR.sup.10R.sup.10, NR.sup.10S(O)R.sup.10,
NR.sup.10S(O).sub.2R.sup.10, NR.sup.10S(O).sub.2NR.sup.10R.sup.10,
S(O)R.sup.10, S(O)NR.sup.10R.sup.10, S(O).sub.2R.sup.10, and
S(O).sub.2NR.sup.10R.sup.10, wherein each R.sup.10 is independently
selected from H, C.sub.1-4 alkyl, C.sub.2-4 alkenyl, C.sub.2-4
alkynyl, C.sub.1-4 alkoxy, C.sub.3-6 cycloalkyl, C.sub.3-6
cycloalkyl-C.sub.1-4alkyl-, C.sub.6-10 aryl,
C.sub.6-10aryl-C.sub.1-4alkyl, 5-10 membered heteroaryl, 4-10
membered heterocycloalkyl, (5-10 membered heteroaryl)-C.sub.1-4
alkyl-, and (4-10 membered heterocycloalkyl)-C.sub.1-4 alkyl-,
wherein the C.sub.1-4 alkyl, C.sub.2-4 alkenyl, C.sub.2-4 alkynyl,
C.sub.1-4 alkoxy, C.sub.3-6 cycloalkyl, C.sub.3-6
cycloalkyl-C.sub.1-4alkyl-, C.sub.6-10 aryl, C.sub.6-10
aryl-C.sub.1-4alkyl-, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, (5-10 membered heteroaryl)-C.sub.1-4 alkyl-, and
(4-10 membered heterocycloalkyl)-C.sub.1-4 alkyl- of R.sup.1,
R.sup.2, R.sup.8a, R.sup.8b, R.sup.10 and R.sup.8c are each
optionally substituted with 1, 2 or 3 independently selected
R.sup.d substituents; R.sup.9 is Cl, Br, I, C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl,
C.sub.1-6 haloalkoxy, C.sub.6-10 aryl, C.sub.3-10 cycloalkyl, 5-14
membered heteroaryl, 4-10 membered heterocycloalkyl, C.sub.6-10
aryl-C.sub.1-4 alkyl-, C.sub.3-10 cycloalkyl-C.sub.1-4 alkyl-,
(5-14 membered heteroaryl)-C.sub.1-4 alkyl-, (4-10 membered
heterocycloalkyl)-C.sub.1-4 alkyl-, CN, NO.sub.2, OR.sup.11a,
SR.sup.11, NH.sub.2, --NHR.sup.11, --NR.sup.11R.sup.11,
NHOR.sup.11, C(O)R.sup.11, C(O)NR.sup.11R.sup.11, C(O)OR.sup.11,
OC(O)R.sup.11, OC(O)NR.sup.11R.sup.11, NR.sup.11C(O)R.sup.11,
NR.sup.11C(O)OR.sup.11, NR.sup.11C(O)NR.sup.11R.sup.11,
C(.dbd.NR.sup.11)R.sup.11, C(.dbd.NR.sup.11)NR.sup.11R.sup.11,
NR.sup.11C(.dbd.NR.sup.11)NR.sup.11R.sup.11, NR.sup.11S(O)R.sup.11,
NR.sup.11S(O).sub.2R.sup.11, NR.sup.11S(O).sub.2NR.sup.11R.sup.11,
S(O)R.sup.11, S(O)NR.sup.11R.sup.11, S(O).sub.2R.sup.11, and
S(O).sub.2NR.sup.11R.sup.11, wherein the C.sub.1-6 alkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl, C.sub.1-6
haloalkoxy, C.sub.6-10 aryl, C.sub.3-10 cycloalkyl, 5-14 membered
heteroaryl, 4-10 membered heterocycloalkyl, C.sub.6-10
aryl-C.sub.1-4 alkyl-, C.sub.3-10 cycloalkyl-C.sub.1-4 alkyl-,
(5-14 membered heteroaryl)-C.sub.1-4 alkyl- and (4-10 membered
heterocycloalkyl)-C.sub.1-4 alkyl- of R.sup.9 are each optionally
substituted with 1, 2 or 3 R.sup.b substituents; each R.sup.11 is
independently selected from H, C.sub.1-6 alkyl, C.sub.1-6
haloalkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.6-10 aryl,
C.sub.3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-, C.sub.3-10
cycloalkyl-C.sub.1-4 alkyl-, (5-10 membered heteroaryl)-C.sub.1-4
alkyl-, and (4-10 membered heterocycloalkyl)-C.sub.1-4 alkyl-,
wherein the C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.6-10 aryl, C.sub.3-10 cycloalkyl, 5-10 membered heteroaryl,
4-10 membered heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-,
C.sub.3-10 cycloalkyl-C.sub.1-4 alkyl-, (5-10 membered
heteroaryl)-C.sub.1-4 alkyl- and (4-10 membered
heterocycloalkyl)-C.sub.1-4 alkyl- of R.sup.11 are each optionally
substituted with 1, 2 or 3 independently selected R.sup.b
substituents; R.sup.11a is selected from C.sub.1-6 alkyl, C.sub.1-6
haloalkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.6-10 aryl,
C.sub.3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-, C.sub.3-10
cycloalkyl-C.sub.1-4 alkyl-, (5-10 membered heteroaryl)-C.sub.1-4
alkyl-, and (4-10 membered heterocycloalkyl)-C.sub.1-4 alkyl-, each
of which is optionally substituted with 1, 2 or 3 independently
selected R.sup.b substituents; R.sup.3, R.sup.4, R.sup.5, R.sup.6
and R.sup.7 are each independently selected from H, halo, C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl,
C.sub.1-6 haloalkoxy, C.sub.6-10 aryl, C.sub.3-10 cycloalkyl, 5-14
membered heteroaryl, 4-10 membered heterocycloalkyl, C.sub.6-10
aryl-C.sub.1-4 alkyl-, C.sub.3-10 cycloalkyl-C.sub.1-4 alkyl-,
(5-14 membered heteroaryl)-C.sub.1-4 alkyl-, (4-10 membered
heterocycloalkyl)-C.sub.1-4 alkyl-, CN, NO.sub.2, OR.sup.a,
SR.sup.a, NHOR.sup.a, C(O)R.sup.a, C(O)NR.sup.aR.sup.a,
C(O)OR.sup.a, OC(O)R.sup.a, OC(O)NR.sup.aR.sup.a, NHR.sup.a,
NR.sup.aR.sup.a, NR.sup.aC(O)R.sup.a, NR.sup.aC(O)OR.sup.a,
NR.sup.aC(O)NR.sup.aR.sup.a, C(.dbd.NR.sup.a)R.sup.a,
C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
NR.sup.aC(.dbd.NR.sup.a)NR.sup.aR.sup.a, NR.sup.aS(O)R.sup.a,
NR.sup.aS(O).sub.2R.sup.a, NR.sup.aS(O).sub.2NR.sup.aR.sup.a,
S(O)R.sup.a, S(O)NR.sup.aR.sup.a, S(O).sub.2R.sup.a, and
S(O).sub.2NR.sup.aR.sup.a, wherein the C.sub.1-6 alkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.6-10 aryl, C.sub.3-10 cycloalkyl,
5-14 membered heteroaryl, 4-10 membered heterocycloalkyl,
C.sub.6-10 aryl-C.sub.1-4 alkyl-, C.sub.3-10 cycloalkyl-C.sub.1-4
alkyl-, (5-14 membered heteroaryl)-C.sub.1-4 alkyl-, and (4-10
membered heterocycloalkyl)-C.sub.1-4 alkyl- of R.sup.3, R.sup.4,
R.sup.5, R.sup.6 and R.sup.7 are each optionally substituted with
1, 2, 3, or 4 R.sup.b substituents, with the proviso that at least
one of R.sup.3, R.sup.4, R.sup.5 and R.sup.6 is other than H; or
two adjacent R.sup.7 substituents on the Cy ring, taken together
with the atoms to which they are attached, form a fused phenyl
ring, a fused 5- to 7-membered heterocycloalkyl ring, a fused 5- or
6-membered heteroaryl ring or a fused C.sub.5-6 cycloalkyl ring,
wherein the fused 5- to 7-membered heterocycloalkyl ring and fused
5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring
members selected from N, O and S and wherein the fused phenyl ring,
fused 5- to 7-membered heterocycloalkyl ring, fused 5- or
6-membered heteroaryl ring and fused C.sub.5-6 cycloalkyl ring are
each optionally substituted with 1, 2 or 3 independently selected
R.sup.b substituents; each R.sup.a is independently selected from
H, CN, C.sub.1-6 alkyl, C.sub.1-4 haloalkyl, C.sub.2-6 alkenyl,
C.sub.2-6 alkynyl, C.sub.6-10 aryl, C.sub.3-10 cycloalkyl, 5-10
membered heteroaryl, 4-10 membered heterocycloalkyl, C.sub.6-10
aryl-C.sub.1-4 alkyl-, C.sub.3-10 cycloalkyl-C.sub.1-4 alkyl-,
(5-10 membered heteroaryl)-C.sub.1-4 alkyl-, and (4-10 membered
heterocycloalkyl)-C.sub.1-4 alkyl-, wherein the C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.6-10 aryl, C.sub.3-10
cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-, C.sub.3-10
cycloalkyl-C.sub.1-4 alkyl-, (5-10 membered heteroaryl)-C.sub.1-4
alkyl- and (4-10 membered heterocycloalkyl)-C.sub.1-4 alkyl- of
R.sup.a are each optionally substituted with 1, 2, 3, 4, or 5
R.sup.d substituents; each R.sup.d is independently selected from
C.sub.1-6 alkyl, C.sub.1-6 haloalkyl, halo, C.sub.6-10aryl, 5-10
membered heteroaryl, C.sub.3-10 cycloalkyl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-, C.sub.3-10
cycloalkyl-C.sub.1-4 alkyl-, (5-10 membered heteroaryl)-C.sub.1-4
alkyl-, (4-10 membered heterocycloalkyl)-C.sub.1-4 alkyl-, CN,
NH.sub.2, NHOR.sup.e, OR.sup.e, SR.sup.e, C(O)R.sup.e,
C(O)NR.sup.eR.sup.e, C(O)OR.sup.e, OC(O)R.sup.e,
OC(O)NR.sup.eR.sup.e, NHR.sup.e, NR.sup.eR.sup.e,
NR.sup.eC(O)R.sup.e, NR.sup.eC(O)NR.sup.eR.sup.e,
NR.sup.eC(O)OR.sup.e, C(.dbd.NR.sup.e)NR.sup.eR.sup.e,
NR.sup.eC(.dbd.NR.sup.e)NR.sup.eR.sup.e,
NR.sup.eC(.dbd.NOH)NR.sup.eR.sup.e,
NR.sup.eC(.dbd.NCN)NR.sup.eR.sup.e, S(O)R.sup.e,
S(O)NR.sup.eR.sup.e, S(O).sub.2R.sup.e, NR.sup.eS(O).sub.2R.sup.e,
NR.sup.eS(O).sub.2NR.sup.eR.sup.e, and S(O).sub.2NR.sup.eR.sup.e,
wherein the C.sub.1-6 alkyl, C.sub.1-6 haloalkyl, C.sub.6-10aryl,
5-10 membered heteroaryl, C.sub.3-10 cycloalkyl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-, C.sub.3-10
cycloalkyl-C.sub.1-4 alkyl-, (5-10 membered heteroaryl)-C.sub.1-4
alkyl-, and (4-10 membered heterocycloalkyl)-C.sub.1-4 alkyl- of
R.sup.d are each optionally substituted with 1-3 independently
selected R.sup.h substituents; each R.sup.b substituent is
independently selected from halo, C.sub.1-4 alkyl, C.sub.1-4
haloalkyl, C.sub.1-4 haloalkoxy, C.sub.6-10 aryl, C.sub.3-10
cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-, C.sub.3-10
cycloalkyl-C.sub.1-4 alkyl-, (5-10 membered heteroaryl)-C.sub.1-4
alkyl-, (4-10 membered heterocycloalkyl)-C.sub.1-4 alkyl-, CN, OH,
NH.sub.2, NO.sub.2, NHOR.sup.c, OR.sup.c, SR.sup.c, C(O)R.sup.c,
C(O)NR.sup.cR.sup.c, C(O)OR.sup.c, OC(O)R.sup.c,
OC(O)NR.sup.cR.sup.c, C(.dbd.NR.sup.c)NR.sup.cR.sup.c,
NR.sup.cC(.dbd.NR.sup.c)NR.sup.cR.sup.c, NHR.sup.c,
NR.sup.cR.sup.c, NR.sup.cC(O)R.sup.c, NR.sup.cC(O)OR.sup.c,
NR.sup.cC(O)NR.sup.cR.sup.c, NR.sup.cS(O)R.sup.c,
NR.sup.cS(O).sub.2R.sup.c, NR.sup.cS(O).sub.2NR.sup.cR.sup.c,
S(O)R.sup.c, S(O)NR.sup.cR.sup.c, S(O).sub.2R.sup.c and
S(O).sub.2NR.sup.cR.sup.c; wherein the C.sub.1-4 alkyl, C.sub.1-4
haloalkyl, C.sub.1-4 haloalkoxy, C.sub.6-10 aryl, C.sub.3-10
cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-, C.sub.3-10
cycloalkyl-C.sub.1-4 alkyl-, (5-10 membered heteroaryl)-C.sub.1-4
alkyl- and (4-10 membered heterocycloalkyl)-C.sub.1-4 alkyl- of
R.sup.b are each further optionally substituted with 1-3
independently selected R.sup.d substituents; each R.sup.c is
independently selected from H, C.sub.1-6 alkyl, C.sub.1-4
haloalkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.6-10 aryl,
C.sub.3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-, C.sub.3-10
cycloalkyl-C.sub.1-4 alkyl-, (5-10 membered heteroaryl)-C.sub.1-4
alkyl-, and (4-10 membered heterocycloalkyl)-C.sub.1-4 alkyl-,
wherein the C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.6-10 aryl, C.sub.3-10 cycloalkyl, 5-10 membered heteroaryl,
4-10 membered heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-,
C.sub.3-10 cycloalkyl-C.sub.1-4 alkyl-, (5-10 membered
heteroaryl)-C.sub.1-4 alkyl- and (4-10 membered
heterocycloalkyl)-C.sub.1-4 alkyl- of R.sup.c are each optionally
substituted with 1, 2, 3, 4, or 5 R.sup.f substituents
independently selected from C.sub.1-4 alkyl, C.sub.1-4 haloalkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.6-10 aryl, C.sub.3-10
cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-, C.sub.3-10
cycloalkyl-C.sub.1-4 alkyl-, (5-10 membered heteroaryl)-C.sub.1-4
alkyl-, (4-10 membered heterocycloalkyl)-C.sub.1-4 alkyl-, halo,
CN, NHOR.sup.g, OR.sup.g, SR.sup.g, C(O)R.sup.g,
C(O)NR.sup.gR.sup.g, C(O)OR.sup.g, OC(O)R.sup.g,
OC(O)NR.sup.gR.sup.g, NHR.sup.g, NR.sup.gR.sup.g,
NR.sup.gC(O)R.sup.g, NR.sup.gC(O)NR.sup.gR.sup.g,
NR.sup.gC(O)OR.sup.g, C(.dbd.NR.sup.g)NR.sup.gR.sup.g,
NR.sup.gC(.dbd.NR.sup.g)NR.sup.gR.sup.g, S(O)R.sup.g,
S(O)NR.sup.gR.sup.g, S(O).sub.2R.sup.g, NR.sup.gS(O).sub.2R.sup.g,
NR.sup.gS(O).sub.2NR.sup.gR.sup.g, and S(O).sub.2NR.sup.gR.sup.g;
wherein the C.sub.1-4 alkyl, C.sub.1-4 haloalkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.6-10 aryl, C.sub.3-10 cycloalkyl,
5-10 membered heteroaryl, 4-10 membered heterocycloalkyl,
C.sub.6-10 aryl-C.sub.1-4 alkyl-, C.sub.3-10 cycloalkyl-C.sub.1-4
alkyl-, (5-10 membered heteroaryl)-C.sub.1-4 alkyl-, and (4-10
membered heterocycloalkyl)-C.sub.1-4 alkyl- of R.sup.f are each
optionally substituted with 1, 2, 3, 4, or 5 R.sup.n substituents
independently selected from C.sub.1-4 alkyl, C.sub.1-4 haloalkyl,
halo, CN, R.sup.o, NHOR.sup.o, OR.sup.o, SR.sup.o, C(O)R.sup.o,
C(O)NR.sup.oR.sup.o, C(O)OR.sup.o, OC(O)R.sup.o,
OC(O)NR.sup.oR.sup.o, NHR.sup.o, NR.sup.oR.sup.o,
NR.sup.oC(O)R.sup.o, NR.sup.oC(O)NR.sup.oR.sup.o,
NR.sup.oC(O)OR.sup.o, C(.dbd.NR.sup.o)NR.sup.oR.sup.o,
NR.sup.oC(.dbd.NR.sup.o)NR.sup.oR.sup.o, S(O)R.sup.o,
S(O)NR.sup.oR.sup.o, S(O).sub.2R.sup.o, NR.sup.oS(O).sub.2R.sup.o,
NR.sup.oS(O).sub.2NR.sup.oR.sup.o, and S(O).sub.2NR.sup.oR.sup.o;
each R.sup.g is independently selected from H, C.sub.1-6 alkyl,
C.sub.1-4 haloalkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.6-10 aryl, C.sub.3-10 cycloalkyl, 5-10 membered heteroaryl,
4-10 membered heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-,
C.sub.3-10 cycloalkyl-C.sub.1-4 alkyl-, (5-10 membered
heteroaryl)-C.sub.1-4 alkyl-, and (4-10 membered
heterocycloalkyl)-C.sub.1-4 alkyl-, wherein the C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.6-10 aryl, C.sub.3-10
cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-, C.sub.3-10
cycloalkyl-C.sub.1-4 alkyl-, (5-10 membered heteroaryl)-C.sub.1-4
alkyl- and (4-10 membered heterocycloalkyl)-C.sub.1-4 alkyl- of
R.sup.g are each optionally substituted with 1-3 R.sup.p
substituents independently selected from C.sub.1-6 alkyl, C.sub.1-6
haloalkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.6-10 aryl,
C.sub.3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-, C.sub.3-10
cycloalkyl-C.sub.1-4 alkyl-(5-10 membered heteroaryl)-C.sub.1-4
alkyl-, (4-10 membered heterocycloalkyl)-C.sub.1-4 alkyl-, halo,
CN, NHOR.sup.r, OR.sup.r, SR.sup.r, C(O)R.sup.r,
C(O)NR.sup.rR.sup.r, C(O)OR.sup.r, OC(O)R.sup.r,
OC(O)NR.sup.rR.sup.r, NHR.sup.r, NR.sup.rR.sup.r,
NR.sup.rC(O)R.sup.r, NR.sup.rC(O)NR.sup.rR.sup.r,
NR.sup.rC(O)OR.sup.r, C(.dbd.NR.sup.r)NR.sup.rR.sup.r,
NR.sup.rC(.dbd.NR.sup.r)NR.sup.rR.sup.r, NR
.sup.rC(.dbd.NOH)NR.sup.rR.sup.r,
NR.sup.rC(.dbd.NCN)NR.sup.rR.sup.r, S(O)R.sup.r,
S(O)NR.sup.rR.sup.r, S(O).sub.2R.sup.r, NR.sup.rS(O).sub.2R.sup.r,
NR.sup.rS(O).sub.2NR.sup.rR.sup.r and S(O).sub.2NR.sup.rR.sup.r,
wherein the C.sub.1-6 alkyl, C.sub.1-6 haloalkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.6-10 aryl, C.sub.3-10 cycloalkyl,
5-10 membered heteroaryl, 4-10 membered heterocycloalkyl,
C.sub.6-10 aryl-C.sub.1-4 alkyl-, C.sub.3-10 cycloalkyl-C.sub.1-4
alkyl-, (5-10 membered heteroaryl)-C.sub.1-4 alkyl- and (4-10
membered heterocycloalkyl)-C.sub.1-4 alkyl- of R.sup.p is
optionally substituted with 1, 2 or 3 R.sup.q substituents; or any
two R.sup.a substituents together with the nitrogen atom to which
they are attached form a 4-, 5-, 6-, 7-, 8-, 9- or 10-membered
heterocycloalkyl group optionally substituted with 1, 2 or 3
R.sup.h substituents independently selected from C.sub.1-6 alkyl,
C.sub.3-10 cycloalkyl, 4-7 membered heterocycloalkyl, C.sub.6-10
aryl, 5-6 membered heteroaryl, C.sub.6-10 aryl-C.sub.1-4alkyl-,
C.sub.3-10 cycloalkyl-C.sub.1-4 alkyl-, (5-6 membered
heteroaryl)-C.sub.1-4 alkyl-, (4-7 membered
heterocycloalkyl)-C.sub.1-4 alkyl-, C.sub.1-6 haloalkyl, C.sub.1-6
haloalkoxy, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, halo, CN,
OR.sup.i, SR.sup.i, NHOR.sup.i, C(O)R.sup.i, C(O)NR.sup.iR.sup.i,
C(O)OR.sup.i, OC(O)R.sup.i, OC(O)NR.sup.iR.sup.i, NHR.sup.i,
NR.sup.iR.sup.i, NR.sup.iC(O)R.sup.i, NR.sup.iC(O)NR.sup.iR.sup.i,
NR.sup.iC(O)OR.sup.i, C(.dbd.NR.sup.i)NR.sup.iR.sup.i,
NR.sup.iC(.dbd.NR.sup.i)NR.sup.iR.sup.i, S(O)R.sup.i,
S(O)NR.sup.iR.sup.i, S(O).sub.2R.sup.i, NR.sup.iS(O).sub.2R.sup.i,
NR.sup.iS(O).sub.2NR.sup.iR.sup.i, and S(O).sub.2NR.sup.iR.sup.i,
wherein the C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.3-10 cycloalkyl, 4-7 membered heterocycloalkyl, C.sub.6-10
aryl, 5-6 membered heteroaryl, C.sub.6-10 aryl-C.sub.1-4alkyl-,
C.sub.3-10 cycloalkyl-C.sub.1-4 alkyl-, (5-6 membered
heteroaryl)-C.sub.1-4 alkyl-, and (4-7 membered
heterocycloalkyl)-C.sub.14 alkyl- of R.sup.h are each further
optionally substituted by 1, 2, or 3 R.sup.j substituents
independently selected from C.sub.3-6 cycloalkyl, C.sub.6-10 aryl,
5 or 6-membered heteroaryl, 4-7 membered heterocycloalkyl,
C.sub.2-4 alkenyl, C.sub.2-4 alkynyl, halo, C.sub.1-4 alkyl,
C.sub.1-4 haloalkyl, CN, NHOR.sup.k, OR.sup.k, SR.sup.k,
C(O)R.sup.k, C(O)NR.sup.kR.sup.k, C(O)OR.sup.k, OC(O)R.sup.k,
OC(O)NR.sup.kR.sup.k, NHR.sup.k, NR.sup.kR.sup.k,
NR.sup.kC(O)R.sup.k, NR.sup.kC(O)NR.sup.kR.sup.k,
NR.sup.kC(O)OR.sup.k, C(.dbd.NR.sup.k)NR.sup.kR.sup.k,
NR.sup.kC(.dbd.NR.sup.k)NR.sup.kR.sup.k, S(O)R.sup.k,
S(O)NR.sup.kR.sup.k, S(O).sub.2R.sup.k, NR.sup.kS(O).sub.2R.sup.k,
NR.sup.kS(O).sub.2NR.sup.kR.sup.k, and S(O).sub.2NR.sup.kR.sup.k,
wherein the C.sub.1-4 alkyl, C.sub.3-6 cycloalkyl, C.sub.6-10 aryl,
5- or 6-membered heteroaryl, 4-6 membered heterocycloalkyl,
C.sub.2-4 alkenyl, C.sub.2-4 alkynyl, C.sub.1-4 haloalkyl, and
C.sub.1-4 haloalkoxy of R.sup.j are each optionally substituted
with 1, 2 or 3 independently selected R.sup.q substituents; or two
R.sup.h groups attached to the same carbon atom of the 4- to
10-membered heterocycloalkyl taken together with the carbon atom to
which they attach form a C.sub.3-6 cycloalkyl or 4- to 6-membered
heterocycloalkyl having 1-2 heteroatoms as ring members selected
from O, N and S; or any two R.sup.c substituents together with the
nitrogen atom to which they are attached form a 4-, 5-, 6-, or
7-membered heterocycloalkyl group optionally substituted with 1, 2,
or 3 independently selected R.sup.h substituents; or any two
R.sup.e substituents together with the nitrogen atom to which they
are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl
group optionally substituted with 1, 2, or 3 independently selected
R.sup.h substituents; or any two R.sup.g substituents together with
the nitrogen atom to which they are attached form a 4-, 5-, 6-, or
7-membered heterocycloalkyl group optionally substituted with 1, 2,
or 3 independently selected R.sup.h substituents; or any two
R.sup.i substituents together with the nitrogen atom to which they
are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl
group optionally substituted with 1, 2, or 3 independently selected
R.sup.h substituents; or any two R.sup.k substituents together with
the nitrogen atom to which they are attached form a 4-, 5-, 6-, or
7-membered heterocycloalkyl group optionally substituted with 1, 2,
or 3 independently selected R.sup.h substituents; or any two
R.sup.o substituents together with the nitrogen atom to which they
are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl
group optionally substituted with 1, 2, or 3 independently selected
R.sup.h substituents; each R.sup.e, R.sup.i, R.sup.k, R.sup.o or
R.sup.p is independently selected from H, C.sub.1-4 alkyl,
C.sub.3-6 cycloalkyl, C.sub.6-10 aryl, 5 or 6-membered heteroaryl,
4-7 membered heterocycloalkyl, C.sub.1-4 haloalkyl, C.sub.2-4
alkenyl, and C.sub.2-4 alkynyl, wherein the C.sub.1-4 alkyl,
C.sub.3-6 cycloalkyl, C.sub.6-10 aryl, 5 or 6-membered heteroaryl,
4-7 membered heterocycloalkyl, C.sub.2-4 alkenyl, and C.sub.2-4
alkynyl of R.sup.e, R.sup.i, R.sup.k, R.sup.o or R.sup.p are each
optionally substituted with 1, 2 or 3 R.sup.q substituents; each
R.sup.q is independently selected from OH, CN, --COOH, NH.sub.2,
halo, C.sub.1-6haloalkyl, C.sub.1-6 alkyl, C.sub.1-6 alkoxy,
C.sub.1-6 alkylthio, phenyl, 5-6 membered heteroaryl, 4-6 membered
heterocycloalkyl, C.sub.3-6cycloalkyl, NHR.sup.12,
NR.sup.12R.sup.12, and C.sub.1-4 haloalkoxy, wherein the C.sub.1-6
alkyl, phenyl, C.sub.3-6 cycloalkyl, 4-6 membered heterocycloalkyl,
and 5-6 membered heteroaryl of R.sup.q are each optionally
substituted with halo, OH, CN, --COOH, NH.sub.2, C.sub.1-4alkyl,
C.sub.1-4 alkoxy, C.sub.1-4 haloalkyl, C.sub.1-4 haloalkoxy,
phenyl, C.sub.3-10 cycloalkyl, 5-6 membered heteroaryl and 4-6
membered heterocycloalkyl and each R.sup.12 is independently
C.sub.1-6 alkyl; is a single bond or a double bond to maintain ring
A being aromatic; when the moiety ##STR00136## in Formula (I') is
2-benzoxazolyl substituted with 1 to 3 substituents independently
selected from methyl, ethyl, isopropyl, methoxy, Cl, Br, and
phenyl, Cy is not 4H-1,2,4-triazol-4-yl, 5-methyl-2-benzoxazolyl or
2-oxopyrrolidinyl substituted with --COOH, --C(O)NH.sub.2,
--C(O)OC.sub.1-2 alkyl or --C(O)Cl; and the compound is not
1-[3-(6-chloro-2-benzoxazolyl)-5-(3,5-dimethylphenyl)-4-pyridinyl]-4-pipe-
ridinamine.
2. The compound of claim 1, or a pharmaceutically acceptable salt
or a stereoisomer thereof, wherein: one of X.sup.1 and X.sup.2 is O
or S and the other of X.sup.1 and X.sup.2 is N, CR.sup.1 or
CR.sup.2; X.sup.3 is N or CR.sup.3; X.sup.4 is N or CR.sup.4;
X.sup.5 is N or CR.sup.5; X.sup.6 is N or CR.sup.6; at least one of
X.sup.1, X.sup.2, X.sup.3, X.sup.4, X.sup.5 and X.sup.6 is N;
Y.sup.1 is N or CR.sup.8a; Y.sup.2 is N or CR.sup.8b; Y.sup.3 is N
or CR.sup.8c; Cy is C.sub.6-10 aryl, C.sub.3-10 cycloalkyl, 5- to
14-membered heteroaryl, or 4- to 10-membered heterocycloalkyl, each
of which is optionally substituted with 1, 2, 3, 4 or 5
independently selected R.sup.7 substituents; R.sup.1, R.sup.2,
R.sup.8a, R.sup.8b and R.sup.8c are each independently selected
from H, C.sub.1-4 alkyl, C.sub.3-6 cycloalkyl, C.sub.2-4 alkenyl,
C.sub.2-4 alkynyl, halo, CN, OH, C.sub.1-4 alkoxy, C.sub.1-4
haloalkyl, C.sub.1-4 haloalkoxy, NH.sub.2, --NH--C.sub.1-4 alkyl,
--N(C.sub.1-4 alkyl).sub.2, NHOR.sup.10, C(O)R.sup.10,
C(O)NR.sup.10R.sup.10, C(O)OR.sup.10, OC(O)R.sup.10,
OC(O)NR.sup.10R.sup.10, NR.sup.10C(O)R.sup.10,
NR.sup.10C(O)OR.sup.10, NR.sup.10C(O)NR.sup.10R.sup.10,
C(.dbd.NR.sup.10)R.sup.10, C(.dbd.NR.sup.10)NR.sup.10R.sup.10,
NR.sup.10C(.dbd.NR.sup.10)NR.sup.10R.sup.10, NR.sup.10S(O)R.sup.10,
NR.sup.10S(O).sub.2R.sup.10, NR.sup.10S(O).sub.2NR.sup.10R.sup.10,
S(O)R.sup.10, S(O)NR.sup.10R.sup.10, S(O).sub.2R.sup.10, and
S(O).sub.2NR.sup.10R.sup.10, wherein each R.sup.10 is independently
H or C.sub.1-4 alkyl optionally substituted with 1 or 2 groups
independently selected from halo, OH, CN and C.sub.1-4 alkoxy and
wherein the C.sub.1-4 alkyl, C.sub.3-4 cycloalkyl, C.sub.2-4
alkenyl and C.sub.2-4 alkynyl of R.sup.1, R.sup.2, R.sup.8a,
R.sup.8b, or R.sup.8c are each optionally substituted with 1 or 2
substituents independently selected from halo, OH, CN, C.sub.1-4
alkyl and C.sub.1-4 alkoxy; R.sup.9 is C.sub.1-4 alkyl, Cl, Br, CN,
cyclopropyl, C.sub.2-4 alkynyl, C.sub.1-4 haloalkyl, C.sub.1-4
haloalkoxy, NH.sub.2, --NH--C.sub.1-4 alkyl, --N(C.sub.1-4
alkyl).sub.2, NHOR.sup.11, C(O)R.sup.11, C(O)NR.sup.11R.sup.11,
C(O)OR.sup.11, OC(O)R.sup.11, OC(O)NR.sup.11R.sup.11,
NR.sup.11C(O)R.sup.11, NR.sup.11C(O)OR.sup.11,
C(.dbd.NR.sup.11)R.sup.11, C(.dbd.NR.sup.11)NR.sup.11R.sup.11,
NR.sup.11S(O)R.sup.11, NR.sup.11S(O).sub.2R.sup.11, S(O)R.sup.11,
S(O)NR.sup.11R.sup.11, S(O).sub.2R.sup.11, and
S(O).sub.2NR.sup.11R.sup.11, wherein the C.sub.1-4 alkyl,
cyclopropyl, C.sub.2-4 alkynyl and C.sub.1-4 alkoxy of R.sup.9 are
each optionally substituted with 1 or 2 halo, OH, CN or OCH.sub.3
substituents and each R.sup.11 is independently H or C.sub.1-4
alkyl optionally substituted with 1 or 2 halo, OH, CN or OCH.sub.3;
R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 are each
independently selected from H, halo, C.sub.1-6 alkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl, C.sub.1-6
haloalkoxy, C.sub.6-10 aryl, C.sub.3-10 cycloalkyl, 5-14 membered
heteroaryl, 4-10 membered heterocycloalkyl, C.sub.6-10
aryl-C.sub.1-4 alkyl-, C.sub.3-10 cycloalkyl-C.sub.1-4 alkyl-,
(5-14 membered heteroaryl)-C.sub.1-4 alkyl-, (4-10 membered
heterocycloalkyl)-C.sub.1-4 alkyl-, CN, NO.sub.2, OR.sup.a,
SR.sup.a, NHOR.sup.a, C(O)R.sup.a, C(O)NR.sup.aR.sup.a,
C(O)OR.sup.a, OC(O)R.sup.a, OC(O)NR.sup.aR.sup.a, NHR.sup.a,
NR.sup.aR.sup.a, NR.sup.aC(O)R.sup.a, NR.sup.aC(O)OR.sup.a,
NR.sup.aC(O)NR.sup.aR.sup.a, C(.dbd.NR.sup.a)R.sup.a,
C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
NR.sup.aC(.dbd.NR.sup.a)NR.sup.aR.sup.a, NR.sup.aS(O)R.sup.a,
NR.sup.aS(O).sub.2R.sup.a, NR.sup.aS(O).sub.2NR.sup.aR.sup.a,
S(O)R.sup.a, S(O)NR.sup.aR.sup.a, S(O).sub.2R.sup.a, and
S(O).sub.2NR.sup.aR.sup.a, wherein the C.sub.1-6 alkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.6-10 aryl, C.sub.3-10 cycloalkyl,
5-14 membered heteroaryl, 4-10 membered heterocycloalkyl,
C.sub.6-10 aryl-C.sub.1-4 alkyl-, C.sub.3-10 cycloalkyl-C.sub.1-4
alkyl-, (5-14 membered heteroaryl)-C.sub.1-4 alkyl-, and (4-10
membered heterocycloalkyl)-C.sub.1-4 alkyl- of R.sup.3, R.sup.4,
R.sup.5, R.sup.6 and R.sup.7 are each optionally substituted with
1, 2, 3, or 4 R.sup.b substituents, with the proviso that at least
one of R.sup.3, R.sup.4, R.sup.5 and R.sup.6 is other than H; or
two adjacent R.sup.7 substituents on the Cy ring, taken together
with the atoms to which they are attached, form a fused phenyl
ring, a fused 5- to 7-membered heterocycloalkyl ring, a fused 5- or
6-membered heteroaryl ring or a fused C.sub.5-6 cycloalkyl ring,
wherein the fused 5- to 7-membered heterocycloalkyl ring and fused
5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring
members selected from N, O and S and wherein the fused phenyl ring,
fused 5- to 7-membered heterocycloalkyl ring, fused 5- or
6-membered heteroaryl ring and fused C.sub.5-6 cycloalkyl ring are
each optionally substituted with 1 or 2 independently selected
R.sup.b substituents; each R.sup.a is independently selected from
H, CN, C.sub.1-6 alkyl, C.sub.1-4 haloalkyl, C.sub.2-6 alkenyl,
C.sub.2-6 alkynyl, C.sub.6-10 aryl, C.sub.3-10 cycloalkyl, 5-10
membered heteroaryl, 4-10 membered heterocycloalkyl, C.sub.6-10
aryl-C.sub.1-4 alkyl-, C.sub.3-10 cycloalkyl-C.sub.1-4 alkyl-,
(5-10 membered heteroaryl)-C.sub.1-4 alkyl-, and (4-10 membered
heterocycloalkyl)-C.sub.1-4 alkyl-, wherein the C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.6-10 aryl, C.sub.3-10
cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-, C.sub.3-10
cycloalkyl-C.sub.1-4 alkyl-, (5-10 membered heteroaryl)-C.sub.1-4
alkyl- and (4-10 membered heterocycloalkyl)-C.sub.1-4 alkyl- of
R.sup.a are each optionally substituted with 1, 2, 3, 4, or 5
R.sup.d substituents; each R.sup.d is independently selected from
C.sub.1-4 alkyl, C.sub.1-4 haloalkyl, halo, C.sub.3-10 cycloalkyl,
4-10 membered heterocycloalkyl, CN, NH.sub.2, NHOR.sup.e, OR.sup.e,
SR.sup.e, C(O)R.sup.e, C(O)NR.sup.eR.sup.e, C(O)OR.sup.e,
OC(O)R.sup.e, OC(O)NR.sup.eR.sup.e, NHR.sup.e, NR.sup.eR.sup.e,
NR.sup.eC(O)R.sup.e, NR.sup.eC(O)NR.sup.eR.sup.e,
NR.sup.eC(O)OR.sup.e, C(.dbd.NR.sup.e)NR.sup.eR.sup.e,
NR.sup.eC(.dbd.NR.sup.e)NR.sup.eR.sup.e, S(O)R.sup.e,
S(O)NR.sup.eR.sup.e, S(O).sub.2R.sup.e, NR.sup.eS(O).sub.2R.sup.e,
NR.sup.eS(O).sub.2NR.sup.eR.sup.e, and S(O).sub.2NR.sup.eR.sup.e,
wherein the C.sub.1-4 alkyl, C.sub.3-10 cycloalkyl and 4-10
membered heterocycloalkyl of R.sup.d are each further optionally
substituted with 1-3 independently selected R.sup.q substituents;
each R.sup.b substituent is independently selected from halo,
C.sub.1-4 alkyl, C.sub.1-4 haloalkyl, C.sub.1-4 haloalkoxy,
C.sub.6-10 aryl, C.sub.3-10 cycloalkyl, 5-10 membered heteroaryl,
4-10 membered heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-,
C.sub.3-10 cycloalkyl-C.sub.1-4 alkyl-, (5-10 membered
heteroaryl)-C.sub.1-4 alkyl-, (4-10 membered
heterocycloalkyl)-C.sub.1-4 alkyl-, CN, OH, NH.sub.2, NO.sub.2,
NHOR.sup.c, SR.sup.c, C(O)R.sup.c, C(O)NR.sup.cR.sup.c,
C(O)OR.sup.c, OC(O)R.sup.c, OC(O)NR.sup.cR.sup.c,
C(.dbd.NR.sup.c)NR.sup.cR.sup.c,
NR.sup.cC(.dbd.NR.sup.c)NR.sup.cR.sup.c, NHR.sup.c,
NR.sup.cR.sup.c, NR.sup.cC(O)R.sup.c, NR.sup.cC(O)OR.sup.c,
NR.sup.cC(O)NR.sup.cR.sup.c, NR.sup.cS(O)R.sup.c,
NR.sup.cS(O).sub.2R.sup.c, NR.sup.cS(O).sub.2NR.sup.cR.sup.c,
S(O)R.sup.c, S(O)NR.sup.cR.sup.c, S(O).sub.2R.sup.c and
S(O).sub.2NR.sup.cR.sup.c; wherein the C.sub.1-4 alkyl, C.sub.1-4
haloalkyl, C.sub.1-4 haloalkoxy, C.sub.6-10 aryl, C.sub.3-10
cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-, C.sub.3-10
cycloalkyl-C.sub.1-4 alkyl-, (5-10 membered heteroaryl)-C.sub.1-4
alkyl- and (4-10 membered heterocycloalkyl)-C.sub.1-4 alkyl- of
R.sup.b are each further optionally substituted with 1-3
independently selected R.sup.d substituents; each R.sup.c is
independently selected from H, C.sub.1-6 alkyl, C.sub.1-4
haloalkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.6-10 aryl,
C.sub.3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-, C.sub.3-10
cycloalkyl-C.sub.1-4 alkyl-, (5-10 membered heteroaryl)-C.sub.1-4
alkyl-, and (4-10 membered heterocycloalkyl)-C.sub.1-4 alkyl-,
wherein the C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.6-10 aryl, C.sub.3-10 cycloalkyl, 5-10 membered heteroaryl,
4-10 membered heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-,
C.sub.3-10 cycloalkyl-C.sub.1-4 alkyl-, (5-10 membered
heteroaryl)-C.sub.1-4 alkyl- and (4-10 membered
heterocycloalkyl)-C.sub.1-4 alkyl- of R.sup.c are each optionally
substituted with 1, 2, 3, 4, or 5 R.sup.f substituents
independently selected from C.sub.1-4 alkyl, C.sub.1-4 haloalkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.6-10 aryl, C.sub.3-10
cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-, C.sub.3-10
cycloalkyl-C.sub.1-4 alkyl-, (5-10 membered heteroaryl)-C.sub.1-4
alkyl-, (4-10 membered heterocycloalkyl)-C.sub.1-4 alkyl-, halo,
CN, NHOR.sup.g, OR.sup.g, SR.sup.g, C(O)R.sup.g,
C(O)NR.sup.gR.sup.g, C(O)OR.sup.g, OC(O)R.sup.g,
OC(O)NR.sup.gR.sup.g, NHR.sup.g, NR.sup.gR.sup.g,
NR.sup.gC(O)R.sup.g, NR.sup.gC(O)NR.sup.gR.sup.g,
NR.sup.gC(O)OR.sup.g, C(.dbd.NR.sup.g)NR.sup.gR.sup.g,
NR.sup.gC(.dbd.NR.sup.g)NR.sup.gR.sup.g, S(O)R.sup.g,
S(O)NR.sup.gR.sup.g, S(O).sub.2R.sup.g, NR.sup.gS(O).sub.2R.sup.g,
NR.sup.gS(O).sub.2NR.sup.gR.sup.g, and S(O).sub.2NR.sup.gR.sup.g;
wherein the C.sub.1-4 alkyl, C.sub.1-4 haloalkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.6-10 aryl, C.sub.3-10 cycloalkyl,
5-10 membered heteroaryl, 4-10 membered heterocycloalkyl,
C.sub.6-10 aryl-C.sub.1-4 alkyl-, C.sub.3-10 cycloalkyl-C.sub.1-4
alkyl-, (5-10 membered heteroaryl)-C.sub.1-4 alkyl-, and (4-10
membered heterocycloalkyl)-C.sub.1-4 alkyl- of R.sup.f are each
optionally substituted with 1, 2, 3, 4, or 5 R.sup.n substituents
independently selected from C.sub.1-4 alkyl, C.sub.1-4 haloalkyl,
halo, CN, R.sup.o, NHOR.sup.o, OR.sup.o, SR.sup.o, C(O)R.sup.o,
C(O)NR.sup.oR.sup.o, C(O)OR), OC(O)R.sup.o, OC(O)NR.sup.oR.sup.o,
NHR.sup.o, NR.sup.oR.sup.o, NR.sup.oC(O)R.sup.o,
NR.sup.oC(O)NR.sup.oR.sup.o, NR.sup.oC(O)OR.sup.o,
C(.dbd.NR.sup.o)NR.sup.oR.sup.o,
NR.sup.oC(.dbd.NR.sup.o)NR.sup.oR.sup.o, S(O)R.sup.o,
S(O)NR.sup.oR.sup.o, S(O).sub.2R.sup.o, NR.sup.oS(O).sub.2R.sup.o,
NR.sup.oS(O).sub.2NR.sup.oR.sup.o, and S(O).sub.2NR.sup.oR.sup.o;
each R.sup.g is independently selected from H, C.sub.1-6 alkyl,
C.sub.1-4 haloalkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.6-10 aryl, C.sub.3-10 cycloalkyl, 5-10 membered heteroaryl,
4-10 membered heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-,
C.sub.3-10 cycloalkyl-C.sub.1-4 alkyl-, (5-10 membered
heteroaryl)-C.sub.1-4 alkyl-, and (4-10 membered
heterocycloalkyl)-C.sub.1-4 alkyl-, wherein the C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.6-10 aryl, C.sub.3-10
cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-, C.sub.3-10
cycloalkyl-C.sub.1-4 alkyl-, (5-10 membered heteroaryl)-C.sub.1-4
alkyl- and (4-10 membered heterocycloalkyl)-C.sub.1-4 alkyl- of
R.sup.g are each optionally substituted with 1-3 independently
selected R.sup.p substituents; or any two R.sup.a substituents
together with the nitrogen atom to which they are attached form a
4-, 5-, 6-, 7-, 8-, 9- or 10-membered heterocycloalkyl group
optionally substituted with 1, 2 or 3 R.sup.h substituents
independently selected from C.sub.1-6 alkyl, C.sub.3-10 cycloalkyl,
4-7 membered heterocycloalkyl, C.sub.6-10 aryl, 5-6 membered
heteroaryl, C.sub.3-10 cycloalkyl-C.sub.1-4 alkyl-, (5-6 membered
heteroaryl)-C.sub.1-4 alkyl-, (4-7 membered
heterocycloalkyl)-C.sub.1-4 alkyl-, C.sub.1-6 haloalkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, halo, CN, OR.sup.i, SR.sup.i,
NHOR.sup.i, C(O)R.sup.i, C(O)NR.sup.iR.sup.i, C(O)OR.sup.i,
OC(O)R.sup.i, OC(O)NR.sup.iR.sup.i, NHR.sup.i, NR.sup.iR.sup.i,
NR.sup.iC(O)R.sup.i, NR.sup.iC(O)NR.sup.iR.sup.i,
NR.sup.iC(O)OR.sup.i, C(.dbd.NR.sup.i)NR.sup.iR.sup.i,
NR.sup.iC(.dbd.NR.sup.i)NR.sup.iR.sup.i, S(O)R.sup.i,
S(O)NR.sup.iR.sup.i, S(O).sub.2R.sup.i, NR.sup.iS(O).sub.2R.sup.i,
NR.sup.iS(O).sub.2NR.sup.iR.sup.i, and S(O).sub.2NR.sup.iR.sup.i,
wherein the C.sub.1-6 alkyl, C.sub.3-10 cycloalkyl, 4-7 membered
heterocycloalkyl, C.sub.6-10 aryl, 5-6 membered heteroaryl,
C.sub.3-10 cycloalkyl-C.sub.1-4 alkyl-, (5-6 membered
heteroaryl)-C.sub.1-4 alkyl-, and (4-7 membered
heterocycloalkyl)-C.sub.1-4 alkyl- of R.sup.h are each further
optionally substituted by 1, 2, or 3 R.sup.j substituents
independently selected from C.sub.3-6 cycloalkyl, C.sub.6-10 aryl,
5 or 6-membered heteroaryl, C.sub.2-4 alkenyl, C.sub.2-4 alkynyl,
halo, C.sub.1-4 alkyl, C.sub.1-4 haloalkyl, CN, NHOR.sup.k,
OR.sup.k, SR.sup.k, C(O)R.sup.k, C(O)NR.sup.kR.sup.k, C(O)OR.sup.k,
OC(O)R.sup.k, OC(O)NR.sup.kR.sup.k, NHR.sup.k, NR.sup.kR.sup.k,
NR.sup.kC(O)R.sup.k, NR.sup.kC(O)NR.sup.kR.sup.k,
NR.sup.kC(O)OR.sup.k, C(.dbd.NR.sup.k)NR.sup.kR.sup.k,
NR.sup.kC(.dbd.NR.sup.k)NR.sup.kR.sup.k, S(O)R.sup.k,
S(O)NR.sup.kR.sup.k, S(O).sub.2R.sup.k, NR.sup.kS(O).sub.2R.sup.k,
NR.sup.kS(O).sub.2NR.sup.kR.sup.k, and S(O).sub.2NR.sup.kR.sup.k;
or two R.sup.h groups attached to the same carbon atom of the 4- to
10-membered heterocycloalkyl taken together with the carbon atom to
which they attach form a C.sub.3-6 cycloalkyl or 4- to 6-membered
heterocycloalkyl having 1-2 heteroatoms as ring members selected
from O, N and S; or any two R.sup.c substituents together with the
nitrogen atom to which they are attached form a 4-, 5-, 6-, or
7-membered heterocycloalkyl group optionally substituted with 1, 2,
or 3 independently selected R.sup.h substituents; or any two
R.sup.e substituents together with the nitrogen atom to which they
are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl
group optionally substituted with 1, 2, or 3 independently selected
R.sup.h substituents; or any two R.sup.g substituents together with
the nitrogen atom to which they are attached form a 4-, 5-, 6-, or
7-membered heterocycloalkyl group optionally substituted with 1, 2,
or 3 independently selected R.sup.h substituents; or any two
R.sup.i substituents together with the nitrogen atom to which they
are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl
group optionally substituted with 1, 2, or 3 independently selected
R.sup.h substituents; or any two R.sup.k substituents together with
the nitrogen atom to which they are attached form a 4-, 5-, 6-, or
7-membered heterocycloalkyl group optionally substituted with 1, 2,
or 3 independently selected R.sup.h substituents; or any two
R.sup.o substituents together with the nitrogen atom to which they
are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl
group optionally substituted with 1, 2, or 3 independently selected
R.sup.h substituents; each R.sup.e, R.sup.i, R.sup.k, R.sup.o or
R.sup.p is independently selected from H, C.sub.1-4 alkyl, C
.sub.3-6 cycloalkyl, 10 aryl, 5 or 6-membered heteroaryl, C.sub.1-4
haloalkyl, C.sub.2-4 alkenyl, and C.sub.2-4 alkynyl, wherein the
C.sub.1-4 alkyl, C.sub.3-6 cycloalkyl, C.sub.6-10 aryl, 5 or
6-membered heteroaryl, C.sub.2-4 alkenyl, and C.sub.2-4 alkynyl of
R.sup.e, R.sup.i, R.sup.k, R.sup.o or R.sup.p are each optionally
substituted with 1, 2 or 3 R.sup.q substituents; each R.sup.q is
independently selected from OH, CN, --COOH, NH.sub.2, halo,
C.sub.1-4 alkyl, C.sub.1-4 alkoxy, C.sub.1-4 alkylthio, phenyl, 5-6
membered heteroaryl, C.sub.3-6 cycloalkyl, NHR.sup.12,
NR.sup.12R.sup.12, and C.sub.1-4 haloalkoxy, wherein the C.sub.1-4
alkyl, phenyl and 5-6 membered heteroaryl of R.sup.q are each
optionally substituted with OH, CN, --COOH, NH.sub.2, C.sub.1-4
alkoxy, C.sub.3-10 cycloalkyl and 4-6 membered heterocycloalkyl and
each R.sup.12 is independently C.sub.1-6 alkyl; is a single bond or
a double bond to maintain ring A being aromatic; and when the
moiety ##STR00137## in Formula (I') is 2-benzoxazolyl substituted
with 1 to 3 substituents independently selected from methyl, ethyl,
isopropyl, methoxy, Cl, Br, and phenyl, Cy is not
4H-1,2,4-triazol-4-yl, 5-methyl-2-benzoxazolyl or 2-oxopyrrolidinyl
substituted with --COOH, --C(O)NH.sub.2, --C(O)OC.sub.1-2 alkyl or
--C(O)Cl.
3. The compound of claim 1, or a pharmaceutically acceptable salt
or a stereoisomer thereof, wherein Cy is phenyl optionally
substituted with 1, 2, 3, 4 or 5 substituents.
4. The compound of any one of claims 1-3, having Formula (I):
##STR00138## or a pharmaceutically acceptable salt or a
stereoisomer thereof, wherein: one of X.sup.1 and X.sup.2 is O or S
and the other of X.sup.1 and X.sup.2 is N, CR.sup.1 or CR.sup.2;
X.sup.3 is N or CR.sup.3; X.sup.4 is N or CR.sup.4; X.sup.5 is N or
CR.sup.5; X.sup.6 is N or CR.sup.6; at least one of X.sup.1,
X.sup.2, X.sup.3, X.sup.4, X.sup.5 and X.sup.6 is N; R.sup.1,
R.sup.2 and R.sup.8 are each independently selected from H,
C.sub.1-4 alkyl, C.sub.3-6 cycloalkyl, C.sub.2-4 alkenyl, C.sub.2-4
alkynyl, halo, CN, OH, C.sub.1-4 alkoxy, C.sub.1-4 haloalkyl,
C.sub.1-4 haloalkoxy, NH.sub.2, --NH--C.sub.1-4 alkyl,
--N(C.sub.1-4 alkyl).sub.2, NHOR.sup.10, C(O)R.sup.10,
C(O)NR.sup.10R.sup.10, C(O)OR.sup.10, OC(O)R.sup.10,
OC(O)NR.sup.10R.sup.10, NR.sup.10C(O)R.sup.10,
NR.sup.10C(O)OR.sup.10, NR.sup.10C(O)NR.sup.10R.sup.10,
C(.dbd.NR.sup.10)R.sup.10, C(.dbd.NR.sup.10)NR.sup.10R.sup.10,
NR.sup.10C(.dbd.NR.sup.10)NR.sup.10R.sup.10, NR.sup.10S(O)R.sup.10,
NR.sup.10S(O).sub.2R.sup.10, NR.sup.10S(O).sub.2NR.sup.10R.sup.10,
S(O)R.sup.10, S(O)NR.sup.10R.sup.10, S(O).sub.2R.sup.10, and
S(O).sub.2NR.sup.10R.sup.10, wherein each R.sup.10 is independently
H or C.sub.1-4 alkyl optionally substituted with 1 or 2 groups
independently selected from halo, OH, CN and C.sub.1-4 alkoxy and
wherein the C.sub.1-4 alkyl, C.sub.3-4 cycloalkyl, C.sub.2-4
alkenyl and C.sub.2-4 alkynyl of R.sup.1, R.sup.2 or R.sup.8 are
each optionally substituted with 1 or 2 substituents independently
selected from halo, OH, CN, C.sub.1-4 alkyl and C.sub.1-4 alkoxy;
R.sup.9 is C.sub.1-4 alkyl, Cl, Br, CN, cyclopropyl, C.sub.2-4
alkynyl, C.sub.1-4 haloalkyl, C.sub.1-4 haloalkoxy, NH.sub.2,
--NH--C.sub.1-4 alkyl, --N(C.sub.1-4 alkyl).sub.2, NHOR.sup.11,
C(O)R.sup.11, C(O)NR.sup.11R.sup.11, C(O)OR.sup.11, OC(O)R.sup.11,
OC(O)NR.sup.11R.sup.11, NR.sup.11C(O)R.sup.11,
NR.sup.11C(O)OR.sup.11, NR.sup.11C(O)NR.sup.11R.sup.11,
C(.dbd.NR.sup.11)R.sup.11, C(.dbd.NR.sup.11)NR.sup.11R.sup.11,
NR.sup.11C(.dbd.NR.sup.11)NR.sup.11R.sup.11, NR.sup.11S(O)R.sup.11,
NR.sup.11S(O).sub.2R.sup.11, NR.sup.11S(O).sub.2NR.sup.11R.sup.11,
S(O)R.sup.11, S(O)NR.sup.11R.sup.11, S(O).sub.2R.sup.11, and
S(O).sub.2NR.sup.11R.sup.11, wherein each R.sup.11 is independently
H or C.sub.1-4 alkyl optionally substituted with 1 or 2 halo, OH,
CN or OCH.sub.3; R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 are
each independently selected from H, halo, C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl,
C.sub.1-6 haloalkoxy, C.sub.6-10 aryl, C.sub.3-10 cycloalkyl, 5-14
membered heteroaryl, 4-10 membered heterocycloalkyl, C.sub.6-10
aryl-C.sub.1-4 alkyl-, C.sub.3-10 cycloalkyl-C.sub.1-4 alkyl-,
(5-14 membered heteroaryl)-C.sub.1-4 alkyl-, (4-10 membered
heterocycloalkyl)-C.sub.1-4 alkyl-, CN, NO.sub.2, OR.sup.a,
SR.sup.a, NHOR.sup.a, C(O)R.sup.a, C(O)NR.sup.aR.sup.a,
C(O)OR.sup.a, OC(O)R.sup.a, OC(O)NR.sup.aR.sup.a, NHR.sup.a,
NR.sup.aR.sup.a, NR.sup.aC(O)R.sup.a, NR.sup.aC(O)OR.sup.a,
NR.sup.aC(O)NR.sup.aR.sup.a, C(.dbd.NR.sup.a)R.sup.a,
C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
NR.sup.aC(.dbd.NR.sup.a)NR.sup.aR.sup.a, NR.sup.aS(O)R.sup.a,
NR.sup.aS(O).sub.2R.sup.a, NR.sup.aS(O).sub.2NR.sup.aR.sup.a,
S(O)R.sup.a, S(O)NR.sup.aR.sup.a, S(O).sub.2R.sup.a, and
S(O).sub.2NR.sup.aR.sup.a, wherein the C.sub.1-6 alkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.6-10 aryl, C.sub.3-10 cycloalkyl,
5-14 membered heteroaryl, 4-10 membered heterocycloalkyl,
C.sub.6-10 aryl-C.sub.1-4 alkyl-, C.sub.3-10 cycloalkyl-C.sub.1-4
alkyl-, (5-14 membered heteroaryl)-C.sub.1-4 alkyl-, and (4-10
membered heterocycloalkyl)-C.sub.1-4 alkyl- of R.sup.3, R.sup.4,
R.sup.5, R.sup.6 and R.sup.7 are each optionally substituted with
1, 2, 3, or 4 R.sup.b substituents, with the proviso that at least
one of R.sup.3, R.sup.4, R.sup.5 and R.sup.6 is other than H; or
two adjacent R.sup.7 substituents on the phenyl ring, taken
together with the carbon atoms to which they are attached, form a
fused phenyl ring, a fused 5- to 7-membered heterocycloalkyl ring,
a fused 5- or 6-membered heteroaryl ring or a fused C.sub.5-6
cycloalkyl ring, wherein the fused 5- to 7-membered
heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring
each have 1-4 heteroatoms as ring members selected from N, O and S
and wherein the fused phenyl ring, fused 5- to 7-membered
heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and
fused C.sub.5-6 cycloalkyl ring are each optionally substituted
with 1 or 2 independently selected R.sup.q substituents; each
R.sup.a is independently selected from H, CN, C.sub.1-6 alkyl,
C.sub.1-4 haloalkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.6-10 aryl, C.sub.3-10 cycloalkyl, 5-10 membered heteroaryl,
4-10 membered heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-,
C.sub.3-10 cycloalkyl-C.sub.1-4 alkyl-, (5-10 membered
heteroaryl)-C.sub.1-4 alkyl-, and (4-10 membered
heterocycloalkyl)-C.sub.1-4 alkyl-, wherein the C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.6-10 aryl, C.sub.3-10
cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-, C.sub.3-10
cycloalkyl-C.sub.1-4 alkyl-, (5-10 membered heteroaryl)-C.sub.1-4
alkyl- and (4-10 membered heterocycloalkyl)-C.sub.1-4 alkyl- of
R.sup.a are each optionally substituted with 1, 2, 3, 4, or 5
R.sup.d substituents; each R.sup.d is independently selected from
C.sub.1-4 alkyl, C.sub.1-4 haloalkyl, halo, C.sub.3-10 cycloalkyl,
4-10 membered heterocycloalkyl, CN, NH.sub.2, NHOR.sup.e, OR.sup.e,
SR.sup.e, C(O)R.sup.e, C(O)NR.sup.eR.sup.e, C(O)OR.sup.e,
OC(O)R.sup.e, OC(O)NR.sup.eR.sup.e, NHR.sup.e, NR.sup.eR.sup.e,
NR.sup.eC(O)R.sup.e, NR.sup.eC(O)NR.sup.eR.sup.e,
NR.sup.eC(O)OR.sup.e, C(.dbd.NR.sup.e)NR.sup.eR.sup.e,
NR.sup.eC(.dbd.NR.sup.e)NR.sup.eR.sup.e, S(O)R.sup.e,
S(O)NR.sup.eR.sup.e, S(O).sub.2R.sup.e, NR.sup.eS(O).sub.2R.sup.e,
NR.sup.eS(O).sub.2NR.sup.eR.sup.e, and S(O).sub.2NR.sup.eR.sup.e,
wherein the C.sub.1-4 alkyl, C.sub.3-10 cycloalkyl and 4-10
membered heterocycloalkyl of R.sup.d are each further optionally
substituted with 1-3 independently selected R.sup.q substituents;
each R.sup.b substituent is independently selected from halo,
C.sub.1-4 alkyl, C.sub.1-4 haloalkyl, C.sub.1-4 haloalkoxy,
C.sub.6-10 aryl, C.sub.3-10 cycloalkyl, 5-10 membered heteroaryl,
4-10 membered heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-,
C.sub.3-10 cycloalkyl-C.sub.1-4 alkyl-, (5-10 membered
heteroaryl)-C.sub.1-4 alkyl-, (4-10 membered
heterocycloalkyl)-C.sub.1-4 alkyl-, CN, OH, NH.sub.2, NO.sub.2,
NHOR.sup.c, OR.sup.c, SR.sup.c, C(O)R.sup.c, C(O)NR.sup.cR.sup.c,
C(O)OR.sup.c, OC(O)R.sup.c, OC(O)NR.sup.cR.sup.c,
C(.dbd.NR.sup.c)NR.sup.cR.sup.c,
NR.sup.cC(.dbd.NR.sup.c)NR.sup.cR.sup.c, NHR.sup.c,
NR.sup.cR.sup.c, NR.sup.cC(O)R.sup.c, NR.sup.cC(O)OR.sup.c,
NR.sup.cC(O)NR.sup.cR.sup.c, NR.sup.cS(O)R.sup.c,
NR.sup.cS(O).sub.2R.sup.c, NR.sup.cS(O).sub.2NR.sup.cR.sup.c,
S(O)R.sup.c, S(O)NR.sup.cR.sup.c, S(O).sub.2R.sup.c and
S(O).sub.2NR.sup.cR.sup.c; wherein the C.sub.1-4 alkyl, C.sub.1-4
haloalkyl, C.sub.1-4 haloalkoxy, C.sub.6-10 aryl, C.sub.3-10
cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-, C.sub.3-10
cycloalkyl-C.sub.1-4 alkyl-, (5-10 membered heteroaryl)-C.sub.1-4
alkyl- and (4-10 membered heterocycloalkyl)-C.sub.1-4 alkyl- of
R.sup.b are each further optionally substituted with 1-3
independently selected R.sup.d substituents; each R.sup.c is
independently selected from H, C.sub.1-6 alkyl, C.sub.1-4
haloalkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.6-10 aryl,
C.sub.3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-, C.sub.3-10
cycloalkyl-C.sub.1-4 alkyl-, (5-10 membered heteroaryl)-C.sub.1-4
alkyl-, and (4-10 membered heterocycloalkyl)-C.sub.1-4 alkyl-,
wherein the C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.6-10 aryl, C.sub.3-10 cycloalkyl, 5-10 membered heteroaryl,
4-10 membered heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-,
C.sub.3-10 cycloalkyl-C.sub.1-4 alkyl-, (5-10 membered
heteroaryl)-C.sub.1-4 alkyl- and (4-10 membered
heterocycloalkyl)-C.sub.1-4 alkyl- of R.sup.c are each optionally
substituted with 1, 2, 3, 4, or 5 R.sup.f substituents
independently selected from C.sub.1-4 alkyl, C.sub.1-4 haloalkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.6-10 aryl, C.sub.3-10
cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-, C.sub.3-10
cycloalkyl-C.sub.1-4 alkyl-, (5-10 membered heteroaryl)-C.sub.1-4
alkyl-, (4-10 membered heterocycloalkyl)-C.sub.1-4 alkyl-, halo,
CN, NHOR.sup.g, OR.sup.g, SR.sup.g, C(O)R.sup.g,
C(O)NR.sup.gR.sup.g, C(O)OR.sup.g, OC(O)R.sup.g,
OC(O)NR.sup.gR.sup.g, NHR.sup.g, NR.sup.gR.sup.g,
NR.sup.gC(O)R.sup.g, NR.sup.gC(O)NR.sup.gR.sup.g,
NR.sup.gC(O)OR.sup.g, C(.dbd.NR.sup.g)NR.sup.gR.sup.g,
NR.sup.gC(.dbd.NR.sup.g)NR.sup.gR.sup.g, S(O)R.sup.g,
S(O)NR.sup.gR.sup.g, S(O).sub.2R.sup.g, NR.sup.gS(O).sub.2R.sup.g,
NR.sup.gS(O).sub.2NR.sup.gR.sup.g, and S(O).sub.2NR.sup.gR.sup.g;
wherein the C.sub.1-4 alkyl, C.sub.1-4 haloalkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.6-10 aryl, C.sub.3-10 cycloalkyl,
5-10 membered heteroaryl, 4-10 membered heterocycloalkyl,
C.sub.6-10 aryl-C.sub.1-4 alkyl-, C.sub.3-10 cycloalkyl-C.sub.1-4
alkyl-, (5-10 membered heteroaryl)-C.sub.1-4 alkyl-, and (4-10
membered heterocycloalkyl)-C.sub.1-4 alkyl- of R.sup.f are each
optionally substituted with 1, 2, 3, 4, or 5 R.sup.n substituents
independently selected from C.sub.1-4 alkyl, C.sub.1-4 haloalkyl,
halo, CN, R.sup.o, NHOR.sup.o, OR.sup.o, SR.sup.o, C(O)R.sup.o,
C(O)NR.sup.oR.sup.o, C(O)OR.sup.o, OC(O)R.sup.o,
OC(O)NR.sup.oR.sup.o, NHR.sup.o, NR.sup.oR.sup.o,
NR.sup.oC(O)R.sup.o, NR.sup.oC(O)NR.sup.oR.sup.o,
NR.sup.oC(O)OR.sup.o, C(.dbd.NR.sup.o)NR.sup.oR.sup.o,
NR.sup.oC(.dbd.NR.sup.o)NR.sup.oR.sup.o, S(O)R.sup.o,
S(O)NR.sup.oR.sup.o, S(O).sub.2R.sup.o, NR.sup.oS(O).sub.2R.sup.o,
NR.sup.oS(O).sub.2NR.sup.oR.sup.o, and S(O).sub.2NR.sup.oR.sup.o;
each R.sup.g is independently selected from H, C.sub.1-6 alkyl,
C.sub.1-4 haloalkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.6-10 aryl, C.sub.3-10 cycloalkyl, 5-10 membered heteroaryl,
4-10 membered heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-,
C.sub.3-10 cycloalkyl-C.sub.1-4 alkyl-, (5-10 membered
heteroaryl)-C.sub.1-4 alkyl-, and (4-10 membered
heterocycloalkyl)-C.sub.1-4 alkyl-, wherein the C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.6-10 aryl, C.sub.3-10
cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-, C.sub.3-10
cycloalkyl-C.sub.1-4 alkyl-, (5-10 membered heteroaryl)-C.sub.1-4
alkyl- and (4-10 membered heterocycloalkyl)-C.sub.1-4 alkyl- of
R.sup.g are each optionally substituted with 1-3 independently
selected R.sup.p substituents; or any two R.sup.a substituents
together with the nitrogen atom to which they are attached form a
4-, 5-, 6-, 7-, 8-, 9- or 10-membered heterocycloalkyl group
optionally substituted with 1, 2 or 3 R.sup.h substituents
independently selected from C.sub.1-6 alkyl, C.sub.3-10 cycloalkyl,
4-7 membered heterocycloalkyl, C.sub.6-10 aryl, 5-6 membered
heteroaryl, C.sub.3-10 cycloalkyl-C.sub.1-4 alkyl-, (5-6 membered
heteroaryl)-C.sub.1-4 alkyl-, (4-7 membered
heterocycloalkyl)-C.sub.1-4 alkyl-, C.sub.1-6 haloalkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, halo, CN, SR.sup.i, NHOR.sup.i,
C(O)R.sup.i, C(O)NR.sup.iR.sup.i, C(O)OR.sup.i, OC(O)R.sup.i,
OC(O)NR.sup.iR.sup.i, NHR.sup.i, NR.sup.iR.sup.i,
NR.sup.iC(O)R.sup.i, NR.sup.iC(O)NR.sup.iR.sup.i,
NR.sup.iC(O)OR.sup.i, C(.dbd.NR.sup.i)NR.sup.iR.sup.i,
NR.sup.iC(.dbd.NR.sup.i)NR.sup.iR.sup.i, S(O)R.sup.i,
S(O)NR.sup.iR.sup.i, S(O).sub.2R.sup.i, NR.sup.iS(O).sub.2R.sup.i,
NR.sup.iS(O).sub.2NR.sup.iR.sup.iR.sup.i, and
S(O).sub.2NR.sup.iR.sup.i, wherein the C.sub.1-6 alkyl, C.sub.3-10
cycloalkyl, 4-7 membered heterocycloalkyl, C.sub.6-10 aryl, 5-6
membered heteroaryl, C.sub.3-10 cycloalkyl-C.sub.1-4 alkyl-, (5-6
membered heteroaryl)-C.sub.1-4 alkyl-, and (4-7 membered
heterocycloalkyl)-C.sub.1-4 alkyl- of R.sup.h are each further
optionally substituted by 1, 2, or 3 R.sup.j substituents
independently selected from C.sub.3-6 cycloalkyl, C.sub.6-10 aryl,
5 or 6-membered heteroaryl, C.sub.2-4 alkenyl, C.sub.2-4 alkynyl,
halo, C.sub.1-4 alkyl, C.sub.1-4 haloalkyl, CN, NHOR.sup.k,
OR.sup.k, SR.sup.k, C(O)R.sup.k, C(O)NR.sup.kR.sup.k, C(O)OR.sup.k,
OC(O)R.sup.k, OC(O)NR.sup.kR.sup.k, NHR.sup.k, NR.sup.kR.sup.k,
NR.sup.kC(O)R.sup.k, NR.sup.kC(O)NR.sup.kR.sup.k,
NR.sup.kC(O)OR.sup.k, C(.dbd.NR.sup.k)NR.sup.kR.sup.k,
NR.sup.kC(.dbd.NR.sup.k)NR.sup.kR.sup.k, S(O)R.sup.k,
S(O)NR.sup.kR.sup.k, S(O).sub.2R.sup.k, NR.sup.kS(O).sub.2R.sup.k,
NR.sup.kS(O).sub.2NR.sup.kR.sup.k, and S(O).sub.2NR.sup.kR.sup.k;
or two R.sup.h groups attached to the same carbon atom of the 4- to
10-membered heterocycloalkyl taken together with the carbon atom to
which they attach form a C.sub.3-6 cycloalkyl or 4- to 6-membered
heterocycloalkyl having 1-2 heteroatoms as ring members selected
from O, N and S; or any two R.sup.c substituents together with the
nitrogen atom to which they are attached form a 4-, 5-, 6-, or
7-membered heterocycloalkyl group optionally substituted with 1, 2,
or 3 independently selected R.sup.h substituents; or any two
R.sup.e substituents together with the nitrogen atom to which they
are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl
group optionally substituted with 1, 2, or 3 independently selected
R.sup.h substituents; or any two R.sup.g substituents together with
the nitrogen atom to which they are attached form a 4-, 5-, 6-, or
7-membered heterocycloalkyl group optionally substituted with 1, 2,
or 3 independently selected R.sup.h substituents; or any two
R.sup.i substituents together with the nitrogen atom to which they
are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl
group optionally substituted with 1, 2, or 3 independently selected
R.sup.h substituents; or any two R.sup.k substituents together with
the nitrogen atom to which they are attached form a 4-, 5-, 6-, or
7-membered heterocycloalkyl group optionally substituted with 1, 2,
or 3 independently selected R.sup.h substituents; or any two
R.sup.o substituents together with the nitrogen atom to which they
are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl
group optionally substituted with 1, 2, or 3 independently selected
R.sup.h substituents; and each R.sup.e, R.sup.i, R.sup.k, R.sup.o
or R.sup.p is independently selected from H, C.sub.1-4 alkyl,
C.sub.3-6 cycloalkyl, C.sub.6-10 aryl, 5 or 6-membered heteroaryl,
C.sub.1-4 haloalkyl, C.sub.2-4 alkenyl, and C.sub.2-4 alkynyl,
wherein the C.sub.1-4 alkyl, C.sub.3-6 cycloalkyl, C.sub.6-10 aryl,
5 or 6-membered heteroaryl, C.sub.2-4 alkenyl, and C.sub.2-4
alkynyl of R.sup.e, R.sup.i, R.sup.k, R.sup.o or R.sup.p are each
optionally substituted with 1, 2 or 3 R
.sup.q substituents; each R.sup.q is independently selected from
OH, CN, --COOH, NH.sub.2, halo, C.sub.1-4 alkyl, C.sub.1-4 alkoxy,
C.sub.1-4 alkylthio, phenyl, 5-6 membered heteroaryl, C.sub.3-6
cycloalkyl, NHR.sup.12, NR.sup.12R.sup.12, and C.sub.1-4
haloalkoxy, wherein the C.sub.1-4 alkyl, phenyl and 5-6 membered
heteroaryl of R.sup.q are each optionally substituted with OH, CN,
--COOH, NH.sub.2, C.sub.1-4 alkoxy, C.sub.3-10 cycloalkyl and 4-6
membered heterocycloalkyl and each R.sup.12 is independently
C.sub.1-6 alkyl; is a single bond or a double bond to maintain ring
A being aromatic; the subscript n is an integer of 1, 2, 3, 4 or 5;
and the subscript m is an integer of 1, 2 or 3.
5. The compound of any one of claims 1-4, having Formula (II):
##STR00139## wherein R.sup.4 is halo, C.sub.1-6 alkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl, C.sub.1-6
haloalkoxy, C.sub.6-10 aryl, C.sub.3-10 cycloalkyl, 5-14 membered
heteroaryl, 4-10 membered heterocycloalkyl, C.sub.6-10
aryl-C.sub.1-4 alkyl-, C.sub.3-10 cycloalkyl-C.sub.1-4 alkyl-,
(5-14 membered heteroaryl)-C.sub.1-4 alkyl-, (4-10 membered
heterocycloalkyl)-C.sub.1-4 alkyl-, CN, NO.sub.2, OR.sup.a,
SR.sup.a, NHOR.sup.a, C(O)R.sup.a, C(O)NR.sup.aR.sup.a,
C(O)OR.sup.a, OC(O)R.sup.a, OC(O)NR.sup.aR.sup.a, NHR.sup.a,
NR.sup.aR.sup.a, NR.sup.aC(O)R.sup.a, NR.sup.aC(O)OR.sup.a,
NR.sup.aC(O)NR.sup.aR.sup.a, C(.dbd.NR.sup.a)R.sup.a,
C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
NR.sup.aC(.dbd.NR.sup.a)NR.sup.aR.sup.a, NR.sup.aS(O)R.sup.a,
NR.sup.aS(O).sub.2R.sup.a, NR.sup.aS(O).sub.2NR.sup.aR.sup.a,
S(O)R.sup.a, S(O)NR.sup.aR.sup.a, S(O).sub.2R.sup.a, and
S(O).sub.2NR.sup.aR.sup.a, wherein the C.sub.1-6 alkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.6-10 aryl, C.sub.3-10 cycloalkyl,
5-14 membered heteroaryl, 4-10 membered heterocycloalkyl,
C.sub.6-10 aryl-C.sub.1-4 alkyl-, C.sub.3-10 cycloalkyl-C.sub.1-4
alkyl-, (5-14 membered heteroaryl)-C.sub.1-4 alkyl-, and (4-10
membered heterocycloalkyl)-C.sub.1-4 alkyl- of R.sup.1 are each
optionally substituted with 1, 2, 3, or 4 R.sup.b substituents, or
a pharmaceutically acceptable salt or a stereoisomer thereof.
6. The compound of any one of claims 1-5, having Formula (III):
##STR00140## or a pharmaceutically acceptable salt or a
stereoisomer thereof.
7. The compound of any one of claims 1-6, having Formula (IV):
##STR00141## or a pharmaceutically acceptable salt or a
stereoisomer thereof.
8. The compound of any one of claims 1-5, having Formula (V):
##STR00142## or a pharmaceutically acceptable salt or a
stereoisomer thereof.
9. The compound of any one of claims 1-5, having Formula (VI):
##STR00143## or a pharmaceutically acceptable salt or a
stereoisomer thereof.
10. The compound of any one of claims 1-5, having Formula (VII):
##STR00144## or a pharmaceutically acceptable salt or a
stereoisomer thereof.
11. The compound of any one of claims 1-5, having Formula (VIII):
##STR00145## or a pharmaceutically acceptable salt or a
stereoisomer thereof.
12. The compound of any one of claims 1-5, having Formula (IX):
##STR00146## or a pharmaceutically acceptable salt or a
stereoisomer thereof, wherein R.sup.9 is CH.sub.3 or CN.
13. The compound of any one of claims 1-9, or a pharmaceutically
acceptable salt or a stereoisomer thereof, wherein the the moiety:
##STR00147## is selected from: ##STR00148##
14. The compound of any one of claims 1-13, or a pharmaceutically
acceptable salt or a stereoisomer thereof, wherein R.sup.1,
R.sup.2, R.sup.3 and R.sup.5, when present, are each H.
15. The compound of any one of claims 1-14, or a pharmaceutically
acceptable salt or stereoisomer thereof, wherein R.sup.3 and
R.sup.5 are each H.
16. The compound of any one of claims 1-15, or a pharmaceutically
acceptable salt or stereoisomer thereof, wherein R.sup.4 and
R.sup.6 are each H.
17. The compound of any one of claims 1-9, or a pharmaceutically
acceptable salt or a stereoisomer thereof, wherein X.sup.1 is CH,
X.sup.2 is O, X.sup.3 is N and X.sup.5 and X.sup.6 are each CH.
18. The compound of any one of claims 1-9, or a pharmaceutically
acceptable salt or a stereoisomer thereof, wherein X.sup.1 is O,
X.sup.2 is CH, X.sup.3 is N, X.sup.5 is CH and X.sup.6 is
CR.sup.6.
19. The compound of any one of claims 1-9, or a pharmaceutically
acceptable salt or a stereoisomer thereof, wherein X.sup.1 is O,
X.sup.2 is CH, X.sup.3 is CH, X.sup.5 is N and X.sup.6 is
CR.sup.6.
20. The compound of any one of claims 1-9, or a pharmaceutically
acceptable salt or a stereoisomer thereof, wherein X.sup.1 is O,
X.sup.2 is N, X.sup.3 is CH, X.sup.5 is CH and X.sup.6 is
CR.sup.6.
21. The compound of any one of claims 1-9, or a pharmaceutically
acceptable salt or a stereoisomer thereof, wherein X.sup.1 is O,
X.sup.2 is CH, X.sup.3 is CH, X.sup.5 is CH and X.sup.6 is N.
22. The compound of any one of claims 1-9, or a pharmaceutically
acceptable salt or a stereoisomer thereof, wherein X.sup.1 is S,
X.sup.2 is N, X.sup.3 is CH, X.sup.5 is CH and X.sup.6 is
CR.sup.6.
23. The compound of any one of claims 1-9, or a pharmaceutically
acceptable salt or a stereoisomer thereof, wherein X.sup.1 is N,
X.sup.2 is S, X.sup.3 is CH, X.sup.5 is CH and X.sup.6 is
CR.sup.6.
24. The compound of any one of claims 1-9, or a pharmaceutically
acceptable salt or a stereoisomer thereof, wherein X.sup.1 is O,
X.sup.2 is CH, X.sup.3 is CH, X.sup.5 is CH and X.sup.6 is N.
25. The compound of any one of claims 1-9, or a pharmaceutically
acceptable salt or a stereoisomer thereof, wherein X.sup.1 is O,
X.sup.2 is N, X.sup.3 is CH and X.sup.6 is CR.sup.6.
26. The compound of any one of claims 1-9, or a pharmaceutically
acceptable salt or a stereoisomer thereof, wherein X.sup.2 is O,
X.sup.1 is N, X.sup.3 is CH and X.sup.6 is CR.sup.6.
27. The compound of any one of claims 1-9, or a pharmaceutically
acceptable salt or a stereoisomer thereof, wherein X.sup.1 is O,
X.sup.2 is N, X.sup.3 is CH, X.sup.5 is N and X.sup.6 is
CR.sup.6.
28. The compound of any one of claims 1-9, or a pharmaceutically
acceptable salt or a stereoisomer thereof, wherein X.sup.1 is O or
S and X.sup.2 is N or CR.sup.2.
29. The compound of any one of claims 1-9, or a pharmaceutically
acceptable salt or a stereoisomer thereof, wherein X.sup.2 is O or
S and X.sup.1 is N or CR.sup.1.
30. The compound of any one of claims 1-15 and 17-29, or a
pharmaceutically acceptable salt or a stereoisomer thereof, wherein
R.sup.4 is --CH.sub.2--R.sup.h.
31. The compound of any one of claims 1-13, 16, and 25-29, or a
pharmaceutically acceptable salt or a stereoisomer thereof, wherein
R.sup.5 is --CH.sub.2--R.sup.h.
32. The compound of claim 30 or 31, or a pharmaceutically
acceptable salt or a stereoisomer thereof, wherein R.sup.h is
--NHR.sup.c.
33. The compound of claim 32, or a pharmaceutically acceptable salt
or a stereoisomer thereof, wherein R.sup.c is C.sub.1-4 alkyl
optionally substituted with a R.sup.d substituent.
34. The compound of any one of claims 1-15 and 17-33, or a
pharmaceutically acceptable salt or a stereoisomer thereof, wherein
R.sup.4 is 2-hydroxyethylaminomethyl.
35. The compound of claim 30 or 31, or a pharmaceutically
acceptable salt or a stereoisomer thereof, wherein R.sup.b is
--NR.sup.cR.sup.c.
36. The compound of claim 35, or a pharmaceutically acceptable salt
or a stereoisomer thereof, wherein two R.sup.c substituents
together with the nitrogen atom to which they are attached form a
4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally
substituted with 1, 2, or 3 independently selected R.sup.h
substituents.
37. The compound of claim 36, or a pharmaceutically acceptable salt
or a stereoisomer thereof, wherein two R.sup.c substituents
together with the nitrogen atom to which they are attached form a
6-membered heterocycloalkyl substituted with 1 R.sup.h
substituent.
38. The compound of any one of claims 1-15 and 17-31, or a
pharmaceutically acceptable salt or a stereoisomer thereof, wherein
R.sup.4 is 2-hydroxyethylaminomethyl,
2-carboxypiperidin-1-ylmethyl, (S)-2-carboxypiperidin-1-ylmethyl or
(R)-2-carboxypiperidin-1-ylmethyl.
39. The compound of any one of claims 1-13 and 25-29 or a
pharmaceutically acceptable salt or a stereoisomer thereof, wherein
R.sup.4 and R.sup.5 are each independently selected from
2-hydroxyethylaminomethyl, 2-carboxypiperidin-1-ylmethyl,
(S)-2-carboxypiperidin-1-ylmethyl,
(R)-2-carboxypiperidin-1-ylmethyl, (3-cyanophenyl)methoxy,
cyanomethoxy, 2-cyanoethoxy, 3-cyanopropoxy,
2-morpholino-4-ylethoxy and pyridin-2-ylmethoxy.
40. The compound of any one of claims 1-4, wherein the compound is
selected from:
2-({[2-(2-methylbiphenyl-3-yl)furo[2,3-b]pyridin-6-yl]methyl}amino)ethano-
l;
(2S)-1-{[2-(2-methylbiphenyl-3-yl)furo[2,3-b]pyridin-6-yl]methyl}piperi-
dine-2-carboxylic acid;
2-({[7-methyl-2-(2-methylbiphenyl-3-yl)furo[3,2-b]pyridin-5-yl]methyl}ami-
no)ethanol;
(2S)-1-{[7-methyl-2-(2-methylbiphenyl-3-yl)furo[3,2-b]pyridin-5-yl]methyl-
}piperidine-2-carboxylic acid;
2-({[7-methyl-2-(2-methylbiphenyl-3-yl)furo[2,3-c]pyridin-5-yl]methyl}ami-
no)ethanol;
(2S)-1-{[7-methyl-2-(2-methylbiphenyl-3-yl)furo[2,3-c]pyridin-5-yl]methyl-
}piperidine-2-carboxylic acid;
(2S)-1-{[2-(2-methylbiphenyl-3-yl)-1,3-benzoxazol-5-yl]methyl}piperidine--
2-carboxylic acid;
2-({[2-(2-methylbiphenyl-3-yl)-1,3-benzoxazol-5-yl]methyl}amino)ethanol;
(2S)-1-{[2-(2-methylbiphenyl-3-yl)furo[2,3-b]pyridin-5-yl]methyl}piperidi-
ne-2-carboxylic acid;
2-({[2-(2-methylbiphenyl-3-yl)furo[2,3-b]pyridin-5-yl]methyl}amino)ethano-
l;
(2S)-1-{[7-methyl-2-(2-methylbiphenyl-3-yl)-1,3-benzoxazol-5-yl]methyl}-
piperidine-2-carboxylic acid;
2-({[7-methyl-2-(2-methylbiphenyl-3-yl)-1,3-benzoxazol-5-yl]methyl}amino)-
ethanol;
(2S)-1-{[2-(2-cyanobiphenyl-3-yl)-7-methyl-1,3-benzoxazol-5-yl]me-
thyl}piperidine-2-carboxylic acid;
3-(5-{[(2-hydroxyethyl)amino]methyl}-7-methyl-1,3-benzoxazol-2-yl)bipheny-
l-2-carbonitrile;
(2S)-1-({2-[3-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-methylphenyl]-7-methyl-
-1,3-benzoxazol-5-yl}methyl)piperidine-2-carboxylic acid;
2-[({2-[3-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-methylphenyl]-7-methyl-1,3-
-benzoxazol-5-yl}methyl)amino]ethanol;
(2S)-1-({2-[2-cyano-3-(2,3-dihydro-1,4-benzodioxin-6-yl)phenyl]-7-methyl--
1,3-benzoxazol-5-yl}methyl)piperidine-2-carboxylic acid;
2-(2,3-dihydro-1,4-benzodioxin-6-yl)-6-(5-{[(2-hydroxyethyl)amino]methyl}-
-7-methyl-1,3-benzoxazol-2-yl)benzonitrile;
(2S)-1-{[2-(2-methylbiphenyl-3-yl)-1,3-benzothiazol-5-yl]methyl}piperidin-
e-2-carboxylic acid;
(2S)-1-{[2-(2-methylbiphenyl-3-yl)furo[3,2-b]pyridin-5-yl]methyl}piperidi-
ne-2-carboxylic acid;
2-({[2-(2-methylbiphenyl-3-yl)furo[3,2-b]pyridin-5-yl]methyl}amino)ethano-
l;
(2S)-1-{[4-methyl-2-(2-methylbiphenyl-3-yl)-1,3-benzothiazol-6-yl]methy-
l}piperidine-2-carboxylic acid;
2-({[4-methyl-2-(2-methylbiphenyl-3-yl)-1,3-benzothiazol-6-yl]methyl}amin-
o)ethanol;
2-({[6-(2-methylbiphenyl-3-yl)furo[2,3-b]pyrazin-2-yl]methyl}am-
ino)ethanol; and (2
S)-1-{[6-(2-methylbiphenyl-3-yl)furo[2,3-b]pyrazin-2-yl]methyl}piperidine-
-2-carboxylic acid; or a pharmaceutically acceptable salt or a
stereoisomer thereof.
41. The compound of any one of claims 1-4, wherein the compound is
selected from:
(2S)-1-{[6-(cyanomethoxy)-2-(2-methylbiphenyl-3-yl)-1,3-benzoxazol-5-yl]m-
ethyl}piperidine-2-carboxylic acid;
{[5-1[(2-hydroxyethyl)amino]methyl}-2-(2-methylbiphenyl-3-yl)-1,3-benzoxa-
zol-6-yl]oxyl acetonitrile;
(2S)-1-{[6-(3-cyanopropoxy)-2-(2-methylbiphenyl-3-yl)-1,3-benzoxazol-5-yl-
]methyl}piperidine-2-carboxylic acid;
3-({[5-{[(2-hydroxyethyl)amino]methyl}-2-(2-methylbiphenyl-3-yl)-1,3-benz-
oxazol-6-yl]oxy}methyl)benzonitrile;
2-({[2-(2-methylbiphenyl-3-yl)-6-(pyridin-2-ylmethoxy)-1,3-benzoxazol-5-y-
l]methyl}amino)ethanol;
2-({[6-methoxy-2-(2-methylbiphenyl-3-yl)-1,3-benzoxazol-5-yl]methyl}amino-
)ethanol;
2-({[2-(2-methylbiphenyl-3-yl)-6-(2-morpholin-4-ylethoxy)-1,3-be-
nzoxazol-5-yl]methyl}amino) ethanol;
2-({[2-(2-methylbiphenyl-3-yl)[1,3]oxazolo[5,4-c]pyridin-6-yl]methyl}amin-
o) ethanol;
4-{[5-{[(2-hydroxyethyl)amino]methyl}-7-methyl-2-(2-methylbiphenyl-3-yl)--
1,3-benzoxazol-6-yl]oxy}butanenitrile;
(2S)-1-({6-(cyanomethoxy)-2-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-methy-
lpyridin-2-yl]-1,3-benzoxazol-5-yl}methyl)piperidine-2-carboxylic
acid;
(2S)-1-({6-(cyanomethoxy)-2-[3-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-methy-
lphenyl]-1,3-benzoxazol-5-yl}methyl)piperidine-2-carboxylic acid;
(2S)-1-{[2-[2-cyano-3-(2,3-dihydro-1,4-benzodioxin-6-yl)phenyl]-6-(cyanom-
ethoxy)-1,3-benzoxazol-5-yl]methyl}piperidine-2-carboxylic acid;
(2S)-1-{[2(2-methylbiphenyl-3-yl)-1,3-benzoxazol-6-yl]methyl}piperidine-2-
-carboxylic acid;
[(2-(2'-fluoro-2-methylbiphenyl-3-yl)-5-{[(2-hydroxyethyl)amino]methyl}-1-
,3-benzoxazol-6-yl)oxy]acetonitrile; and
[(2-(3-cyclohex-1-en-1-yl-2-methylphenyl)-5-{[(2-hydroxyethyl)amino]methy-
l}-1,3-benzoxazol-6-yl)oxy]acetonitrile; or a pharmaceutically
acceptable salt or a stereoisomer thereof.
42. A pharmaceutical composition comprising a compound of any of
claims 1-41 or a pharmaceutically acceptable salt or a stereoisomer
thereof, and at least one pharmaceutically acceptable carrier or
excipient.
43. A method of inhibiting PD-1/PD-L1 interaction in an individual,
said method comprising administering to the individual a compound
of any of claims 1-41 or a pharmaceutically acceptable salt or a
stereoisomer thereof.
44. A method of treating a disease or disorder associated with
inhibition of PD-1/PD-L1 interaction, said method comprising
administering to a patient in need thereof a therapeutically
effective amount of a compound of any of claims 1-41, or a
pharmaceutically acceptable salt, or a stereoisomer thereof or a
composition of claim 42.
45. The method of claim 44, wherein the disease or disorder is a
viral infection or cancer.
46. A method of enhancing, stimulating and/or increasing the immune
response in a patient, said method comprising administering to the
patient in need thereof a therapeutically effective amount of a
compound of any of claims 1-41, or a pharmaceutically acceptable
salt or a stereoisomer thereof, or a composition of claim 42.
Description
FIELD OF THE INVENTION
[0001] The present application is concerned with pharmaceutically
active compounds. The disclosure provides compounds as well as
their compositions and methods of use. The compounds modulate
PD-1/PD-L1 protein/protein interaction and are useful in the
treatment of various diseases including infectious diseases and
cancer.
BACKGROUND OF THE INVENTION
[0002] The immune system plays an important role in controlling and
eradicating diseases such as cancer. However, cancer cells often
develop strategies to evade or to suppress the immune system in
order to favor their growth. One such mechanism is altering the
expression of costimulatory and co-inhibitory molecules expressed
on immune cells (Postow et al, J. Clinical Oncology 2015, 1-9).
Blocking the signaling of an inhibitory immune checkpoint, such as
PD-1, has proven to be a promising and effective treatment
modality.
[0003] Programmed cell death-1 (PD-1), also known as CD279, is a
cell surface receptor expressed on activated T cells, natural
killer T cells, B cells, and macrophages (Greenwald et al, Annu.
Rev. Immunol 2005, 23:515-548; Okazaki and Honjo, Trends Immunol
2006, (4):195-201). It functions as an intrinsic negative feedback
system to prevent the activation of T-cells, which in turn reduces
autoimmunity and promotes self-tolerance. In addition, PD-1 is also
known to play a critical role in the suppression of
antigen-specific T cell response in diseases like cancer and viral
infection (Sharpe et al, Nat Immunol 2007 8, 239-245; Postow et al,
J. Clinical Oncol 2015, 1-9).
[0004] The structure of PD-1 consists of an extracellular
immunoglobulin variable-like domain followed by a transmembrane
region and an intracellular domain (Parry et al, Mol Cell Biol
2005, 9543-9553). The intracellular domain contains two
phosphorylation sites located in an immunoreceptor tyrosine-based
inhibitory motif and an immunoreceptor tyrosine-based switch motif,
which suggests that PD-1 negatively regulates T cell
receptor-mediated signals. PD-1 has two ligands, PD-L1 and PD-L2
(Parry et al, Mol Cell Biol 2005, 9543-9553; Latchman et al, Nat
Immunol 2001, 2, 261-268), and they differ in their expression
patterns. PD-L1 protein is upregulated on macrophages and dendritic
cells in response to lipopolysaccharide and GM-CSF treatment, and
on T cells and B cells upon T cell receptor and B cell receptor
signaling. PD-L1 is also highly expressed on almost all tumor
cells, and the expression is further increased after IFN-.gamma.
treatment (Iwai et al, PNAS 2002, 99(19):12293-7; Blank et al,
Cancer Res 2004, 64(3):1140-5). In fact, tumor PD-L1 expression
status has been shown to be prognostic in multiple tumor types
(Wang et al, Eur J Surg Oncol 2015; Huang et al, Oncol Rep 2015;
Sabatier et al, Oncotarget 2015, 6(7): 5449-5464). PD-L2
expression, in contrast, is more restricted and is expressed mainly
by dendritic cells (Nakae et al, J Immunol 2006, 177:566-73).
Ligation of PD-1 with its ligands PD-L1 and PD-L2 on T cells
delivers a signal that inhibits IL-2 and IFN-.gamma. production, as
well as cell proliferation induced upon T cell receptor activation
(Carter et al, Eur J Immunol 2002, 32(3):634-43; Freeman et al, J
Exp Med 2000, 192(7):1027-34). The mechanism involves recruitment
of SHP-2 or SHP-1 phosphatases to inhibit T cell receptor signaling
such as Syk and Lck phosphorylation (Sharpe et al, Nat Immunol
2007, 8, 239-245). Activation of the PD-1 signaling axis also
attenuates PKC-.theta. activation loop phosphorylation, which is
necessary for the activation of NF-.kappa.3 and AP1 pathways, and
for cytokine production such as IL-2, IFN-.gamma. and TNF (Sharpe
et al, Nat Immunol 2007, 8, 239-245; Carter et al, Eur J Immunol
2002, 32(3):634-43; Freeman et al, J Exp Med 2000,
192(7):1027-34).
[0005] Several lines of evidence from preclinical animal studies
indicate that PD-1 and its ligands negatively regulate immune
responses. PD-1-deficient mice have been shown to develop
lupus-like glomerulonephritis and dilated cardiomyopathy (Nishimura
et al, Immunity 1999, 11:141-151; Nishimura et al, Science 2001,
291:319-322). Using an LCMV model of chronic infection, it has been
shown that PD-1/PD-L1 interaction inhibits activation, expansion
and acquisition of effector functions of virus-specific CD8 T cells
(Barber et al, Nature 2006, 439, 682-7). Together, these data
support the development of a therapeutic approach to block the
PD-1-mediated inhibitory signaling cascade in order to augment or
"rescue" T cell response. Accordingly, there is a need for new
compounds that block PD-1/PD-L1 protein/protein interaction.
SUMMARY
[0006] The present disclosure provides, inter alia, a compound of
Formula (I'):
##STR00002##
or a pharmaceutically acceptable salt or a stereoisomer thereof,
wherein constituent variables are defined herein.
[0007] The present disclosure provides, inter alia, a compound of
Formula (I):
##STR00003##
or a pharmaceutically acceptable salt or a stereoisomer thereof,
wherein constituent variables are defined herein.
[0008] The present disclosure further provides a pharmaceutical
composition comprising a compound of the disclosure, or a
pharmaceutically acceptable salt or a stereoisomer thereof, and at
least one pharmaceutically acceptable carrier or excipient.
[0009] The present disclosure further provides methods of
modulating or inhibiting PD-1/PD-L1 protein/protein interaction in
an individual, which comprises administering to the individual a
compound of the disclosure, or a pharmaceutically acceptable salt
or a stereoisomer thereof.
[0010] The present disclosure further provides methods of treating
a disease or disorder in a patient comprising administering to the
patient a therapeutically effective amount of a compound of the
disclosure, or a pharmaceutically acceptable salt or a stereoisomer
thereof.
DETAILED DESCRIPTION
I. Compounds
[0011] The present disclosure provides, inter alia, compounds of
Formula (I'):
##STR00004##
[0012] or a pharmaceutically acceptable salt or a stereoisomer
thereof, wherein:
[0013] one of X.sup.1 and X.sup.2 is O or S and the other of
X.sup.1 and X.sup.2 is N, CR.sup.1 or CR.sup.2;
[0014] X.sup.3 is N or CR.sup.3;
[0015] X.sup.4 is N or CR.sup.4;
[0016] X.sup.5 is N or CR.sup.5;
[0017] X.sup.6 is N or CR.sup.6;
[0018] at least one of X.sup.1, X.sup.2, X.sup.3, X.sup.4, X.sup.5
and X.sup.6 is N;
[0019] Y.sup.1 is N or CR.sup.8a;
[0020] Y.sup.2 is N or CR.sup.8b;
[0021] Y.sup.3 is N or CR.sup.8c;
[0022] Cy is C.sub.6-10 aryl, C.sub.3-10 cycloalkyl, 5- to
14-membered heteroaryl, or 4- to 10-membered heterocycloalkyl, each
of which is optionally substituted with 1, 2, 3, 4 or 5
independently selected R.sup.7 substituents;
[0023] R.sup.1, R.sup.2, R.sup.8a, R.sup.8b and R.sup.8c are each
independently selected from H, C.sub.1-4 alkyl, C.sub.3-6
cycloalkyl, C.sub.3-6 cycloalkyl-C.sub.1-4alkyl-, C.sub.6-10 aryl,
C.sub.6-10aryl-C.sub.1-4alkyl-, 5-10 membered heteroaryl, 4-10
membered heterocycloalkyl, (5-10 membered heteroaryl)-C.sub.1-4
alkyl-, (4-10 membered heterocycloalkyl)-C.sub.1-4 alkyl-,
C.sub.2-4 alkenyl, C.sub.2-4 alkynyl, halo, CN, OR.sup.10,
C.sub.1-4 haloalkyl, C.sub.1-4 haloalkoxy, NH.sub.2, --NHR.sup.10,
--NR.sup.10R.sup.10, NHOR.sup.10, C(O)R.sup.10,
C(O)NR.sup.10R.sup.10, C(O)OR.sup.10, OC(O)R.sup.10,
OC(O)NR.sup.10R.sup.10, NR.sup.10C(O)R.sup.10,
NR.sup.10C(O)OR.sup.10, NR.sup.10C(O)NR.sup.10R.sup.10,
C(.dbd.NR.sup.10)R.sup.10, C(.dbd.NR.sup.10)NR.sup.10R.sup.10,
NR.sup.10C(.dbd.NR.sup.10NR.sup.10R.sup.10, NR.sup.10S(O)R.sup.10,
NR.sup.10S(O).sub.2R.sup.10, NR.sup.10S(O).sub.2NR.sup.10R.sup.10,
S(O)R.sup.10, S(O)NR.sup.10R.sup.10, S(O).sub.2R.sup.10, and
S(O).sub.2NR.sup.10R.sup.10, wherein each R.sup.10 is independently
selected from H, C.sub.1-4 alkyl, C.sub.2-4 alkenyl, C.sub.2-4
alkynyl, C.sub.1-4 alkoxy, C.sub.3-6 cycloalkyl, C.sub.3-6
cycloalkyl-C.sub.1-4alkyl-, C.sub.6-10aryl,
C.sub.6-10aryl-C.sub.1-4alkyl, 5-10 membered heteroaryl, 4-10
membered heterocycloalkyl, (5-10 membered heteroaryl)-C.sub.1-4
alkyl-, and (4-10 membered heterocycloalkyl)-C.sub.1-4 alkyl-,
wherein the C.sub.1-4 alkyl, C.sub.2-4 alkenyl, C.sub.2-4 alkynyl,
C.sub.1-4 alkoxy, C.sub.3-6 cycloalkyl, C.sub.3-6
cycloalkyl-C.sub.1-4alkyl-, C.sub.6-10aryl,
C.sub.6-10aryl-C.sub.1-4alkyl-, 5-10 membered heteroaryl, 4-10
membered heterocycloalkyl, (5-10 membered heteroaryl)-C.sub.1-4
alkyl-, and (4-10 membered heterocycloalkyl)-C.sub.1-4 alkyl- of
R.sup.1, R.sup.2, R.sup.8a, R.sup.8b, R.sup.10 and R.sup.8c are
each optionally substituted with 1, 2 or 3 independently selected
R.sup.d substituents;
[0024] R.sup.9 is Cl, Br, I, C.sub.1-6 alkyl, C.sub.2-6 alkenyl,
C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl, C.sub.1-6 haloalkoxy,
C.sub.6-10 aryl, C.sub.3-10 cycloalkyl, 5-14 membered heteroaryl,
4-10 membered heterocycloalkyl, C.sub.6-10aryl-C.sub.1-4alkyl-,
C.sub.3-10 cycloalkyl-C.sub.1-4 alkyl-, (5-14 membered
heteroaryl)-C.sub.1-4 alkyl-, (4-10 membered
heterocycloalkyl)-C.sub.1-4 alkyl-, CN, NO.sub.2, OR.sup.11a,
SR.sup.11, NH.sub.2, --NHR.sup.11, --NR.sup.11R.sup.11,
NHOR.sup.11, C(O)R.sup.11, C(O)NR.sup.11R.sup.11, C(O)OR.sup.11,
OC(O)R.sup.11, OC(O)NR.sup.11R.sup.11, NR.sup.11C(O)R.sup.11,
NR.sup.11C(O)OR.sup.11, NR.sup.11C(O)NR.sup.11R.sup.11,
C(.dbd.NR.sup.11)R.sup.11, C(.dbd.NR.sup.11)NR.sup.11R.sup.11,
NR.sup.11C(.dbd.NR.sup.11)NR.sup.11R.sup.11, NR.sup.11S(O)R.sup.11,
NR.sup.11S(O).sub.2R.sup.11, NR.sup.11S(O).sub.2NR.sup.11R.sup.11,
S(O)R.sup.11, S(O)NR.sup.11R.sup.11, S(O).sub.2R.sup.11, and
S(O).sub.2NR.sup.11R.sup.11, wherein the C.sub.1-6 alkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl, C.sub.1-6
haloalkoxy, C.sub.6-10 aryl, C.sub.3-10 cycloalkyl, 5-14 membered
heteroaryl, 4-10 membered heterocycloalkyl, C.sub.6-10
aryl-C.sub.1-4 alkyl-, C.sub.3-10 cycloalkyl-C.sub.1-4 alkyl-,
(5-14 membered heteroaryl)-C.sub.1-4 alkyl- and (4-10 membered
heterocycloalkyl)-C.sub.1-4 alkyl- of R.sup.9 are each optionally
substituted with 1, 2 or 3 R.sup.b substituents;
[0025] each R.sup.11 is independently selected from H, C.sub.1-6
alkyl, C.sub.1-6 haloalkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.6-10 aryl, C.sub.3-10 cycloalkyl, 5-10 membered heteroaryl,
4-10 membered heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-,
C.sub.3-10 cycloalkyl-C.sub.1-4 alkyl-, (5-10 membered
heteroaryl)-C.sub.1-4 alkyl-, and (4-10 membered
heterocycloalkyl)-C.sub.1-4 alkyl-, wherein the C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.6-10 aryl, C.sub.3-10
cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-, C.sub.3-10
cycloalkyl-C.sub.1-4 alkyl-, (5-10 membered heteroaryl)-C.sub.1-4
alkyl- and (4-10 membered heterocycloalkyl)-C.sub.1-4 alkyl- of
R.sup.11 are each optionally substituted with 1, 2 or 3
independently selected R.sup.b substituents;
[0026] R.sup.11a is selected from C.sub.1-6 alkyl, C.sub.1-6
haloalkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.6-10 aryl,
C.sub.3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-, C.sub.3-10
cycloalkyl-C.sub.1-4 alkyl-, (5-10 membered heteroaryl)-C.sub.1-4
alkyl-, and (4-10 membered heterocycloalkyl)-C.sub.1-4 alkyl-, each
of which is optionally substituted with 1, 2 or 3 independently
selected R.sup.b substituents;
[0027] R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 are each
independently selected from H, halo, C.sub.1-6 alkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl, C.sub.1-6
haloalkoxy, C.sub.6-10 aryl, C.sub.3-10 cycloalkyl, 5-14 membered
heteroaryl, 4-10 membered heterocycloalkyl, C.sub.6-10
aryl-C.sub.1-4 alkyl-, C.sub.3-10 cycloalkyl-C.sub.1-4 alkyl-,
(5-14 membered heteroaryl)-C.sub.1-4 alkyl-, (4-10 membered
heterocycloalkyl)-C.sub.1-4 alkyl-, CN, NO.sub.2, OR.sup.a,
SR.sup.a, NHOR.sup.a, C(O)R.sup.a, C(O)NR.sup.aR.sup.a,
C(O)OR.sup.a, OC(O)R.sup.a, OC(O)NR.sup.aR.sup.a, NHR.sup.a,
NR.sup.aR.sup.a, NR.sup.aC(O)R.sup.a, NR.sup.aC(O)OR.sup.a,
NR.sup.aC(O)NR.sup.aR.sup.a, C(.dbd.NR.sup.a)R.sup.a,
C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
NR.sup.aC(.dbd.NR.sup.a)NR.sup.aR.sup.a, NR.sup.aS(O)R.sup.a,
NR.sup.aS(O).sub.2R.sup.a, NR.sup.aS(O).sub.2NR.sup.aR.sup.a,
S(O)R.sup.a, S(O)NR.sup.aR.sup.a, S(O).sub.2R.sup.a, and
S(O).sub.2NR.sup.aR.sup.a, wherein the C.sub.1-6 alkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.6-10 aryl, C.sub.3-10 cycloalkyl,
5-14 membered heteroaryl, 4-10 membered heterocycloalkyl,
C.sub.6-10 aryl-C.sub.1-4 alkyl-, C.sub.3-10 cycloalkyl-C.sub.1-4
alkyl-, (5-14 membered heteroaryl)-C.sub.1-4 alkyl-, and (4-10
membered heterocycloalkyl)-C.sub.1-4 alkyl- of R.sup.3, R.sup.4,
R.sup.5, R.sup.6 and R.sup.7 are each optionally substituted with
1, 2, 3, or 4 R.sup.b substituents, with the proviso that at least
one of R.sup.3, R.sup.4, R.sup.5 and R.sup.6 is other than H;
[0028] or two adjacent R.sup.7 substituents on the Cy ring, taken
together with the atoms to which they are attached, form a fused
phenyl ring, a fused 5- to 7-membered heterocycloalkyl ring, a
fused 5- or 6-membered heteroaryl ring or a fused C.sub.5-6
cycloalkyl ring, wherein the fused 5- to 7-membered
heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring
each have 1-4 heteroatoms as ring members selected from N, O and S
and wherein the fused phenyl ring, fused 5- to 7-membered
heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and
fused C.sub.5-6 cycloalkyl ring are each optionally substituted
with 1, 2 or 3 independently selected R.sup.b substituents;
[0029] each R.sup.a is independently selected from H, CN, C.sub.1-6
alkyl, C.sub.1-4 haloalkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.6-10 aryl, C.sub.3-10 cycloalkyl, 5-10 membered heteroaryl,
4-10 membered heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-,
C.sub.3-10 cycloalkyl-C.sub.1-4 alkyl-, (5-10 membered
heteroaryl)-C.sub.1-4 alkyl-, and (4-10 membered
heterocycloalkyl)-C.sub.1-4 alkyl-, wherein the C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.6-10 aryl, C.sub.3-10
cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-, C.sub.3-10
cycloalkyl-C.sub.1-4 alkyl-, (5-10 membered heteroaryl)-C.sub.1-4
alkyl- and (4-10 membered heterocycloalkyl)-C.sub.1-4 alkyl- of
R.sup.a are each optionally substituted with 1, 2, 3, 4, or 5
R.sup.d substituents;
[0030] each R.sup.d is independently selected from C.sub.1-6 alkyl,
C.sub.1-6 haloalkyl, halo, C.sub.6-10aryl, 5-10 membered
heteroaryl, C.sub.3-10 cycloalkyl, 4-10 membered heterocycloalkyl,
C.sub.6-10 aryl-C.sub.1-4 alkyl-, C.sub.3-10 cycloalkyl-C.sub.1-4
alkyl-, (5-10 membered heteroaryl)-C.sub.1-4 alkyl-, (4-10 membered
heterocycloalkyl)-C.sub.1-4 alkyl-, CN, NH.sub.2, NHOR.sup.e,
OR.sup.e, SR.sup.e, C(O)R.sup.e, C(O)NR.sup.eR.sup.e, C(O)OR.sup.e,
OC(O)R.sup.e, OC(O)NR.sup.eR.sup.e, NHR.sup.e, NR.sup.eR.sup.e,
NR.sup.eC(O)R.sup.e, NR.sup.eC(O)NR.sup.eR.sup.e,
NR.sup.eC(O)OR.sup.e, C(.dbd.NR.sup.e)NR.sup.eR.sup.e,
NR.sup.eC(.dbd.NR.sup.e)NR.sup.eR.sup.e,
NR.sup.eC(.dbd.NOH)NR.sup.eR.sup.e,
NR.sup.eC(.dbd.NCN)NR.sup.eR.sup.e, S(O)R.sup.e,
S(O)NR.sup.eR.sup.e, S(O).sub.2R.sup.e, NR.sup.eS(O).sub.2R.sup.e,
NR.sup.eS(O).sub.2NR.sup.eR.sup.e, and S(O).sub.2NR.sup.eR.sup.e,
wherein the C.sub.1-6 alkyl, C.sub.6-10aryl, 5-10 membered
heteroaryl, C.sub.3-10 cycloalkyl, 4-10 membered heterocycloalkyl,
C.sub.6-10 aryl-C.sub.1-4 alkyl-, C.sub.3-10 cycloalkyl-C.sub.1-4
alkyl-, (5-10 membered heteroaryl)-C.sub.1-4 alkyl-, and (4-10
membered heterocycloalkyl)-C.sub.1-4 alkyl- of R.sup.d are each
optionally substituted with 1-3 independently selected R.sup.h
substituents;
[0031] each R.sup.b substituent is independently selected from
halo, C.sub.1-4 alkyl, C.sub.1-4 haloalkyl, C.sub.1-4 haloalkoxy,
C.sub.6-10 aryl, C.sub.3-10 cycloalkyl, 5-10 membered heteroaryl,
4-10 membered heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-,
C.sub.3-10 cycloalkyl-C.sub.1-4 alkyl-, (5-10 membered
heteroaryl)-C.sub.1-4 alkyl-, (4-10 membered
heterocycloalkyl)-C.sub.1-4 alkyl-, CN, OH, NH.sub.2, NO.sub.2,
NHOR.sup.c, OR.sup.c, SR.sup.c, C(O)R.sup.c, C(O)NR.sup.cR.sup.c,
C(O)OR.sup.c, OC(O)R.sup.c, OC(O)NR.sup.cR.sup.c,
C(.dbd.NR.sup.c)NR.sup.cR.sup.c,
NR.sup.cC(.dbd.NR.sup.c)NR.sup.cR.sup.c, NHR.sup.c,
NR.sup.cR.sup.c, NR.sup.cC(O)R.sup.c, NR.sup.cC(O)OR.sup.c,
NR.sup.cC(O)NR.sup.cR.sup.c, NR.sup.cS(O)R.sup.c,
NR.sup.cS(O).sub.2R.sup.c, NR.sup.cS(O).sub.2NR.sup.cR.sup.c,
S(O)R.sup.c, S(O)NR.sup.cR.sup.c, S(O).sub.2R.sup.c and
S(O).sub.2NR.sup.cR.sup.c; wherein the C.sub.1-4 alkyl, C.sub.1-4
haloalkyl, C.sub.1-4 haloalkoxy, C.sub.6-10 aryl, C.sub.3-10
cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-, C.sub.3-10
cycloalkyl-C.sub.1-4 alkyl-, (5-10 membered heteroaryl)-C.sub.1-4
alkyl- and (4-10 membered heterocycloalkyl)-C.sub.1-4 alkyl- of
R.sup.b are each further optionally substituted with 1-3
independently selected R.sup.d substituents;
[0032] each R.sup.c is independently selected from H, C.sub.1-6
alkyl, C.sub.1-4 haloalkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.6-10 aryl, C.sub.3-10 cycloalkyl, 5-10 membered heteroaryl,
4-10 membered heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-,
C.sub.3-10 cycloalkyl-C.sub.1-4 alkyl-, (5-10 membered
heteroaryl)-C.sub.1-4 alkyl-, and (4-10 membered
heterocycloalkyl)-C.sub.1-4 alkyl-, wherein the C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.6-10 aryl, C.sub.3-10
cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-, C.sub.3-10
cycloalkyl-C.sub.1-4 alkyl-, (5-10 membered heteroaryl)-C.sub.1-4
alkyl- and (4-10 membered heterocycloalkyl)-C.sub.1-4 alkyl- of
R.sup.c are each optionally substituted with 1, 2, 3, 4, or 5
R.sup.f substituents independently selected from C.sub.1-4 alkyl,
C.sub.1-4 haloalkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.6-10 aryl, C.sub.3-10 cycloalkyl, 5-10 membered heteroaryl,
4-10 membered heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-,
C.sub.3-10 cycloalkyl-C.sub.1-4 alkyl-, (5-10 membered
heteroaryl)-C.sub.1-4 alkyl-, (4-10 membered
heterocycloalkyl)-C.sub.1-4 alkyl-, halo, CN, NHOR.sup.g, OR.sup.g,
SR.sup.g, C(O)R.sup.g, C(O)NR.sup.gR.sup.g, C(O)OR.sup.g,
OC(O)R.sup.g, OC(O)NR.sup.gR.sup.g, NHR.sup.g, NR.sup.gR.sup.g,
NR.sup.gC(O)R.sup.g, NR.sup.gC(O)NR.sup.gR.sup.g,
NR.sup.gC(O)OR.sup.g, C(.dbd.NR.sup.g)NR.sup.gR.sup.g,
NR.sup.gC(.dbd.NR.sup.g)NR.sup.gR.sup.g, S(O)R.sup.g,
S(O)NR.sup.gR.sup.g, S(O).sub.2R.sup.g, NR.sup.gS(O).sub.2R.sup.g,
NR.sup.gS(O).sub.2NR.sup.gR.sup.g, and S(O).sub.2NR.sup.gR.sup.g;
wherein the C.sub.1-4 alkyl, C.sub.1-4 haloalkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.6-10 aryl, C.sub.3-10 cycloalkyl,
5-10 membered heteroaryl, 4-10 membered heterocycloalkyl,
C.sub.6-10 aryl-C.sub.1-4 alkyl-, C.sub.3-10 cycloalkyl-C.sub.1-4
alkyl-, (5-10 membered heteroaryl)-C.sub.1-4 alkyl-, and (4-10
membered heterocycloalkyl)-C.sub.1-4 alkyl- of R.sup.f are each
optionally substituted with 1, 2, 3, 4, or 5 R.sup.n substituents
independently selected from C.sub.1-4 alkyl, C.sub.1-4 haloalkyl,
halo, CN, R.sup.o, NHOR.sup.o, OR.sup.o, SR.sup.o, C(O)R.sup.o,
C(O)NR.sup.oR.sup.o, C(O)OR.sup.o, OC(O)R.sup.o,
OC(O)NR.sup.oR.sup.o, NHR.sup.o, NR.sup.oR.sup.o,
NR.sup.oC(O)R.sup.o, NR.sup.oC(O)NR.sup.oR.sup.o,
NR.sup.oC(O)OR.sup.o, C(.dbd.NR.sup.o)NR.sup.oR.sup.o,
NR.sup.oC(.dbd.NR.sup.o)NR.sup.oR.sup.o, S(O)R.sup.o,
S(O)NR.sup.oR.sup.o, S(O).sub.2R.sup.o, NR.sup.oS(O).sub.2R.sup.o,
NR.sup.oS(O).sub.2NR.sup.oR.sup.o, and
S(O).sub.2NR.sup.oR.sup.o;
[0033] each R.sup.g is independently selected from H, C.sub.1-6
alkyl, C.sub.1-4 haloalkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.6-10 aryl, C.sub.3-10 cycloalkyl, 5-10 membered heteroaryl,
4-10 membered heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-,
C.sub.3-10 cycloalkyl-C.sub.1-4 alkyl-, (5-10 membered
heteroaryl)-C.sub.1-4 alkyl-, and (4-10 membered
heterocycloalkyl)-C.sub.1-4 alkyl-, wherein the C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.6-10 aryl, C.sub.3-10
cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-, C.sub.3-10
cycloalkyl-C.sub.1-4 alkyl-, (5-10 membered heteroaryl)-C.sub.1-4
alkyl- and (4-10 membered heterocycloalkyl)-C.sub.1-4 alkyl- of
R.sup.g are each optionally substituted with 1-3 R.sup.p
substituents independently selected from C.sub.1-6 alkyl, C.sub.1-6
haloalkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.6-10 aryl,
C.sub.3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-, C.sub.3-10
cycloalkyl-C.sub.1-4 alkyl-, (5-10 membered heteroaryl)-C.sub.1-4
alkyl-, (4-10 membered heterocycloalkyl)-C.sub.1-4 alkyl-, halo,
CN, NHOR.sup.r, OR.sup.r, SR.sup.r, C(O)R.sup.r,
C(O)NR.sup.rR.sup.r, C(O)OR.sup.r, OC(O)R.sup.r,
OC(O)NR.sup.rR.sup.r, NHR.sup.r, NR.sup.rR.sup.r,
NR.sup.rC(O)R.sup.r, NR.sup.rC(O)NR.sup.rR.sup.r,
NR.sup.rC(O)OR.sup.r, C(.dbd.NR.sup.r)NR.sup.rR.sup.r,
NR.sup.rC(.dbd.NR.sup.r)NR.sup.rR.sup.r,
NR.sup.rC(.dbd.NOH)NR.sup.rR.sup.r,
NR.sup.rC(.dbd.NCN)NR.sup.rR.sup.r, S(O)R.sup.r,
S(O)NR.sup.rR.sup.r, S(O).sub.2R.sup.r, NR.sup.rS(O).sub.2R.sup.r,
NR.sup.rS(O).sub.2NR.sup.rR.sup.r and S(O).sub.2NR.sup.rR.sup.r,
wherein the C.sub.1-6 alkyl, C.sub.1-6 haloalkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.6-10 aryl, C.sub.3-10 cycloalkyl,
5-10 membered heteroaryl, 4-10 membered heterocycloalkyl,
C.sub.6-10 aryl-C.sub.1-4 alkyl-, C.sub.3-10 cycloalkyl-C.sub.1-4
alkyl-, (5-10 membered heteroaryl)-C.sub.1-4 alkyl- and (4-10
membered heterocycloalkyl)-C.sub.1-4 alkyl- of R.sup.p is
optionally substituted with 1, 2 or 3 R.sup.q substituents;
[0034] or any two R.sup.a substituents together with the nitrogen
atom to which they are attached form a 4-, 5-, 6-, 7-, 8-, 9- or
10-membered heterocycloalkyl group optionally substituted with 1, 2
or 3 R.sup.h substituents independently selected from C.sub.1-6
alkyl, C.sub.3-10 cycloalkyl, 4-7 membered heterocycloalkyl,
C.sub.6-10 aryl, 5-6 membered heteroaryl, C.sub.6-10
aryl-C.sub.1-4alkyl-, C.sub.3-10 cycloalkyl-C.sub.1-4 alkyl-, (5-6
membered heteroaryl)-C.sub.1-4 alkyl-, (4-7 membered
heterocycloalkyl)-C.sub.1-4 alkyl-, C.sub.1-6 haloalkyl, C.sub.1-6
haloalkoxy, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, halo, CN,
OR.sup.i, SR.sup.i, NHOR.sup.i, C(O)R.sup.i, C(O)NR.sup.iR.sup.i,
C(O)OR.sup.i, OC(O)R.sup.i, OC(O)NR.sup.iR.sup.i, NHR.sup.i,
NR.sup.iR.sup.i, NR.sup.iC(O)R.sup.i, NR.sup.iC(O)NR.sup.iR.sup.i,
NR.sup.iC(O)OR.sup.i, C(.dbd.NR.sup.i)NR.sup.iR.sup.i,
NR.sup.iC(.dbd.NR.sup.i)NR.sup.iR.sup.i, S(O)R.sup.i,
S(O)NR.sup.iR.sup.i, S(O).sub.2R.sup.i, NR.sup.iS(O).sub.2R.sup.i,
NR.sup.iS(O).sub.2NR.sup.iR.sup.i, and S(O).sub.2NR.sup.iR.sup.i,
wherein the C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.3-10 cycloalkyl, 4-7 membered heterocycloalkyl, C.sub.6-10
aryl, 5-6 membered heteroaryl, C.sub.6-10 aryl-C.sub.1-4alkyl-,
C.sub.3-10 cycloalkyl-C.sub.1-4 alkyl-, (5-6 membered
heteroaryl)-C.sub.1-4 alkyl-, and (4-7 membered
heterocycloalkyl)-C.sub.1-4 alkyl- of R.sup.h are each further
optionally substituted by 1, 2, or 3 R.sup.j substituents
independently selected from C.sub.3-6 cycloalkyl, C.sub.6-10 aryl,
5 or 6-membered heteroaryl, 4-7 membered heterocycloalkyl,
C.sub.2-4 alkenyl, C.sub.2-4 alkynyl, halo, C.sub.1-4 alkyl,
C.sub.1-4 haloalkyl, CN, NHOR.sup.k, OR.sup.k, SR.sup.k,
C(O)R.sup.k, C(O)NR.sup.kR.sup.k, C(O)OR.sup.k, OC(O)R.sup.k,
OC(O)NR.sup.kR.sup.k, NHR.sup.k, NR.sup.kR.sup.k,
NR.sup.kC(O)R.sup.k, NR.sup.kC(O)NR.sup.kR.sup.k,
NR.sup.kC(O)OR.sup.k, C(.dbd.NR.sup.k)NR.sup.kR.sup.k,
NR.sup.kC(.dbd.NR.sup.k)NR.sup.kR.sup.k, S(O)R.sup.k,
S(O)NR.sup.kR.sup.k, S(O).sub.2R.sup.k, NR.sup.kS(O).sub.2R.sup.k,
NR.sup.kS(O).sub.2NR.sup.kR.sup.k, and S(O).sub.2NR.sup.kR.sup.k,
wherein the C.sub.1-4 alkyl, C.sub.3-6 cycloalkyl, C.sub.6-10 aryl,
5- or 6-membered heteroaryl, 4-6 membered heterocycloalkyl,
C.sub.2-4 alkenyl, C.sub.2-4 alkynyl, C.sub.1-4 haloalkyl, and
C.sub.1-4 haloalkoxy of R.sup.j are each optionally substituted
with 1, 2 or 3 independently selected R.sup.q substituents; or two
R.sup.h groups attached to the same carbon atom of the 4- to
10-membered heterocycloalkyl taken together with the carbon atom to
which they attach form a C.sub.3-6 cycloalkyl or 4- to 6-membered
heterocycloalkyl having 1-2 heteroatoms as ring members selected
from O, N and S;
[0035] or any two R.sup.c substituents together with the nitrogen
atom to which they are attached form a 4-, 5-, 6-, or 7-membered
heterocycloalkyl group optionally substituted with 1, 2, or 3
independently selected R.sup.h substituents;
[0036] or any two R.sup.e substituents together with the nitrogen
atom to which they are attached form a 4-, 5-, 6-, or 7-membered
heterocycloalkyl group optionally substituted with 1, 2, or 3
independently selected R.sup.h substituents;
[0037] or any two R.sup.g substituents together with the nitrogen
atom to which they are attached form a 4-, 5-, 6-, or 7-membered
heterocycloalkyl group optionally substituted with 1, 2, or 3
independently selected R.sup.h substituents;
[0038] or any two R.sup.i substituents together with the nitrogen
atom to which they are attached form a 4-, 5-, 6-, or 7-membered
heterocycloalkyl group optionally substituted with 1, 2, or 3
independently selected R.sup.h substituents;
[0039] or any two R.sup.k substituents together with the nitrogen
atom to which they are attached form a 4-, 5-, 6-, or 7-membered
heterocycloalkyl group optionally substituted with 1, 2, or 3
independently selected R.sup.h substituents;
[0040] or any two R.sup.o substituents together with the nitrogen
atom to which they are attached form a 4-, 5-, 6-, or 7-membered
heterocycloalkyl group optionally substituted with 1, 2, or 3
independently selected R.sup.h substituents; [0041] each R.sup.e,
R.sup.i, R.sup.k, R.sup.o or R.sup.p is independently selected from
H, C.sub.1-4 alkyl, C.sub.3-6 cycloalkyl, C.sub.6-10 aryl, 5 or
6-membered heteroaryl, 4-7 membered heterocycloalkyl, C.sub.1-4
haloalkyl, C.sub.2-4 alkenyl, and C.sub.2-4 alkynyl, wherein the
C.sub.1-4 alkyl, C.sub.3-6 cycloalkyl, C.sub.6-10 aryl, 5 or
6-membered heteroaryl, 4-7 membered heterocycloalkyl, C.sub.2-4
alkenyl, and C.sub.2-4 alkynyl of R.sup.e, R.sup.i, R.sup.k,
R.sup.o or R.sup.p are each optionally substituted with 1, 2 or 3
R.sup.q substituents;
[0042] each R.sup.q is independently selected from OH, CN, --COOH,
NH.sub.2, halo, C.sub.1-6haloalkyl, C.sub.1-6 alkyl, C.sub.1-6
alkoxy, C.sub.1-6 alkylthio, phenyl, 5-6 membered heteroaryl, 4-6
membered heterocycloalkyl, C.sub.3-6cycloalkyl, NHR.sup.12,
NR.sup.12R.sup.12, and C.sub.1-4 haloalkoxy, wherein the C.sub.1-6
alkyl, phenyl, C.sub.3-6 cycloalkyl, 4-6 membered heterocycloalkyl,
and 5-6 membered heteroaryl of R.sup.q are each optionally
substituted with halo, OH, CN, --COOH, NH.sub.2, C.sub.1-4alkyl,
C.sub.1-4 alkoxy, C.sub.1-4 haloalkyl, C.sub.1-4 haloalkoxy,
phenyl, C.sub.3-10 cycloalkyl, 5-6 membered heteroaryl and 4-6
membered heterocycloalkyl and each R.sup.12 is independently
C.sub.1-6 alkyl;
[0043] is a single bond or a double bond to maintain ring A being
aromatic;
[0044] when the moiety
##STR00005##
in Formula (I') is 2-benzoxazolyl substituted with 1 to 3
substituents independently selected from methyl, ethyl, isopropyl,
methoxy, Cl, Br, and phenyl, Cy is not 4H-1,2,4-triazol-4-yl,
5-methyl-2-benzoxazolyl or 2-oxopyrrolidinyl substituted with
--COOH, --C(O)NH.sub.2, --C(O)OC.sub.1-2 alkyl or C(O)Cl; and
[0045] the compound is not
1-[3-(6-chloro-2-benzoxazolyl)-5-(3,5-dimethylphenyl)-4-pyridinyl]-4-pipe-
ridinamine.
[0046] The present disclosure provides a compound of Formula (I'),
or a pharmaceutically acceptable salt or a stereoisomer thereof,
wherein:
[0047] one of X.sup.1 and X.sup.2 is O or S and the other of
X.sup.1 and X.sup.2 is N, CR.sup.1 or CR.sup.2;
[0048] X.sup.3 is N or CR.sup.3;
[0049] X.sup.4 is N or CR.sup.4;
[0050] X.sup.5 is N or CR.sup.5;
[0051] X.sup.6 is N or CR.sup.6;
[0052] at least one of X.sup.1, X.sup.2, X.sup.3, X.sup.4, X.sup.5
and X.sup.6 is N;
[0053] Y.sup.1 is N or CR.sup.8a;
[0054] Y.sup.2 is N or CR.sup.8b;
[0055] Y.sup.3 is N or CR.sup.8c;
[0056] Cy is C.sub.6-10 aryl, C.sub.3-10 cycloalkyl, 5- to
14-membered heteroaryl, or 4- to 10-membered heterocycloalkyl, each
of which is optionally substituted with 1, 2, 3, 4 or 5
independently selected R.sup.7 substituents;
[0057] R.sup.1, R.sup.2, R.sup.8a, R.sup.8b and R.sup.8c are each
independently selected from H, C.sub.1-4 alkyl, C.sub.3-6
cycloalkyl, C.sub.2-4 alkenyl, C.sub.2-4 alkynyl, halo, CN, OH,
C.sub.1-4 alkoxy, C.sub.1-4 haloalkyl, C.sub.1-4 haloalkoxy,
NH.sub.2, --NH--C.sub.1-4 alkyl, --N(C.sub.1-4 alkyl).sub.2,
NHOR.sup.10, C(O)R.sup.10, C(O)NR.sup.10R.sup.10, C(O)OR.sup.10,
OC(O)R.sup.10, OC(O)NR.sup.10R.sup.10, NR.sup.10C(O)R.sup.10,
NR.sup.10C(O)OR.sup.10, NR.sup.10C(O)NR.sup.10R.sup.10,
C(.dbd.NR.sup.10)R.sup.10, C(.dbd.NR.sup.10)NR.sup.10R.sup.10,
NR.sup.10C(.dbd.NR.sup.10)NR.sup.10R.sup.10, NR.sup.10S(O)R.sup.10,
NR.sup.10S(O).sub.2R.sup.10, NR.sup.10S(O).sub.2NR.sup.10R.sup.10,
S(O)R.sup.10, S(O)NR.sup.10R.sup.10, S(O).sub.2R.sup.10, and
S(O).sub.2NR.sup.10R.sup.10, wherein each R.sup.10 is independently
H or C.sub.1-4 alkyl optionally substituted with 1 or 2 groups
independently selected from halo, OH, CN and C.sub.1-4 alkoxy and
wherein the C.sub.1-4 alkyl, C.sub.3-4 cycloalkyl, C.sub.2-4
alkenyl and C.sub.2-4 alkynyl of R.sup.1, R.sup.2 R.sup.8a,
R.sup.8b or R.sup.8c are each optionally substituted with 1 or 2
substituents independently selected from halo, OH, CN, C.sub.1-4
alkyl and C.sub.1-4 alkoxy;
[0058] R.sup.9 is C.sub.1-4 alkyl, Cl, Br, CN, cyclopropyl,
C.sub.2-4 alkynyl, C.sub.1-4 haloalkyl, C.sub.1-4 haloalkoxy,
NH.sub.2, --NH--C.sub.1-4 alkyl, --N(C.sub.1-4 alkyl).sub.2,
NHOR.sup.11, C(O)R.sup.11, C(O)NR.sup.11R.sup.11, C(O)OR.sup.11,
OC(O)R.sup.11, OC(O)NR.sup.11R.sup.11, NR.sup.11C(O)R.sup.11,
NR.sup.11C(O)OR.sup.11, NR.sup.11C(O)NR.sup.11R.sup.11,
C(.dbd.NR.sup.11)R.sup.11, C(.dbd.NR.sup.11)NR.sup.11R.sup.11,
NR.sup.11C(.dbd.NR.sup.11)NR.sup.11R.sup.11, NR.sup.11S(O)R.sup.11,
NR.sup.11S(O).sub.2R.sup.11, NR.sup.11S(O).sub.2NR.sup.11R.sup.11,
S(O)R.sup.11, S(O)NR.sup.11R.sup.11, S(O).sub.2R.sup.11, and
S(O).sub.2NR.sup.11R.sup.11, wherein the C.sub.1-4 alkyl,
cyclopropyl, C.sub.2-4 alkynyl and C.sub.1-4 alkoxy of R.sup.9 are
each optionally substituted with 1 or 2 halo, OH, CN or OCH.sub.3
substituents and each R.sup.11 is independently H or C.sub.1-4
alkyl optionally substituted with 1 or 2 halo, OH, CN or
OCH.sub.3;
[0059] R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 are each
independently selected from H, halo, C.sub.1-6 alkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl, C.sub.1-6
haloalkoxy, C.sub.6-10 aryl, C.sub.3-10 cycloalkyl, 5-14 membered
heteroaryl, 4-10 membered heterocycloalkyl, C.sub.6-10
aryl-C.sub.1-4 alkyl-, C.sub.3-10 cycloalkyl-C.sub.1-4 alkyl-,
(5-14 membered heteroaryl)-C.sub.1-4 alkyl-, (4-10 membered
heterocycloalkyl)-C.sub.1-4 alkyl-, CN, NO.sub.2, OR.sup.a,
SR.sup.a, NHOR.sup.a, C(O)R.sup.a, C(O)NR.sup.aR.sup.a,
C(O)OR.sup.a, OC(O)R.sup.a, OC(O)NR.sup.aR.sup.a, NHR.sup.a,
NR.sup.aR.sup.a, NR.sup.aC(O)R.sup.a, NR.sup.aC(O)OR.sup.a,
NR.sup.aC(O)NR.sup.aR.sup.a, C(.dbd.NR.sup.a)R.sup.a,
C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
NR.sup.aC(.dbd.NR.sup.a)NR.sup.aR.sup.a, NR.sup.aS(O)R.sup.a,
NR.sup.aS(O).sub.2R.sup.a, NR.sup.aS(O).sub.2NR.sup.aR.sup.a,
S(O)R.sup.a, S(O)NR.sup.aR.sup.a, S(O).sub.2R.sup.a, and
S(O).sub.2NR.sup.aR.sup.a, wherein the C.sub.1-6 alkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.6-10 aryl, C.sub.3-10 cycloalkyl,
5-14 membered heteroaryl, 4-10 membered heterocycloalkyl,
C.sub.6-10 aryl-C.sub.1-4 alkyl-, C.sub.3-10 cycloalkyl-C.sub.1-4
alkyl-, (5-14 membered heteroaryl)-C.sub.1-4 alkyl-, and (4-10
membered heterocycloalkyl)-C.sub.1-4 alkyl- of R.sup.3, R.sup.4,
R.sup.5, R.sup.6 and R.sup.7 are each optionally substituted with
1, 2, 3, or 4 R.sup.b substituents, with the proviso that at least
one of R.sup.3, R.sup.4, R.sup.5 and R.sup.6 is other than H;
[0060] or two adjacent R.sup.7 substituents on the Cy ring, taken
together with the atoms to which they are attached, form a fused
phenyl ring, a fused 5- to 7-membered heterocycloalkyl ring, a
fused 5- or 6-membered heteroaryl ring or a fused C.sub.5-6
cycloalkyl ring, wherein the fused 5- to 7-membered
heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring
each have 1-4 heteroatoms as ring members selected from N, O and S
and wherein the fused phenyl ring, fused 5- to 7-membered
heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and
fused C.sub.5-6 cycloalkyl ring are each optionally substituted
with 1 or 2 independently selected R.sup.b substituents; or 1 or 2
independently selected R.sup.q substituents
[0061] each R.sup.a is independently selected from H, CN, C.sub.1-6
alkyl, C.sub.1-4 haloalkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.6-10 aryl, C.sub.3-10 cycloalkyl, 5-10 membered heteroaryl,
4-10 membered heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-,
C.sub.3-10 cycloalkyl-C.sub.1-4 alkyl-, (5-10 membered
heteroaryl)-C.sub.1-4 alkyl-, and (4-10 membered
heterocycloalkyl)-C.sub.1-4 alkyl-, wherein the C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.6-10 aryl, C.sub.3-10
cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-, C.sub.3-10
cycloalkyl-C.sub.1-4 alkyl-, (5-10 membered heteroaryl)-C.sub.1-4
alkyl- and (4-10 membered heterocycloalkyl)-C.sub.1-4 alkyl- of
R.sup.a are each optionally substituted with 1, 2, 3, 4, or 5
R.sup.d substituents;
[0062] each R.sup.d is independently selected from C.sub.1-4 alkyl,
C.sub.1-4 haloalkyl, halo, C.sub.3-10 cycloalkyl, 4-10 membered
heterocycloalkyl, CN, NH.sub.2, NHOR.sup.e, OR.sup.e, SR.sup.e,
C(O)R.sup.e, C(O)NR.sup.eR.sup.e, C(O)OR.sup.e, OC(O)R.sup.e,
OC(O)NR.sup.eR.sup.e, NHR.sup.e, NR.sup.eR.sup.e,
NR.sup.eC(O)R.sup.e, NR.sup.eC(O)NR.sup.eR.sup.e,
NR.sup.eC(O)OR.sup.e, C(.dbd.NR.sup.e)NR.sup.eR.sup.e,
NR.sup.eC(.dbd.NR.sup.e)NR.sup.eR.sup.e, S(O)R.sup.e,
S(O)NR.sup.eR.sup.e, S(O).sub.2R.sup.e, NR.sup.eS(O).sub.2R.sup.e,
NR.sup.eS(O).sub.2NR.sup.eR.sup.e, and S(O).sub.2NR.sup.eR.sup.e,
wherein the C.sub.1-4 alkyl, C.sub.3-10 cycloalkyl and 4-10
membered heterocycloalkyl of R.sup.d are each further optionally
substituted with 1-3 independently selected R.sup.q
substituents;
[0063] each R.sup.b substituent is independently selected from
halo, C.sub.1-4 alkyl, C.sub.1-4 haloalkyl, C.sub.1-4 haloalkoxy,
C.sub.6-10 aryl, C.sub.3-10 cycloalkyl, 5-10 membered heteroaryl,
4-10 membered heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-,
C.sub.3-10 cycloalkyl-C.sub.1-4 alkyl-, (5-10 membered
heteroaryl)-C.sub.1-4 alkyl-, (4-10 membered
heterocycloalkyl)-C.sub.1-4 alkyl-, CN, OH, NH.sub.2, NO.sub.2,
NHOR.sup.c, SR.sup.c, C(O)R.sup.c, C(O)NR.sup.cR.sup.c,
C(O)OR.sup.c, OC(O)R.sup.c, OC(O)NR.sup.cR.sup.c,
C(.dbd.NR.sup.c)NR.sup.cR.sup.c,
NR.sup.cC(.dbd.NR.sup.c)NR.sup.cR.sup.c, NHR.sup.c,
NR.sup.cR.sup.c, NR.sup.cC(O)R.sup.c, NR.sup.cC(O)OR.sup.c,
NR.sup.cC(O)NR.sup.cR.sup.c, NR.sup.cS(O)R.sup.c,
NR.sup.cS(O).sub.2R.sup.c, NR.sup.cS(O).sub.2NR.sup.cR.sup.c, S(O)
R.sup.c, S(O)NR.sup.cR.sup.c, S(O).sub.2R.sup.c and
S(O).sub.2NR.sup.cR.sup.c; wherein the C.sub.1-4 alkyl, C.sub.1-4
haloalkyl, C.sub.1-4 haloalkoxy, C.sub.6-10 aryl, C.sub.3-10
cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-, C.sub.3-10
cycloalkyl-C.sub.1-4 alkyl-, (5-10 membered heteroaryl)-C.sub.1-4
alkyl- and (4-10 membered heterocycloalkyl)-C.sub.1-4 alkyl- of
R.sup.b are each further optionally substituted with 1-3
independently selected R.sup.d substituents;
[0064] each R.sup.c is independently selected from H, C.sub.1-6
alkyl, C.sub.1-4 haloalkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.6-10 aryl, C.sub.3-10 cycloalkyl, 5-10 membered heteroaryl,
4-10 membered heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-,
C.sub.3-10 cycloalkyl-C.sub.1-4 alkyl-, (5-10 membered
heteroaryl)-C.sub.1-4 alkyl-, and (4-10 membered
heterocycloalkyl)-C.sub.1-4 alkyl-, wherein the C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.6-10 aryl, C.sub.3-10
cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-, C.sub.3-10
cycloalkyl-C.sub.1-4 alkyl-, (5-10 membered heteroaryl)-C.sub.1-4
alkyl- and (4-10 membered heterocycloalkyl)-C.sub.1-4 alkyl- of
R.sup.c are each optionally substituted with 1, 2, 3, 4, or 5
R.sup.f substituents independently selected from C.sub.1-4 alkyl,
C.sub.1-4 haloalkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.6-10 aryl, C.sub.3-10 cycloalkyl, 5-10 membered heteroaryl,
4-10 membered heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-,
C.sub.3-10 cycloalkyl-C.sub.1-4 alkyl-, (5-10 membered
heteroaryl)-C.sub.1-4 alkyl-, (4-10 membered
heterocycloalkyl)-C.sub.1-4 alkyl-, halo, CN, NHOR.sup.g, OR.sup.g,
SR.sup.g, C(O)R.sup.g, C(O)NR.sup.gR.sup.g, C(O)OR.sup.g,
OC(O)R.sup.g, OC(O)NR.sup.gR.sup.g, NHR.sup.g, NR.sup.gR.sup.g,
NR.sup.gC(O)R.sup.g, NR.sup.gC(O)NR.sup.gR.sup.g,
NR.sup.gC(O)OR.sup.g, C(.dbd.NR.sup.g)NR.sup.gR.sup.g,
NR.sup.gC(.dbd.NR.sup.g)NR.sup.gR.sup.g, S(O)R.sup.g,
S(O)NR.sup.gR.sup.g, S(O).sub.2R.sup.g, NR.sup.gS(O).sub.2R.sup.g,
NR.sup.gS(O).sub.2NR.sup.gR.sup.g, and S(O).sub.2NR.sup.gR.sup.g;
wherein the C.sub.1-4 alkyl, C.sub.1-4 haloalkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.6-10 aryl, C.sub.3-10 cycloalkyl,
5-10 membered heteroaryl, 4-10 membered heterocycloalkyl,
C.sub.6-10 aryl-C.sub.1-4 alkyl-, C.sub.3-10 cycloalkyl-C.sub.1-4
alkyl-, (5-10 membered heteroaryl)-C.sub.1-4 alkyl-, and (4-10
membered heterocycloalkyl)-C.sub.1-4 alkyl- of R.sup.f are each
optionally substituted with 1, 2, 3, 4, or 5 R.sup.n substituents
independently selected from C.sub.1-4 alkyl, C.sub.1-4 haloalkyl,
halo, CN, R.sup.o, NHOR.sup.o, OR.sup.o, SR.sup.o, C(O)R.sup.o,
C(O)NR.sup.oR.sup.o, C(O)OR.sup.o, OC(O)R.sup.o,
OC(O)NR.sup.oR.sup.o, NHR.sup.o, NR.sup.oR.sup.o,
NR.sup.oC(O)R.sup.o, NR.sup.oC(O)NR.sup.oR.sup.o,
NR.sup.oC(O)OR.sup.o, C(.dbd.NR.sup.o)NR.sup.oR.sup.o,
NR.sup.oC(.dbd.NR.sup.o)NR.sup.oR.sup.o, S(O)R.sup.o,
S(O)NR.sup.oR.sup.o, S(O).sub.2R.sup.o, NR.sup.oS(O).sub.2R.sup.o,
NR.sup.oS(O).sub.2NR.sup.oR.sup.o, and
S(O).sub.2NR.sup.oR.sup.o;
[0065] each R.sup.g is independently selected from H, C.sub.1-6
alkyl, C.sub.1-4 haloalkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.6-10 aryl, C.sub.3-10 cycloalkyl, 5-10 membered heteroaryl,
4-10 membered heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-,
C.sub.3-10 cycloalkyl-C.sub.1-4 alkyl-, (5-10 membered
heteroaryl)-C.sub.1-4 alkyl-, and (4-10 membered
heterocycloalkyl)-C.sub.1-4 alkyl-, wherein the C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, 10 aryl, C.sub.3-10
cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-, C.sub.3-10
cycloalkyl-C.sub.1-4 alkyl-, (5-10 membered heteroaryl)-C.sub.1-4
alkyl- and (4-10 membered heterocycloalkyl)-C.sub.1-4 alkyl- of
R.sup.g are each optionally substituted with 1-3 independently
selected R.sup.p substituents;
[0066] or any two R.sup.a substituents together with the nitrogen
atom to which they are attached form a 4-, 5-, 6-, 7-, 8-, 9- or
10-membered heterocycloalkyl group optionally substituted with 1, 2
or 3 R.sup.h substituents independently selected from C.sub.1-6
alkyl, C.sub.3-10 cycloalkyl, 4-7 membered heterocycloalkyl,
C.sub.6-10 aryl, 5-6 membered heteroaryl, C.sub.3-10
cycloalkyl-C.sub.1-4 alkyl-, (5-6 membered heteroaryl)-C.sub.1-4
alkyl-, (4-7 membered heterocycloalkyl)-C.sub.1-4 alkyl-, C.sub.1-6
haloalkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, halo, CN,
OR.sup.i, SR.sup.i, NHOR.sup.i, C(O)R.sup.i, C(O)NR.sup.iR.sup.i,
C(O)OR.sup.i, OC(O)R.sup.i, OC(O)NR.sup.iR.sup.i, NHR.sup.i,
NR.sup.iR.sup.i, NR.sup.iC(O)R.sup.i, NR.sup.iC(O)NR.sup.iR.sup.i,
NR.sup.iC(O)OR.sup.i, C(.dbd.NR.sup.i)NR.sup.iR.sup.i,
NR.sup.iC(.dbd.NR.sup.i)NR.sup.iR.sup.i, S(O)R.sup.i,
S(O)NR.sup.iR.sup.i, S(O).sub.2R.sup.i, NR.sup.iS(O).sub.2R.sup.i,
NR.sup.iS(O).sub.2NR.sup.iR.sup.i, and S(O).sub.2NR.sup.iR.sup.i,
wherein the C.sub.1-6 alkyl, C.sub.3-10 cycloalkyl, 4-7 membered
heterocycloalkyl, C.sub.6-10 aryl, 5-6 membered heteroaryl,
C.sub.3-10 cycloalkyl-C.sub.1-4 alkyl-, (5-6 membered
heteroaryl)-C.sub.1-4 alkyl-, (4-7 membered
heterocycloalkyl)-C.sub.1-4 alkyl- of R.sup.h are each further
optionally substituted by 1, 2, or 3 substituents independently
selected from C.sub.3-6 cycloalkyl, C.sub.6-10 aryl, 5 or
6-membered heteroaryl, C.sub.2-4 alkenyl, C.sub.2-4 alkynyl, halo,
C.sub.1-4 alkyl, C.sub.1-4 haloalkyl, CN, NHOR.sup.k, OR.sup.k,
SR.sup.k, C(O)R.sup.k, C(O)NR.sup.kR.sup.k, C(O)OR.sup.k,
OC(O)R.sup.k, OC(O)NR.sup.kR.sup.k, NHR.sup.k, NR.sup.kR.sup.k,
NR.sup.kC(O)R.sup.k, NR.sup.kC(O)NR.sup.kR.sup.k,
NR.sup.kC(O)OR.sup.k, C(.dbd.NR.sup.k)NR.sup.kR.sup.k,
NR.sup.kC(.dbd.NR.sup.k)NR.sup.kR.sup.k, S(O)R.sup.k,
S(O)NR.sup.kR.sup.k, S(O).sub.2R.sup.k, NR.sup.kS(O).sub.2R.sup.k,
NR.sup.kS(O).sub.2NR.sup.kR.sup.k, and S(O).sub.2NR.sup.kR.sup.k;
or two R.sup.h groups attached to the same carbon atom of the 4- to
10-membered heterocycloalkyl taken together with the carbon atom to
which they attach form a C.sub.3-6 cycloalkyl or 4- to 6-membered
heterocycloalkyl having 1-2 heteroatoms as ring members selected
from O, N or S;
[0067] or any two R.sup.c substituents together with the nitrogen
atom to which they are attached form a 4-, 5-, 6-, or 7-membered
heterocycloalkyl group optionally substituted with 1, 2, or 3
independently selected R.sup.h substituents; [0068] or any two
R.sup.e substituents together with the nitrogen atom to which they
are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl
group optionally substituted with 1, 2, or 3 independently selected
R.sup.h substituents;
[0069] or any two R.sup.g substituents together with the nitrogen
atom to which they are attached form a 4-, 5-, 6-, or 7-membered
heterocycloalkyl group optionally substituted with 1, 2, or 3
independently selected R.sup.h substituents;
[0070] or any two R.sup.i substituents together with the nitrogen
atom to which they are attached form a 4-, 5-, 6-, or 7-membered
heterocycloalkyl group optionally substituted with 1, 2, or 3
independently selected R.sup.h substituents;
[0071] or any two R.sup.k substituents together with the nitrogen
atom to which they are attached form a 4-, 5-, 6-, or 7-membered
heterocycloalkyl group optionally substituted with 1, 2, or 3
independently selected R.sup.h substituents;
[0072] or any two R.sup.o substituents together with the nitrogen
atom to which they are attached form a 4-, 5-, 6-, or 7-membered
heterocycloalkyl group optionally substituted with 1, 2, or 3
independently selected R.sup.h substituents; and
[0073] each R.sup.e, R.sup.i, R.sup.k, R.sup.o or R.sup.p is
independently selected from H, C.sub.1-4 alkyl, C.sub.3-6
cycloalkyl, C.sub.6-10 aryl, 5 or 6-membered heteroaryl, C.sub.1-4
haloalkyl, C.sub.2-4 alkenyl, and C.sub.2-4 alkynyl, wherein the
C.sub.1-4 alkyl, C.sub.3-6 cycloalkyl, C.sub.6-10 aryl, 5 or
6-membered heteroaryl, C.sub.2-4 alkenyl, and C.sub.2-4 alkynyl of
R.sup.e, R.sup.i, R.sup.k, R.sup.o or R.sup.p are each optionally
substituted with 1, 2 or 3 R.sup.q substituents;
[0074] each R.sup.q is independently selected from OH, CN, --COOH,
NH.sub.2, halo, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, C.sub.1-4
alkylthio, phenyl, 5-6 membered heteroaryl, C.sub.3-6 cycloalkyl,
NHR.sup.12, NR.sup.12R.sup.12, and C.sub.1-4 haloalkoxy, wherein
the C.sub.1-4 alkyl, phenyl and 5-6 membered heteroaryl of R.sup.q
are each optionally substituted with OH, CN, --COOH, NH.sub.2,
C.sub.1-4 alkoxy, C.sub.3-10 cycloalkyl and 4-6 membered
heterocycloalkyl and each R.sup.12 is independently C.sub.1-6
alkyl;
[0075] is a single bond or a double bond to maintain ring A being
aromatic; and
[0076] when the moiety
##STR00006##
in Formula (I') is 2-benzoxazolyl substituted with 1 to 3
substituents independently selected from methyl, ethyl, isopropyl,
methoxy, Cl, Br, and phenyl, then Cy is not 4H-1,2,4-triazol-4-yl,
5-methyl-2-benzoxazolyl or 2-oxopyrrolidinyl substituted with COOH,
--C(O)NH.sub.2, --C(O)OC.sub.1-2 alkyl or C(O)Cl.
[0077] In certain embodiments of compounds of Formula (I'), when
the moiety
##STR00007##
in Formula (I') is 2-benzoxazolyl substituted with 1 to 3
substituents independently selected from C.sub.1-3 alkyl, C.sub.1-3
alkoxy, halo, and phenyl, then Cy is not 4H-1,2,4-triazol-4-yl,
5-methyl-2-benzoxazolyl or 2-oxopyrrolidinyl optionally substituted
with --COOH, --C(O)NH.sub.2, --C(O)OC.sub.1-2 alkyl or C(O)Cl.
[0078] In other embodiments of compounds of Formula (I'), when the
moiety
##STR00008##
in Formula (I') is 2-benzoxazolyl substituted with 1 to 3
substituents independently selected from C.sub.1-3 alkyl, C.sub.1-3
alkoxy, halo, and phenyl, then Cy is not 4H-1,2,4-triazol-4-yl,
5-methyl-2-benzoxazolyl or 2-oxopyrrolidinyl optionally substituted
with a R.sup.7 group.
[0079] In other embodiments of compounds of Formula (I'), when the
moiety
##STR00009##
in Formula (I') is 2-benzoxazolyl, wherein X.sup.3 is CR.sup.3,
X.sup.4 is CR.sup.4, X.sup.5 is CR.sup.5 and X.sup.6 is CR.sup.6,
Cy is not 4H-1,2,4-triazol-4-yl, 5-methyl-2-benzoxazolyl or
2-oxopyrrolidinyl substituted with a R.sup.7 group.
[0080] In some embodiments of compounds of Formula (I'), Cy is
C.sub.6-10 aryl, optionally substituted with 1 to 5 independently
selected R.sup.7 substituents. In certain embodiments, Cy is phenyl
or naphthyl, each of which is optionally substituted with 1 to 4
independently selected R.sup.7 substituents. In certain
embodiments, Cy is phenyl optionally substituted with 1 to 5
independently selected R.sup.7 substituents. In certain
embodiments, Cy is unsubstituted phenyl. In certain embodiments, Cy
is 2,3-dihydro-1,4-benzodioxin-6-yl, optionally substituted with 1
to 5 independently selected R.sup.7 substituents.
[0081] In some embodiments of compounds of Formula (I'), Cy is
C.sub.3-10 cycloalkyl, optionally substituted with 1 to 5
independently selected R.sup.7 substituents. In certain
embodiments, Cy is cyclopropyl, cyclobutyl, cyclopentyl,
cyclohexyl, cyclohexenyl, cycloheptyl or cyclooctyl, each of which
is optionally substituted with 1 to 5 independently selected
R.sup.7 substituents.
[0082] In some embodiments of compounds of Formula (I'), Cy is 5-
to 14-membered heteroaryl, optionally substituted with 1 to 5
independently selected R.sup.7 substituents. In certain
embodiments, Cy is pyridyl, primidinyl, pyrazinyl, pyridazinyl,
triazinyl, pyrrolyl, pyrazolyl, azolyl, oxazolyl, thiazolyl,
imidazolyl, furanyl, thiophenyl, quinolinyl, isoquinolinyl,
naphthyridinyl, indolyl, benzothiophenyl, benzofuranyl,
benzisoxazolyl, imidazo[1,2-b]thiazolyl, purinyl, thienyl, furyl,
pyrrolyl, imidazolyl, thiazolyl, oxazolyl, pyrazolyl, isothiazolyl,
isoxazolyl, 1,2,3-triazolyl, tetrazolyl, 1,2,3-thiadiazolyl,
1,2,3-oxadiazolyl, 1,2,4-triazolyl, 1,2,4-thiadiazolyl,
1,2,4-oxadiazolyl, 1,3,4-triazolyl, 1,3,4-thiadiazolyl and
1,3,4-oxadiazolyl, each of which is optionally substituted with 1
to 5 independently selected R.sup.7 substituents.
[0083] In some embodiments of compounds of Formula (I'), Cy is 4-
to 10-membered heterocycloalkyl, optionally substituted with 1 to 5
independently selected R.sup.7 substituents. In certain
embodiments, Cy is azetidinyl, azepanyl, dihydrobenzofuranyl,
dihydrofuranyl, dihydropyranyl, morpholino,
3-oxa-9-azaspiro[5.5]undecanyl, 1-oxa-8-azaspiro[4.5]decanyl,
piperidinyl, piperazinyl, oxopiperazinyl, pyranyl, pyrrolidinyl,
quinuclidinyl, tetrahydrofuranyl, tetrahydropyranyl,
1,2,3,4-tetrahydroquinolinyl, tropanyl,
2,3-dihydro-1,4-benzodioxin-6-yl, or thiomorpholino, each of which
is optionally substituted with 1 to 4 independently selected
R.sup.7 substituents. In some embodiments, Cy is
3,6-dihydro-2H-pyran-4-yl, optionally substituted with 1 to 5
independently selected R.sup.7 substituents.
[0084] In some embodiments of compounds of Formula (I'), Cy is
phenyl, 5- or 6-membered heteroaryl, C.sub.3-6 cycloalkyl or 5- or
6-membered heterocycloalkyl, each of which is optionally
substituted with 1 to 5 independently selected R.sup.7
substituents. In certain instances, Cy is phenyl, 2-thiophenyl,
3-thiophenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, C.sub.3-6 cycloalkyl
or 3,6-dihydro-2H-pyran-4-yl, each of which is optionally
substituted with 1 to 5 R.sup.7 substituents.
[0085] In some embodiments of compounds of Formula (I'), Y.sup.1,
Y.sup.2 and Y.sup.3 are each CH.
[0086] In some embodiments, the present disclosure provides a
compound of Formula (I):
##STR00010##
or a pharmaceutically acceptable salt or a stereoisomer thereof,
wherein:
[0087] one of X.sup.1 and X.sup.2 is O or S and the other of
X.sup.1 and X.sup.2 is N, CR' or CR.sup.2;
[0088] X.sup.3 is N or CR.sup.3;
[0089] X.sup.4 is N or CR.sup.4;
[0090] X.sup.5 is N or CR.sup.5;
[0091] X.sup.6 is N or CR.sup.6;
[0092] at least one of X.sup.1, X.sup.2, X.sup.3, X.sup.4, X.sup.5
and X.sup.6 is N;
[0093] R.sup.1, R.sup.2 and R.sup.8 are each independently selected
from H, C.sub.1-4 alkyl, C.sub.3-6 cycloalkyl, C.sub.2-4 alkenyl,
C.sub.2-4 alkynyl, halo, CN, OH, C.sub.1-4 alkoxy, C.sub.1-4
haloalkyl, C.sub.1-4 haloalkoxy, NH.sub.2, --NH--C.sub.1-4 alkyl,
--N(C.sub.1-4 alkyl).sub.2, NHOR.sup.10, C(O)R.sup.10,
C(O)NR.sup.10R.sup.10, C(O)OR.sup.10, OC(O)R.sup.10,
OC(O)NR.sup.10R.sup.10, NR.sup.10C(O)R.sup.10,
NR.sup.10C(O)OR.sup.10, NR.sup.10C(O)NR.sup.10R.sup.10,
C(.dbd.NR.sup.10)R.sup.10, C(.dbd.NR.sup.10)NR.sup.10R.sup.10,
NR.sup.10C(.dbd.NR.sup.10)NR.sup.10R.sup.10, NR.sup.10S(O)R.sup.10,
NR.sup.10S(O).sub.2R.sup.10, NR.sup.10S(O).sub.2NR.sup.10R.sup.10,
S(O)R.sup.10, S(O)NR.sup.10R.sup.10, S(O).sub.2R.sup.10, and
S(O).sub.2NR.sup.10R.sup.10, wherein each R.sup.10 is independently
H or C.sub.1-4 alkyl optionally substituted with 1 or 2 groups
independently selected from halo, OH, CN and C.sub.1-4 alkoxy and
wherein the C.sub.1-4 alkyl, C.sub.3-4 cycloalkyl, C.sub.2-4
alkenyl and C.sub.2-4 alkynyl of R.sup.1, R.sup.2 or R.sup.8 are
each optionally substituted with 1 or 2 substituents independently
selected from halo, OH, CN, C.sub.1-4 alkyl and C.sub.1-4
alkoxy;
[0094] R.sup.9 is C.sub.1-4 alkyl, Cl, Br, CN, cyclopropyl,
C.sub.2-4 alkynyl, C.sub.1-4 haloalkyl, C.sub.1-4 haloalkoxy,
NH.sub.2, --NH--C.sub.1-4alkyl, --N(C.sub.1-4 alkyl).sub.2,
NHOR.sup.11, C(O)R.sup.11, C(O)NR.sup.11R.sup.11, C(O)OR.sup.11,
OC(O)R.sup.11, OC(O)NR.sup.11R.sup.11, NR.sup.11C(O)R.sup.11,
NR.sup.11C(O)OR.sup.11, NR.sup.11C(O)NR.sup.11R.sup.11,
C(.dbd.NR.sup.11)R.sup.11, C(.dbd.NR.sup.11)NR.sup.11R.sup.11,
NR.sup.11C(.dbd.NR.sup.11)NR.sup.11R.sup.11, NR.sup.11S(O)R.sup.11,
NR.sup.11S(O).sub.2R.sup.11, S(O)R.sup.11, S(O)NR.sup.11R.sup.11,
S(O).sub.2R.sup.11, and S(O).sub.2NR.sup.11R.sup.11, wherein each
R.sup.11 is independently H or C.sub.1-4 alkyl optionally
substituted with 1 or 2 halo, OH, CN or OCH.sub.3;
[0095] R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 are each
independently selected from H, halo, C.sub.1-6 alkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl, C.sub.1-6
haloalkoxy, C.sub.6-10 aryl, C.sub.3-10 cycloalkyl, 5-14 membered
heteroaryl, 4-10 membered heterocycloalkyl, C.sub.6-10
aryl-C.sub.1-4 alkyl-, C.sub.3-10 cycloalkyl-C.sub.1-4 alkyl-,
(5-14 membered heteroaryl)-C.sub.1-4 alkyl-, (4-10 membered
heterocycloalkyl)-C.sub.1-4 alkyl-, CN, NO.sub.2, OR.sup.a,
SR.sup.a, NHOR.sup.a, C(O)R.sup.a, C(O)NR.sup.aR.sup.a,
C(O)OR.sup.a, OC(O)R.sup.a, OC(O)NR.sup.aR.sup.a, NHR.sup.a,
NR.sup.aR.sup.a, NR.sup.aC(O)R.sup.a, NR.sup.aC(O)OR.sup.a,
NR.sup.aC(O)NR.sup.aR.sup.a, C(.dbd.NR.sup.a)R.sup.a,
C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
NR.sup.aC(.dbd.NR.sup.a)NR.sup.aR.sup.a, NR.sup.aS(O)R.sup.a,
NR.sup.aS(O).sub.2R.sup.a, NR.sup.aS(O).sub.2NR.sup.aR.sup.a,
S(O)R.sup.a, S(O)NR.sup.aR.sup.a, S(O).sub.2R.sup.a, and
S(O).sub.2NR.sup.aR.sup.a, wherein the C.sub.1-6 alkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.6-10 aryl, C.sub.3-10 cycloalkyl,
5-14 membered heteroaryl, 4-10 membered heterocycloalkyl,
C.sub.6-10 aryl-C.sub.1-4 alkyl-, C.sub.3-10 cycloalkyl-C.sub.1-4
alkyl-, (5-14 membered heteroaryl)-C.sub.1-4 alkyl-, and (4-10
membered heterocycloalkyl)-C.sub.1-4 alkyl- of R.sup.3, R.sup.4,
R.sup.5, R.sup.6 and R.sup.7 are each optionally substituted with
1, 2, 3, or 4 R.sup.b substituents, with the proviso that at least
one of R.sup.3, R.sup.4, R.sup.5 and R.sup.6 is other than H;
[0096] or two adjacent R.sup.7 substituents on the phenyl ring,
taken together with the carbon atoms to which they are attached,
form a fused phenyl ring, a fused 5- to 7-membered heterocycloalkyl
ring, a fused 5- or 6-membered heteroaryl ring or a fused C.sub.5-6
cycloalkyl ring, wherein the fused 5- to 7-membered
heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring
each have 1-4 heteroatoms as ring members selected from N, O and S
and wherein the fused phenyl ring, fused 5- to 7-membered
heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and
fused C.sub.5-6 cycloalkyl ring are each optionally substituted
with 1 or 2 independently selected R.sup.q substituents
[0097] each R.sup.a is independently selected from H, CN, C.sub.1-6
alkyl, C.sub.1-4 haloalkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.6-10 aryl, C.sub.3-10 cycloalkyl, 5-10 membered heteroaryl,
4-10 membered heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-,
C.sub.3-10 cycloalkyl-C.sub.1-4 alkyl-, (5-10 membered
heteroaryl)-C.sub.1-4 alkyl-, and (4-10 membered
heterocycloalkyl)-C.sub.1-4 alkyl-, wherein the C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.6-10 aryl, C.sub.3-10
cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-, C.sub.3-10
cycloalkyl-C.sub.1-4 alkyl-, (5-10 membered heteroaryl)-C.sub.1-4
alkyl- and (4-10 membered heterocycloalkyl)-C.sub.1-4 alkyl- of W
are each optionally substituted with 1, 2, 3, 4, or 5 R.sup.d
substituents;
[0098] each R.sup.d is independently selected from C.sub.1-4 alkyl,
C.sub.1-4 haloalkyl, halo, C.sub.3-10 cycloalkyl, 4-10 membered
heterocycloalkyl, CN, NH.sub.2, NHOR.sup.e, OR.sup.e, SR.sup.e,
C(O)R.sup.e, C(O)NR.sup.eR.sup.e, C(O)OR.sup.e, OC(O)R.sup.e,
OC(O)NR.sup.eR.sup.e, NHR.sup.e, NR.sup.eR.sup.e,
NR.sup.eC(O)R.sup.e, NR.sup.eC(O)NR.sup.eR.sup.e,
NR.sup.eC(O)OR.sup.e, C(.dbd.NR.sup.e)NR.sup.eR.sup.e,
NR.sup.eC(.dbd.NR.sup.e)NR.sup.eR.sup.e, S(O)R.sup.e,
S(O)NR.sup.eR.sup.e, S(O).sub.2R.sup.e, NR.sup.eS(O).sub.2R.sup.e,
NR.sup.eS(O).sub.2NR.sup.eR.sup.e, and S(O).sub.2NR.sup.eR.sup.e,
wherein the C.sub.1-4 alkyl, C.sub.3-10 cycloalkyl and 4-10
membered heterocycloalkyl of R.sup.d are each further optionally
substituted with 1-3 independently selected R.sup.q
substituents;
[0099] each R.sup.b substituent is independently selected from
halo, C.sub.1-4 alkyl, C.sub.1-4 haloalkyl, C.sub.1-4 haloalkoxy,
C.sub.6-10 aryl, C.sub.3-10 cycloalkyl, 5-10 membered heteroaryl,
4-10 membered heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-,
C.sub.3-10 cycloalkyl-C.sub.1-4 alkyl-, (5-10 membered
heteroaryl)-C.sub.1-4 alkyl-, (4-10 membered
heterocycloalkyl)-C.sub.1-4 alkyl-, CN, OH, NH.sub.2, NO.sub.2,
NHOR.sup.c, OR.sup.c, SR.sup.cC(O)R.sup.c, C(O)NR.sup.cR.sup.c,
C(O)OR.sup.c, OC(O)R.sup.c, OC(O)NR.sup.cR.sup.c,
C(.dbd.NR.sup.c)NR.sup.cR.sup.c,
NR.sup.cC(.dbd.NR.sup.c)NR.sup.cR.sup.c, NHR.sup.c,
NR.sup.cR.sup.c, NR.sup.cC(O)R.sup.c, NR.sup.cC(O)OR.sup.c,
NR.sup.cC(O)NR.sup.cR.sup.c, NR.sup.cS(O)R.sup.c,
NR.sup.cS(O).sub.2R.sup.c, NR.sup.cS(O).sub.2NR.sup.cR.sup.c,
S(O)R.sup.c, S(O)NR.sup.cR.sup.c, S(O).sub.2R.sup.c and
S(O).sub.2NR.sup.cR.sup.c; wherein the C.sub.1-4 alkyl, C.sub.1-4
haloalkyl, C.sub.1-4 haloalkoxy, C.sub.6-10 aryl, C.sub.3-10
cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-, C.sub.3-10
cycloalkyl-C.sub.1-4 alkyl-, (5-10 membered heteroaryl)-C.sub.1-4
alkyl- and (4-10 membered heterocycloalkyl)-C.sub.1-4 alkyl- of
R.sup.b are each further optionally substituted with 1-3
independently selected R.sup.d substituents;
[0100] each R.sup.c is independently selected from H, C.sub.1-6
alkyl, C.sub.1-4 haloalkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.6-10 aryl, C.sub.3-10 cycloalkyl, 5-10 membered heteroaryl,
4-10 membered heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-,
C.sub.3-10 cycloalkyl-C.sub.1-4 alkyl-, (5-10 membered
heteroaryl)-C.sub.1-4 alkyl-, and (4-10 membered
heterocycloalkyl)-C.sub.1-4 alkyl-, wherein the C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.6-10 aryl, C.sub.3-10
cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-, C.sub.3-10
cycloalkyl-C.sub.1-4 alkyl-, (5-10 membered heteroaryl)-C.sub.1-4
alkyl- and (4-10 membered heterocycloalkyl)-C.sub.1-4 alkyl- of
R.sup.c are each optionally substituted with 1, 2, 3, 4, or 5
R.sup.f substituents independently selected from C.sub.1-4 alkyl,
C.sub.1-4 haloalkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.6-10 aryl, C.sub.3-10 cycloalkyl, 5-10 membered heteroaryl,
4-10 membered heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-,
C.sub.3-10 cycloalkyl-C.sub.1-4 alkyl-, (5-10 membered
heteroaryl)-C.sub.1-4 alkyl-, (4-10 membered
heterocycloalkyl)-C.sub.1-4 alkyl-, halo, CN, NHOR.sup.g, OR.sup.g,
SR.sup.g, C(O)R.sup.g, C(O)NR.sup.gR.sup.g, C(O)OR.sup.g,
OC(O)R.sup.g, OC(O)NR.sup.gR.sup.g, NHR.sup.g, NR.sup.gR.sup.g,
NR.sup.gC(O)R.sup.g, NR.sup.gC(O)NR.sup.gR.sup.g,
NR.sup.gC(O)OR.sup.g, C(.dbd.NR.sup.g)NR.sup.gR.sup.g,
NR.sup.gC(.dbd.NR.sup.g)NR.sup.gR.sup.g, S(O)R.sup.g,
S(O)NR.sup.gR.sup.g, S(O).sub.2R.sup.g, NR.sup.gS(O).sub.2R.sup.g,
NR.sup.gS(O).sub.2NR.sup.gR.sup.g, and S(O).sub.2NR.sup.gR.sup.g;
wherein the C.sub.1-4 alkyl, C.sub.1-4 haloalkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.6-10 aryl, C.sub.3-10 cycloalkyl,
5-10 membered heteroaryl, 4-10 membered heterocycloalkyl,
C.sub.6-10 aryl-C.sub.1-4 alkyl-, C.sub.3-10 cycloalkyl-C.sub.1-4
alkyl-, (5-10 membered heteroaryl)-C.sub.1-4 alkyl-, and (4-10
membered heterocycloalkyl)-C.sub.1-4 alkyl- of R.sup.f are each
optionally substituted with 1, 2, 3, 4, or 5 R.sup.n substituents
independently selected from C.sub.1-4 alkyl, C.sub.1-4 haloalkyl,
halo, CN, R.sup.o, NHOR.sup.o, OR.sup.o, SR.sup.o, C(O)R.sup.o,
C(O)NR.sup.oR.sup.o, C(O)OR.sup.o, OC(O)R.sup.o,
OC(O)NR.sup.oR.sup.o, NHR.sup.o, NR.sup.oR.sup.o,
NR.sup.oC(O)R.sup.o, NR.sup.oC(O)NR.sup.oR.sup.o,
NR.sup.oC(O)OR.sup.o, C(.dbd.NR.sup.o)NR.sup.oR.sup.o,
NR.sup.oC(.dbd.NR.sup.o)NR.sup.oR.sup.o, S(O)R.sup.o,
S(O)NR.sup.oR.sup.o, S(O).sub.2R.sup.o, NR.sup.oS(O).sub.2R.sup.o,
NR.sup.oS(O).sub.2NR.sup.oR.sup.o, and
S(O).sub.2NR.sup.oR.sup.o;
[0101] each R.sup.g is independently selected from H, C.sub.1-6
alkyl, C.sub.1-4 haloalkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.6-10 aryl, C.sub.3-10 cycloalkyl, 5-10 membered heteroaryl,
4-10 membered heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-,
C.sub.3-10 cycloalkyl-C.sub.1-4 alkyl-, (5-10 membered
heteroaryl)-C.sub.1-4 alkyl-, and (4-10 membered
heterocycloalkyl)-C.sub.1-4 alkyl-, wherein the C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.6-10 aryl, C.sub.3-10
cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-, C.sub.3-10
cycloalkyl-C.sub.1-4 alkyl-, (5-10 membered heteroaryl)-C.sub.1-4
alkyl- and (4-10 membered heterocycloalkyl)-C.sub.1-4 alkyl- of
R.sup.g are each optionally substituted with 1-3 independently
selected R.sup.p substituents;
[0102] or any two R.sup.a substituents together with the nitrogen
atom to which they are attached form a 4-, 5-, 6-, 7-, 8-, 9- or
10-membered heterocycloalkyl group optionally substituted with 1, 2
or 3 R.sup.h substituents independently selected from C.sub.1-6
alkyl, C.sub.3-10 cycloalkyl, 4-7 membered heterocycloalkyl,
C.sub.6-10 aryl, 5-6 membered heteroaryl, C.sub.3-10
cycloalkyl-C.sub.1-4 alkyl-, (5-6 membered heteroaryl)-C.sub.1-4
alkyl-, (4-7 membered heterocycloalkyl)-C.sub.1-4 alkyl-, C.sub.1-6
haloalkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, halo, CN,
OR.sup.i, SR.sup.i, NHOR.sup.i, C(O)R.sup.i, C(O)NR.sup.iR.sup.i,
C(O)OR.sup.i, OC(O)R.sup.i, OC(O)NR.sup.iR.sup.i, NHR.sup.i,
NR.sup.iR.sup.i, NR.sup.iC(O)R.sup.i, NR.sup.iC(O)NR.sup.iR.sup.i,
NR.sup.iC(O)OR.sup.i, C(.dbd.NR.sup.i)NR.sup.iR.sup.i,
NR.sup.iC(.dbd.NR.sup.i)NR.sup.iR.sup.i, S(O)R.sup.i,
S(O)NR.sup.iR.sup.i, S(O).sub.2R.sup.i, NR.sup.iS(O).sub.2R.sup.i,
NR.sup.iS(O).sub.2NR.sup.iR.sup.i, and S(O).sub.2NR.sup.iR.sup.i,
wherein the C.sub.1-6 alkyl, C.sub.3-10 cycloalkyl, 4-7 membered
heterocycloalkyl, C.sub.6-10 aryl, 5-6 membered heteroaryl,
C.sub.3-10 cycloalkyl-C.sub.1-4 alkyl-, (5-6 membered
heteroaryl)-C.sub.1-4 alkyl-, (4-7 membered
heterocycloalkyl)-C.sub.1-4 alkyl- of R.sup.h are each further
optionally substituted by 1, 2, or 3 R.sup.j substituents
independently selected from C.sub.3-6 cycloalkyl, C.sub.6-10 aryl,
5 or 6-membered heteroaryl, C.sub.2-4 alkenyl, C.sub.2-4 alkynyl,
halo, C.sub.1-4 alkyl, C.sub.1-4 haloalkyl, CN, NHOR.sup.k,
OR.sup.k, SR.sup.k, C(O)R.sup.k, C(O)NR.sup.kR.sup.k, C(O)OR.sup.k,
OC(O)R.sup.k, OC(O)NR.sup.kR.sup.k, NHR.sup.k, NR.sup.kR.sup.k,
NR.sup.kC(O)R.sup.k, NR.sup.kC(O)NR.sup.kR.sup.k,
NR.sup.kC(O)OR.sup.k, C(.dbd.NR.sup.k)NR.sup.kR.sup.k,
NR.sup.kC(.dbd.NR.sup.k)NR.sup.kR.sup.k, S(O)R.sup.k,
S(O)NR.sup.kR.sup.k, S(O).sub.2R.sup.k, NR.sup.kS(O).sub.2R.sup.k,
NR.sup.kS(O).sub.2NR.sup.kR.sup.k, and S(O).sub.2NR.sup.kR.sup.k;
or two R.sup.h groups attached to the same carbon atom of the 4- to
10-membered heterocycloalkyl taken together with the carbon atom to
which they attach form a C.sub.3-6 cycloalkyl or 4- to 6-membered
heterocycloalkyl having 1-2 heteroatoms as ring members selected
from O, N or S;
[0103] or any two R.sup.c substituents together with the nitrogen
atom to which they are attached form a 4-, 5-, 6-, or 7-membered
heterocycloalkyl group optionally substituted with 1, 2, or 3
independently selected R.sup.h substituents;
[0104] or any two R.sup.e substituents together with the nitrogen
atom to which they are attached form a 4-, 5-, 6-, or 7-membered
heterocycloalkyl group optionally substituted with 1, 2, or 3
independently selected R.sup.h substituents;
[0105] or any two R.sup.g substituents together with the nitrogen
atom to which they are attached form a 4-, 5-, 6-, or 7-membered
heterocycloalkyl group optionally substituted with 1, 2, or 3
independently selected R.sup.h substituents; [0106] or any two
R.sup.i substituents together with the nitrogen atom to which they
are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl
group optionally substituted with 1, 2, or 3 independently selected
R.sup.h substituents;
[0107] or any two R.sup.k substituents together with the nitrogen
atom to which they are attached form a 4-, 5-, 6-, or 7-membered
heterocycloalkyl group optionally substituted with 1, 2, or 3
independently selected R.sup.h substituents;
[0108] or any two R.sup.o substituents together with the nitrogen
atom to which they are attached form a 4-, 5-, 6-, or 7-membered
heterocycloalkyl group optionally substituted with 1, 2, or 3
independently selected R.sup.h substituents; and
[0109] each R.sup.e, R.sup.i, R.sup.k, R.sup.o or R.sup.p is
independently selected from H, C.sub.1-4 alkyl, C.sub.3-6
cycloalkyl, C.sub.6-10 aryl, 5 or 6-membered heteroaryl, C.sub.1-4
haloalkyl, C.sub.2-4 alkenyl, and C.sub.2-4 alkynyl, wherein the
C.sub.1-4 alkyl, C.sub.3-6 cycloalkyl, C.sub.6-10 aryl, 5 or
6-membered heteroaryl, C.sub.2-4 alkenyl, and C.sub.2-4 alkynyl of
R.sup.e, R.sup.i, R.sup.k, R.sup.o or R.sup.p are each optionally
substituted with 1, 2 or 3 R.sup.q substituents;
[0110] each R.sup.q is independently selected from OH, CN, --COOH,
NH.sub.2, halo, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, C.sub.1-4
alkylthio, phenyl, 5-6 membered heteroaryl, C.sub.3-6 cycloalkyl,
NHR.sup.12, NR.sup.12R.sup.12, and C.sub.1-4 haloalkoxy, wherein
the C.sub.1-4 alkyl, phenyl and 5-6 membered heteroaryl of R.sup.q
are each optionally substituted with OH, CN, --COOH, NH.sub.2,
C.sub.1-4 alkoxy, C.sub.3-10 cycloalkyl and 4-6 membered
heterocycloalkyl and each R.sup.12 is independently C.sub.1-6
alkyl;
[0111] is a single bond or a double bond to maintain ring A being
aromatic;
[0112] the subscript n is an integer of 1, 2, 3, 4 or 5; and the
subscript m is an integer of 1, 2, 3 or 4. In some embodiments of
compounds of Formula (I), the subscript m is an integer of 1, 2 or
3. The compounds, or pharmaceutically acceptable salts or
stereoisomers thereof, as described herein are useful as inhibitors
of the PD-1/PD-L1 protein/protein interaction. For example,
compounds or pharmaceutically acceptable salts or stereoisomers
thereof as described herein can disrupt the PD-1/PD-L1
protein/protein interaction in the PD-1 pathway.
[0113] In some embodiments, the present disclosure provides
compounds having Formula (II):
##STR00011##
[0114] or a pharmaceutically acceptable salt or a stereoisomer
thereof, wherein R.sup.4 is halo, C.sub.1-6 alkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl, C.sub.1-6
haloalkoxy, C.sub.6-10 aryl, C.sub.3-10 cycloalkyl, 5-14 membered
heteroaryl, 4-10 membered heterocycloalkyl, C.sub.6-10
aryl-C.sub.1-4 alkyl-, C.sub.3-10 cycloalkyl-C.sub.1-4 alkyl-,
(5-14 membered heteroaryl)-C.sub.1-4 alkyl-, (4-10 membered
heterocycloalkyl)-C.sub.1-4 alkyl-, CN, NO.sub.2, OR.sup.a,
SR.sup.a, NHOR.sup.a, C(O)R.sup.a, C(O)NR.sup.aR.sup.a,
C(O)OR.sup.a, OC(O)R.sup.a, OC(O)NR.sup.aR.sup.a, NHR.sup.a,
NR.sup.aR.sup.a, NR.sup.aC(O)R.sup.a, NR.sup.aC(O)OR.sup.a,
NR.sup.aC(O)NR.sup.aR.sup.a, C(.dbd.NR.sup.a)R.sup.a,
C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
NR.sup.aC(.dbd.NR.sup.a)NR.sup.aR.sup.a, NR.sup.aS(O)R.sup.a,
NR.sup.aS(O).sub.2R.sup.a, NR.sup.aS(O).sub.2NR.sup.aR.sup.a,
S(O)R.sup.a, S(O)NR.sup.aR.sup.a, S(O).sub.2R.sup.a, and
S(O).sub.2NR.sup.aR.sup.a, wherein the C.sub.1-6 alkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.6-10 aryl, C.sub.3-10 cycloalkyl,
5-14 membered heteroaryl, 4-10 membered heterocycloalkyl,
C.sub.6-10 aryl-C.sub.1-4 alkyl-, C.sub.3-10 cycloalkyl-C.sub.1-4
alkyl-, (5-14 membered heteroaryl)-C.sub.1-4 alkyl-, and (4-10
membered heterocycloalkyl)-C.sub.1-4 alkyl- of W are each
optionally substituted with 1, 2, 3, or 4 R.sup.b substituents.
Other variables of Formula (II) are as defined in Formula (I'),
Formula (I) or any embodiment of compounds of Formula (I') or
Formula (I) as described herein. In one embodiment of compounds of
Formula (II), R.sup.9 is CN or C.sub.1-4 alkyl optionally
substituted with R.sup.q. In another embodiment, R.sup.9 is
CH.sub.3 or CN.
[0115] In some embodiments, the present disclosure provides
compounds having Formula (IIa):
##STR00012##
or a pharmaceutically acceptable salt or a stereoisomer thereof,
wherein R.sup.5 is halo, C.sub.1-6 alkyl, C.sub.2-6 alkenyl,
C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl, C.sub.1-6 haloalkoxy,
C.sub.6-10 aryl, C.sub.3-10 cycloalkyl, 5-14 membered heteroaryl,
4-10 membered heterocycloalkyl, C.sub.6-10 aryl-C.sub.1-4 alkyl-,
C.sub.3-10 cycloalkyl-C.sub.1-4 alkyl-, (5-14 membered
heteroaryl)-C.sub.1-4 alkyl-, (4-10 membered
heterocycloalkyl)-C.sub.1-4 alkyl-, CN, NO.sub.2, OR.sup.a,
SR.sup.a, NHOR.sup.a, C(O)R.sup.a, C(O)NR.sup.aR.sup.a,
C(O)OR.sup.a, OC(O)R.sup.a, OC(O)NR.sup.aR.sup.a, NHR.sup.a,
NR.sup.aR.sup.a, NR.sup.aC(O)R.sup.a, NR.sup.aC(O)OR.sup.a,
NR.sup.aC(O)NR.sup.aR.sup.a, C(.dbd.NR.sup.a)R.sup.a,
C(.dbd.NR.sup.a)NR.sup.aR.sup.a,
NR.sup.aC(.dbd.NR.sup.a)NR.sup.aR.sup.a, NR.sup.aS(O)R.sup.a,
NR.sup.aS(O).sub.2R.sup.a, NR.sup.aS(O).sub.2NR.sup.aR.sup.a,
S(O)R.sup.a, S(O)NR.sup.aR.sup.a, S(O).sub.2R.sup.a, and
S(O).sub.2NR.sup.aR.sup.a, wherein the C.sub.1-6 alkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.6-10 aryl, C.sub.3-10 cycloalkyl,
5-14 membered heteroaryl, 4-10 membered heterocycloalkyl,
C.sub.6-10 aryl-C.sub.1-4 alkyl-, C.sub.3-10 cycloalkyl-C.sub.1-4
alkyl-, (5-14 membered heteroaryl)-C.sub.1-4 alkyl-, and (4-10
membered heterocycloalkyl)-C.sub.1-4 alkyl- of R.sup.1 are each
optionally substituted with 1, 2, 3, or 4 R.sup.b substituents.
Other variables of Formula (IIa) are as defined in Formula (I'),
Formula (I) or any embodiment of compounds of Formula (I') or
Formula (I) as described herein. In one embodiment of compounds of
Formula (IIa), R.sup.9 is CN or C.sub.1-4 alkyl optionally
substituted with R.sup.q. In another embodiment, R.sup.9 is
CH.sub.3 or CN.
[0116] In some embodiments, the present disclosure provides
compounds having Formula (III):
##STR00013##
or a pharmaceutically acceptable salt or a stereoisomer thereof,
wherein the variables of Formula (III) are as defined in Formula
(I'), Formula (I) or any embodiment of compounds of Formula (I') or
Formula (I) as described herein.
[0117] In some embodiments, the present disclosure provides
compounds having Formula (IV):
##STR00014##
or a pharmaceutically acceptable salt or a stereoisomer thereof,
wherein the variables of Formula (IV) are as defined in Formula
(I'), Formula (I) or any embodiment of compounds of Formula (I') or
Formula (I) as described herein.
[0118] In some embodiments, the present disclosure provides
compounds having Formula (V):
##STR00015##
or a pharmaceutically acceptable salt or a stereoisomer thereof,
wherein the variables of Formula (V) are as defined in Formula
(I'), Formula (I) or any embodiment of compounds of Formula (I') or
Formula (I) as described herein.
[0119] In some embodiments, the present disclosure provides
compounds having Formula (VI):
##STR00016##
or a pharmaceutically acceptable salt or a stereoisomer thereof,
wherein the variables of Formula (VI) are as defined in Formula
(I'), Formula (I) or any embodiment of compounds of Formula (I') or
Formula (I) as described herein.
[0120] In some embodiments, the present disclosure provides
compounds having Formula (VII):
##STR00017##
or a pharmaceutically acceptable salt or a stereoisomer thereof,
wherein the variables of Formula (VII) are as defined in Formula
(I'), Formula (I) or any embodiment of compounds of Formula (I') or
Formula (I) as described herein.
[0121] In some embodiments, the present disclosure provides
compounds having Formula (VIII):
##STR00018##
or a pharmaceutically acceptable salt or a stereoisomer thereof,
wherein the variables of Formula (VIII) are as defined in Formula
(I'), Formula (I) or any embodiment of compounds of Formula (I') or
Formula (I) as described herein.
[0122] In some embodiments, the present disclosure provides
compounds having Formula (IX):
##STR00019##
[0123] or a pharmaceutically acceptable salt or a stereoisomer
thereof, wherein the variables R.sup.4, R.sup.5, X.sup.3, X.sup.6,
R.sup.7, R.sup.9 and n of Formula (IX) are as defined in Formula
(I'), Formula (I) or any embodiment of compounds of Formula (I') or
Formula (I) as described herein.
[0124] In some embodiments of compounds of Formula (I'), (I), (II),
(IIa), (III), (IV), (V) or (VI), or a pharmaceutically acceptable
salt or a stereoisomer thereof, the moiety:
##STR00020##
is selected from:
##STR00021##
wherein the substituents R.sup.1, R.sup.2, R.sup.3, R.sup.4,
R.sup.5 and R.sup.6 are as defined in Formula (I'), Formula (I) or
any embodiment of compounds of Formula (I') or Formula (I) as
described herein.
[0125] In some embodiments, the moiety:
##STR00022##
is selected from:
##STR00023##
wherein the substituents R.sup.1, R.sup.2, R.sup.3, R.sup.4,
R.sup.5 and R.sup.6 are as defined in Formula (I'), Formula (I) or
any embodiment of compounds of Formula (I') or Formula (I) as
described herein.
[0126] In certain embodiments, at each occurrence, R.sup.1,
R.sup.2, R.sup.3 and R.sup.5 are each H. In some embodiments,
R.sup.1, R.sup.3, and R.sup.5 are each H. In some embodiments,
R.sup.3 and R.sup.5 are each H. In some embodiments, R.sup.1 and
R.sup.3 are each H. In some embodiments, R.sup.2 and R.sup.5 are
each H.
[0127] In some embodiments of compounds of Formula I', I, II, IIa,
III, IV, V or VI, X.sup.1 is CH, X.sup.2 is O, X.sup.3 is N and
X.sup.5 and X.sup.6 are each CH.
[0128] In some embodiments of compounds of Formula I', I, II, IIa,
III, IV, V or VI, X.sup.1 is O, X.sup.2 is CH, X.sup.3 is N,
X.sup.5 is CH and X.sup.6 is CR.sup.6. In one embodiment, R.sup.6
is H or C.sub.1-6 alkyl optionally substituted with 1 or 2
R.sup.q.
[0129] In some embodiments of compounds of Formula I', I, II, III,
IV, V or VI, X.sup.1 is O, X.sup.2 is CH, X.sup.3 is CH, X.sup.5 is
N and X.sup.6 is CR.sup.6. In one embodiment, R.sup.6 is H or
C.sub.1-6 alkyl optionally substituted with 1 or 2 R.sup.q.
[0130] In some embodiments of compounds of Formula I', I, II, IIa,
III, IV, V or VI, X.sup.1 is O, X.sup.2 is N, X.sup.3 is CH,
X.sup.5 is CH and X.sup.6 is CR.sup.6. In one embodiment, R.sup.6
is H or C.sub.1-6 alkyl optionally substituted with 1 or 2
R.sup.q.
[0131] In some embodiments of compounds of Formula I', I, II, IIa,
III, IV, V or VI, X.sup.1 is O, X.sup.2 is CH, X.sup.3 is CH,
X.sup.5 is CH and X.sup.6 is N.
[0132] In some embodiments of compounds of Formula I', I, II, IIa,
III, IV, V or VI, X.sup.1 is S, X.sup.2 is N, X.sup.3 is CH,
X.sup.5 is CH and X.sup.6 is CR.sup.6. In one embodiment, R.sup.6
is H or C.sub.1-6 alkyl optionally substituted with 1 or 2
R.sup.q.
[0133] In some embodiments of compounds of Formula I', I, II, IIa,
III, IV, V or VI, X.sup.1 is N, X.sup.2 is S, X.sup.3 is CH,
X.sup.5 is CH and X.sup.6 is CR.sup.6. In one embodiment, R.sup.6
is H or C.sub.1-6 alkyl optionally substituted with 1 or 2
R.sup.q.
[0134] In some embodiments of compounds of Formula I', I, II, IIa,
III, IV, V or VI, X.sup.1 is O, X.sup.2 is CH, X.sup.3 is CH,
X.sup.5 is CH and X.sup.6 is N.
[0135] In some embodiments of compounds of Formula I', I, II, IIa,
III, IV, V or VI, X.sup.1 is N, X.sup.2 is O, X.sup.3 is CH,
X.sup.5 is CH and X.sup.6 is CR.sup.6. In one embodiment, R.sup.6
is H or C.sub.1-6 alkyl optionally substituted with 1 or 2
R.sup.q.
[0136] In some embodiments of compounds of Formula I', I, II, IIa,
III, IV, V or VI, X.sup.1 is O, X.sup.2 is CH, X.sup.3 is CH,
X.sup.5 is CH, and X.sup.6 is CR.sup.6. In one embodiment, R.sup.6
is H or C.sub.1-6 alkyl optionally substituted with 1 or 2
R.sup.q.
[0137] In some embodiments of compounds of Formula I', I, II, IIa,
III, IV, V or VI, X.sup.1 is O, X.sup.2 is CH, X.sup.3 is CH,
X.sup.5 is CH, and X.sup.6 is CR.sup.6. In one embodiment, R.sup.6
is H or C.sub.1-6 alkyl optionally substituted with 1 or 2
R.sup.q.
[0138] In some embodiments of compounds of Formula I', I, II, IIa,
III, IV, V or VI, X.sup.1 is CH, X.sup.2 is O, X.sup.3 is CH,
X.sup.5 is CH, and X.sup.6 is CR.sup.6. In one embodiment, R.sup.6
is H or C.sub.1-6 alkyl optionally substituted with 1 or 2
R.sup.q.
[0139] In some embodiments of compounds of Formula I', I, II, IIa,
III, IV, V or VI, X.sup.1 is O or S and X.sup.2 is N or
CR.sup.2.
[0140] In some embodiments of compounds of Formula I', I, II, IIa,
III, IV, V or VI, X.sup.2 is O or S and X.sup.1 is N or
CR.sup.1.
[0141] In some embodiments, R.sup.9 is C.sub.1-4 alkyl, F, Cl, Br,
CN, OH, cyclopropyl, C.sub.2-4 alkynyl, C.sub.1-4 alkoxy, C.sub.1-4
haloalkyl, C.sub.1-4 haloalkoxy, NH.sub.2, --NH--C.sub.1-4 alkyl,
--N(C.sub.1-4 alkyl).sub.2, NHOR.sup.11, C(O)R.sup.11,
C(O)NR.sup.11R.sup.11, C(O)OR.sup.11, OC(O)R.sup.11,
OC(O)NR.sup.11R.sup.11, NR.sup.11C(O)R.sup.11,
NR.sup.11C(O)OR.sup.11, NR.sup.11C(O)NR.sup.11R.sup.11,
C(.dbd.NR.sup.11)R.sup.11, C(.dbd.NR.sup.11)NR.sup.11R.sup.11,
NR.sup.11C(.dbd.NR.sup.11)R.sup.11R.sup.11, NR.sup.11S(O)R.sup.11,
NR.sup.11S(O).sub.2R.sup.11, NR.sup.11S(O).sub.2NR.sup.11R.sup.11,
S(O)R.sup.11, S(O)NR.sup.11R.sup.11, S(O).sub.2R.sup.11, and
S(O).sub.2NR.sup.11R.sup.11, wherein each R.sup.11 is independently
H or C.sub.1-4 alkyl optionally substituted with 1 or 2 halo, OH,
CN or OCH.sub.3, with the proviso when R.sup.9 is F, OH or
C.sub.1-4 alkoxy, R.sup.4 is other than CN,
C(.dbd.NR.sup.11)NR.sup.11R.sup.11 or C.sub.1-6 alkyl optionally
substituted with 1 or 2 R.sup.q substituents. In some instances,
when R.sup.9 is F, OH or C.sub.1-4 alkoxy, R.sup.4 is other than
CN, C(.dbd.NH)NH.sub.2 or C.sub.1-6 alkyl optionally substituted
with 1 or 2 R.sup.q substituents. In some instances, when R.sup.9
is F, OH or OCH.sub.3, R.sup.4 is other than CN,
C(.dbd.NH)NH.sub.2, t-butyl or --CH(R.sup.q).sub.2. In some
instances, when R.sup.9 is F, OH or OCH.sub.3, R.sup.4 is other
than CN, C(.dbd.NH)NH.sub.2, t-butyl or
CH(COOH)(OC(CH.sub.3).sub.3). In some instances, when R.sup.9 is F,
R.sup.4 is other than CH(COOH)(OC(CH.sub.3).sub.3). In some
instances, when R.sup.9 is OH, R.sup.4 is other than CN,
C(.dbd.NH)NH.sub.2 or C.sub.1-6 alkyl. In some instances, when
R.sup.9 is OH, R.sup.4 is other than CN, C(.dbd.NH)NH.sub.2 or
t-butyl.
[0142] In some embodiments, R.sup.9 is CN or C.sub.1-4 alkyl
optionally substituted with R.sup.q.
[0143] In some embodiments, R.sup.9 is CN.
[0144] In some embodiments, R.sup.9 is C.sub.1-4 alkyl optionally
substituted with R.sup.q.
[0145] In some embodiments, R.sup.9 is CH.sub.3 or CN. In some
embodiments, R.sup.9 is CH.sub.3. In some embodiments, R.sup.9 is
CN.
[0146] In some embodiments, R.sup.7 and R.sup.8 are each H.
[0147] In some embodiments of compounds of Formula I', I, II, III,
IV, V, VI, VII, or VIII, X.sup.3, X.sup.5 and X.sup.6 are each CH.
In other embodiments of compounds of Formula IIa, X.sup.3, X.sup.4
and X.sup.6 are each CH. In some embodiments of compounds of
Formula IX, X.sup.3 and X.sup.6 are each CH and R.sup.5 is H.
[0148] In some embodiments of compounds of Formula I', I, II, III,
IV, V, VI, VII or VIII, X.sup.5 and X.sup.6 are each CH and X.sup.3
is N. In some embodiments of compounds of Formula IIa, X.sup.4 and
X.sup.6 are each CH and X.sup.3 is N. In some embodiments of
compounds of Formula IX, X.sup.6 is CH, R.sup.5 is H, and X.sup.3
is N.
[0149] In some embodiments of compounds of Formula I', I, II, III,
IV, V, VI, VII, or VIII, X.sup.3 is N, X.sup.5 is CH and X.sup.6 is
CR.sup.6. In some embodiments of compounds of Formula IIa or IX,
X.sup.3 is N, R.sup.5 is H, and X.sup.6 is CR.sup.6. In one
embodiment, R.sup.6 is H or C.sub.1-6 alkyl optionally substituted
with 1 or 2 R.sup.q.
[0150] In some embodiments of compounds of Formula I', I, II, III,
IV, V, VI, VII, or VIII, X.sup.3 is CH, X.sup.5 is N and X.sup.6 is
CR.sup.6. In some embodiments of compounds of Formula IIa or IX,
X.sup.3 is CH and X.sup.6 is CR.sup.6. In one embodiment, R.sup.6
is H or C.sub.1-6 alkyl optionally substituted with 1 or 2
R.sup.q.
[0151] In some embodiments of compounds of Formula I', I, II, III,
IV, V, VI, VII, or VIII, X.sup.3 and X.sup.5 are each CH and
X.sup.6 is N. In some embodiments of compounds of Formula IIa,
X.sup.3 and X.sup.4 are each CH and X.sup.6 is N. In some
embodiments of compounds of Formula IX, X.sup.3 is CH, R.sup.5 is
H, and X.sup.6 is N. In other embodiments, X.sup.3 and X.sup.4 are
each CH and X.sup.6 is N.
[0152] In some embodiments of compounds of Formula I', I, II, III,
IV, V, VI, VII, or VIII, X.sup.3 and X.sup.5 are each CH and
X.sup.6 is CR.sup.6. In some embodiments of compounds of Formula
IIa or IX, X.sup.3 is CH, R.sup.5 is H, and X.sup.6 is CR.sup.6. In
other embodiments, X.sup.3 and X.sup.4 are each CH and X.sup.6 is
CR.sup.6. In one embodiment, R.sup.6 is H or C.sub.1-6 alkyl
optionally substituted with 1 or 2 R.sup.q.
[0153] In some embodiments of compounds of Formula I', I, II, III,
IV, V, VI, VII, or VIII, X.sup.3 and X.sup.6 are each N and X.sup.5
is CH. In some embodiments of compounds of Formula IIa or IX,
X.sup.3 and X.sup.6 are each N and R.sup.5 is H. In other
embodiments, X.sup.3 and X.sup.6 are each N and X.sup.4 is CH.
[0154] In some embodiments of compounds of Formula I', I, II, III,
IV, V, VI, VII, or VIII, X.sup.3 and X.sup.5 are each N and X.sup.6
is CR.sup.6. In other embodiments, X.sup.4 and X.sup.6 are each N
and X.sup.2 is CR.sup.2.
[0155] In some embodiments of compounds of Formula I', I, II, III,
IV, V, or VI, X.sup.5 and X.sup.6 are each N and X.sup.2 is
CR.sup.2.
[0156] In some embodiments of compounds of Formula I', I, II, IIa,
III, IV, V, VI, VII, VIII, or
[0157] IX, R.sup.4 is C.sub.1-4 alkyl substituted with R.sup.h. In
certain embodiments, R.sup.h is NHR.sup.c or NR.sup.cR.sup.c. In
some embodiments, R.sup.b is NHR.sup.c. In some embodiments,
R.sup.h is NR.sup.cR.sup.c. In other embodiments, R.sup.h is
2-hydroxyethylamino, 2-hydroxyethyl(methyl)amino,
2-carboxypiperidin-1-yl, (cyanomethyl)amino,
(S)-2-carboxypiperidin-1-yl, (R)-2-carboxypiperidin-1-yl or
2-carboxypiperidin-1-yl.
[0158] In other embodiments, R.sup.4 is C.sub.1-4 alkyl substituted
with R.sup.d. In other embodiments, R.sup.4 is C.sub.1-4 alkyl
substituted with R.sup.f. In other embodiments, R.sup.4 is
C.sub.1-4 alkyl substituted with R.sup.h. In other embodiments,
R.sup.4 is C.sub.1-4 alkyl substituted with R.sup.n. In other
embodiments, R.sup.4 is C.sub.1-4 alkyl substituted with R.sup.n.
In other embodiments, R.sup.4 is C.sub.1-4 alkyl substituted with
R.sup.q.
[0159] In some embodiments of compounds of Formula I', I, II, IIa,
III, IV, V, VI, VII, VIII, or IX, R.sup.4 is CH.sub.2R.sup.h. In
certain embodiments, R.sup.h is NHR.sup.c or NR.sup.cR.sup.c. In
some embodiments, R.sup.h is NHR.sup.c. In some embodiments,
R.sup.c is C.sub.1-4 alkyl optionally substituted with 1 R.sup.d
substituent. In some embodiments, R.sup.h is NR.sup.cR.sup.c. In
some embodiments, two R.sup.c substituents together with the
nitrogen atom to which they are attached form a 4-, 5-, 6-, or
7-membered heterocycloalkyl group optionally substituted with 1, 2,
or 3 independently selected R.sup.h substituents. In some
embodiments, two R.sup.c substituents together with the nitrogen
atom to which they are attached form a 6-membered heterocycloalkyl
substituted with 1 R.sup.h substituent. In other embodiments,
R.sup.h is 2-hydroxyethylamino, 2-hydroxyethyl(methyl)amino,
2-carboxypiperidin-1-yl, (cyanomethyl)amino,
(S)-2-carboxypiperidin-1-yl, (R)-2-carboxypiperidin-1-yl or
2-carboxypiperidin-1-yl.
[0160] In other embodiments, R.sup.4 is CH.sub.2--R.sup.d. In other
embodiments, R.sup.4 is --CH.sub.2--R.sup.f. In other embodiments,
R.sup.4 is --CH.sub.2--R.sup.h. In other embodiments, R.sup.4 is
--CH.sub.2--R.sup.j. In other embodiments, R.sup.4 is
--CH.sub.2--R.sup.n. In other embodiments, R.sup.4 is
--CH.sub.2--R.sup.q.
[0161] In some embodiments of compounds of Formula I', I, II, IIa,
III, IV, V, VI, VII, VIII, or IX, R.sup.4 is
2-hydroxyethylaminomethyl, 2-hydroxyethyl(methyl)aminomethyl,
2-carboxypiperidin-1-ylmethyl, (cyanomethyl)aminomethyl,
(S)-2-carboxypiperidin-1-ylmethyl,
(R)-2-carboxypiperidin-1-ylmethyl or 2-carboxypiperidin-1-ylmethyl.
In other embodiments, R.sup.4 is 2-hydroxyethylaminomethyl,
2-carboxypiperidin-1-ylmethyl, (S)-2-carboxypiperidin-1-ylmethyl or
(R)-2-carboxypiperidin-1-ylmethyl. In other embodiments, R.sup.4 is
2-hydroxyethylaminomethyl. In other embodiments, R.sup.4 is
2-carboxypiperidin-1-ylmethyl, (S)-2-carboxypiperidin-1-ylmethyl or
(R)-2-carboxypiperidin-1-ylmethyl. In other embodiments, R.sup.4 is
2-hydroxyethylaminomethyl, 2-carboxypiperidin-1-ylmethyl,
(S)-2-carboxypiperidin-1-ylmethyl,
(R)-2-carboxypiperidin-1-ylmethyl, (3-cyanophenyl)methoxy,
cyanomethoxy, 2-cyanoethoxy, 3-cyanopropoxy,
2-morpholino-4-ylethoxy or pyridin-2-ylmethoxy.
[0162] In some embodiments, R.sup.4 and R.sup.5 are each
independently 2-hydroxyethylaminomethyl,
2-carboxypiperidin-1-ylmethyl, (S)-2-carboxypiperidin-1-ylmethyl,
(R)-2-carboxypiperidin-1-ylmethyl, (3-cyanophenyl)methoxy,
cyanomethoxy, 2-cyanoethoxy, 3-cyanopropoxy,
2-morpholino-4-ylethoxy or pyridin-2-ylmethoxy.
[0163] In some embodiments of compounds of Formula I', I, II, IIa,
III, IV, V, VI, VII, VIII, or IX, R.sup.6 is H, halo or C.sub.1-6
alkyl optionally substituted with 1-3 R.sup.q substituents.
[0164] In some embodiments of compounds of Formula I', I, II, IIa,
III, IV, V, VI, VII, VIII, or IX, R.sup.6 is H, halo or
CH.sub.3.
[0165] In some embodiments of compounds of Formula I', I, II, IIa,
III, IV, V, VI, VII, VIII, or IX, R.sup.6 is H or CH.sub.3.
[0166] In some embodiments of compounds of Formula I', I, II, IIa,
III, IV, V, VI, VII, VIII, or IX, R.sup.6 is H.
[0167] In some embodiments of compounds of Formula I', I, II, IIa,
III, IV, V, VI, VII, VIII, or IX, R.sup.6 is CH.sub.3.
[0168] It is further appreciated that certain features of the
invention, which are, for clarity, described in the context of
separate embodiments, can also be provided in combination in a
single embodiment (while the embodiments are intended to be
combined as if written in multiply dependent form). Conversely,
various features of the invention which are, for brevity, described
in the context of a single embodiment, can also be provided
separately or in any suitable subcombination. Thus, it is
contemplated as features described as embodiments of the compounds
of Formula (I'), Formula (I) can be combined in any suitable
combination.
[0169] At various places in the present specification, certain
features of the compounds are disclosed in groups or in ranges. It
is specifically intended that such a disclosure include each and
every individual subcombination of the members of such groups and
ranges. For example, the term "C.sub.1-6 alkyl" is specifically
intended to individually disclose (without limitation) methyl,
ethyl, C.sub.3 alkyl, C.sub.4 alkyl, C.sub.5 alkyl and C.sub.6
alkyl.
[0170] The term "n-membered," where n is an integer, typically
describes the number of ring-forming atoms in a moiety where the
number of ring-forming atoms is n. For example, piperidinyl is an
example of a 6-membered heterocycloalkyl ring, pyrazolyl is an
example of a 5-membered heteroaryl ring, pyridyl is an example of a
6-membered heteroaryl ring and 1,2,3,4-tetrahydro-naphthalene is an
example of a 10-membered cycloalkyl group.
[0171] At various places in the present specification, variables
defining divalent linking groups may be described. It is
specifically intended that each linking substituent include both
the forward and backward forms of the linking substituent. For
example, --NR(CR'R'').sub.n-- includes both --NR(CR'R'').sub.n--
and --(CR'R'').sub.nNR-- and is intended to disclose each of the
forms individually. Where the structure requires a linking group,
the Markush variables listed for that group are understood to be
linking groups. For example, if the structure requires a linking
group and the Markush group definition for that variable lists
"alkyl" or "aryl" then it is understood that the "alkyl" or "aryl"
represents a linking alkylene group or arylene group,
respectively.
[0172] The term "substituted" means that an atom or group of atoms
formally replaces hydrogen as a "substituent" attached to another
group. The term "substituted", unless otherwise indicated, refers
to any level of substitution, e.g., mono-, di-, tri-, tetra- or
penta-substitution, where such substitution is permitted. The
substituents are independently selected, and substitution may be at
any chemically accessible position. It is to be understood that
substitution at a given atom is limited by valency. It is to be
understood that substitution at a given atom results in a
chemically stable molecule. The phrase "optionally substituted"
means unsubstituted or substituted. The term "substituted" means
that a hydrogen atom is removed and replaced by a substituent. A
single divalent substituent, e.g., oxo, can replace two hydrogen
atoms.
[0173] The term "C.sub.n-m" indicates a range which includes the
endpoints, wherein n and m are integers and indicate the number of
carbons. Examples include C.sub.1-4, C.sub.1-6 and the like.
[0174] The term "alkyl" employed alone or in combination with other
terms, refers to a saturated hydrocarbon group that may be
straight-chained or branched. The term "C.sub.n-m alkyl", refers to
an alkyl group having n to m carbon atoms. An alkyl group formally
corresponds to an alkane with one C--H bond replaced by the point
of attachment of the alkyl group to the remainder of the compound.
In some embodiments, the alkyl group contains from 1 to 6 carbon
atoms, from 1 to 4 carbon atoms, from 1 to 3 carbon atoms, or 1 to
2 carbon atoms. Examples of alkyl moieties include, but are not
limited to, chemical groups such as methyl, ethyl, n-propyl,
isopropyl, n-butyl, tert-butyl, isobutyl, sec-butyl; higher
homologs such as 2-methyl-1-butyl, n-pentyl, 3-pentyl, n-hexyl,
1,2,2-trimethylpropyl and the like.
[0175] The term "alkenyl" employed alone or in combination with
other terms, refers to a straight-chain or branched hydrocarbon
group corresponding to an alkyl group having one or more double
carbon-carbon bonds. An alkenyl group formally corresponds to an
alkene with one C--H bond replaced by the point of attachment of
the alkenyl group to the remainder of the compound. The term
"C.sub.n-m alkenyl" refers to an alkenyl group having n to m
carbons. In some embodiments, the alkenyl moiety contains 2 to 6, 2
to 4, or 2 to 3 carbon atoms. Example alkenyl groups include, but
are not limited to, ethenyl, n-propenyl, isopropenyl, n-butenyl,
sec-butenyl and the like.
[0176] The term "alkynyl" employed alone or in combination with
other terms, refers to a straight-chain or branched hydrocarbon
group corresponding to an alkyl group having one or more triple
carbon-carbon bonds. An alkynyl group formally corresponds to an
alkyne with one C--H bond replaced by the point of attachment of
the alkyl group to the remainder of the compound. The term
"C.sub.n-m alkynyl" refers to an alkynyl group having n to m
carbons. Example alkynyl groups include, but are not limited to,
ethynyl, propyn-1-yl, propyn-2-yl and the like. In some
embodiments, the alkynyl moiety contains 2 to 6, 2 to 4, or 2 to 3
carbon atoms.
[0177] The term "alkylene", employed alone or in combination with
other terms, refers to a divalent alkyl linking group. An alkylene
group formally corresponds to an alkane with two C--H bond replaced
by points of attachment of the alkylene group to the remainder of
the compound. The term "C.sub.n-m alkylene" refers to an alkylene
group having n to m carbon atoms. Examples of alkylene groups
include, but are not limited to, ethan-1,2-diyl, propan-1,3-diyl,
propan-1,2-diyl, butan-1,4-diyl, butan-1,3-diyl, butan-1,2-diyl,
2-methyl-propan-1,3-diyl and the like.
[0178] The term "alkoxy", employed alone or in combination with
other terms, refers to a group of formula --O-alkyl, wherein the
alkyl group is as defined above. The term "C.sub.n-m alkoxy" refers
to an alkoxy group, the alkyl group of which has n to m carbons.
Example alkoxy groups include methoxy, ethoxy, propoxy (e.g.,
n-propoxy and isopropoxy), t-butoxy and the like. In some
embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon
atoms.
[0179] The term "amino" refers to a group of formula
--NH.sub.2.
[0180] The term "carbamyl" refers to a group of formula
--C(O)NH.sub.2.
[0181] The term "carbonyl", employed alone or in combination with
other terms, refers to a --C(.dbd.O)-- group, which also may be
written as C(O).
[0182] The term "cyano" or "nitrile" refers to a group of formula
--C.ident.N, which also may be written as --CN.
[0183] The terms "halo" or "halogen", used alone or in combination
with other terms, refers to fluoro, chloro, bromo and iodo. In some
embodiments, "halo" refers to a halogen atom selected from F, Cl,
or Br. In some embodiments, halo groups are F.
[0184] The term "haloalkyl" as used herein refers to an alkyl group
in which one or more of the hydrogen atoms has been replaced by a
halogen atom. The term "C.sub.n-m haloalkyl" refers to a C.sub.n-m
alkyl group having n to m carbon atoms and from at least one up to
{2(n to m)+1} halogen atoms, which may either be the same or
different. In some embodiments, the halogen atoms are fluoro atoms.
In some embodiments, the haloalkyl group has 1 to 6 or 1 to 4
carbon atoms. Example haloalkyl groups include CF.sub.3,
C.sub.2F.sub.5, CHF.sub.2, CCl.sub.3, CHCl.sub.2, C.sub.2Cl.sub.5
and the like. In some embodiments, the haloalkyl group is a
fluoroalkyl group.
[0185] The term "haloalkoxy", employed alone or in combination with
other terms, refers to a group of formula --O-haloalkyl, wherein
the haloalkyl group is as defined above. The term "C.sub.n-m
haloalkoxy" refers to a haloalkoxy group, the haloalkyl group of
which has n to m carbons. Example haloalkoxy groups include
trifluoromethoxy and the like. In some embodiments, the haloalkoxy
group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
[0186] The term "oxo" refers to an oxygen atom as a divalent
substituent, forming a carbonyl group when attached to carbon, or
attached to a heteroatom forming a sulfoxide or sulfone group, or
an N-oxide group. In some embodiments, heterocyclic groups may be
optionally substituted by 1 or 2 oxo (.dbd.O) substituents.
[0187] The term "sulfido" refers to a sulfur atom as a divalent
substituent, forming a thiocarbonyl group (C.dbd.S) when attached
to carbon.
[0188] The term "aromatic" refers to a carbocycle or heterocycle
having one or more polyunsaturated rings having aromatic character
(i.e., having (4n+2) delocalized .pi.(pi) electrons where n is an
integer).
[0189] The term "aryl," employed alone or in combination with other
terms, refers to an aromatic hydrocarbon group, which may be
monocyclic or polycyclic (e.g., having 2 fused rings). The term
"C.sub.n-m aryl" refers to an aryl group having from n to m ring
carbon atoms. Aryl groups include, e.g., phenyl, naphthyl, indanyl,
indenyl and the like. In some embodiments, aryl groups have from 6
to about 10 carbon atoms. In some embodiments aryl groups have 6
carbon atoms. In some embodiments aryl groups have 10 carbon atoms.
In some embodiments, the aryl group is phenyl. In some embodiments,
the aryl group is naphthyl.
[0190] The term "heteroaryl" or "heteroaromatic," employed alone or
in combination with other terms, refers to a monocyclic or
polycyclic aromatic heterocycle having at least one heteroatom ring
member selected from sulfur, oxygen and nitrogen. In some
embodiments, the heteroaryl ring has 1, 2, 3 or 4 heteroatom ring
members independently selected from nitrogen, sulfur and oxygen. In
some embodiments, any ring-forming N in a heteroaryl moiety can be
an N-oxide. In some embodiments, the heteroaryl has 5-14 ring atoms
including carbon atoms and 1, 2, 3 or 4 heteroatom ring members
independently selected from nitrogen, sulfur and oxygen. In some
embodiments, the heteroaryl has 5-10 ring atoms including carbon
atoms and 1, 2, 3 or 4 heteroatom ring members independently
selected from nitrogen, sulfur and oxygen. In some embodiments, the
heteroaryl has 5-6 ring atoms and 1 or 2 heteroatom ring members
independently selected from nitrogen, sulfur and oxygen. In some
embodiments, the heteroaryl is a five-membered or six-membered
heteroaryl ring. In other embodiments, the heteroaryl is an
eight-membered, nine-membered or ten-membered fused bicyclic
heteroaryl ring. Example heteroaryl groups include, but are not
limited to, pyridinyl (pyridyl), pyrimidinyl, pyrazinyl,
pyridazinyl, pyrrolyl, pyrazolyl, azolyl, oxazolyl, thiazolyl,
imidazolyl, furanyl, thiophenyl, quinolinyl, isoquinolinyl,
naphthyridinyl (including 1,2-, 1,3-, 1,4-, 1,5-, 1,6-, 1,7-, 1,8-,
2,3- and 2,6-naphthyridine), indolyl, benzothiophenyl,
benzofuranyl, benzisoxazolyl, imidazo[1,2-b]thiazolyl, purinyl, and
the like.
[0191] A five-membered heteroaryl ring is a heteroaryl group having
five ring atoms wherein one or more (e.g., 1, 2 or 3) ring atoms
are independently selected from N, O and S. Exemplary five-membered
ring heteroaryls include thienyl, furyl, pyrrolyl, imidazolyl,
thiazolyl, oxazolyl, pyrazolyl, isothiazolyl, isoxazolyl,
1,2,3-triazolyl, tetrazolyl, 1,2,3-thiadiazolyl, 1,2,3-oxadiazolyl,
1,2,4-triazolyl, 1,2,4-thiadiazolyl, 1,2,4-oxadiazolyl,
1,3,4-triazolyl, 1,3,4-thiadiazolyl and 1,3,4-oxadiazolyl.
[0192] A six-membered heteroaryl ring is a heteroaryl group having
six ring atoms wherein one or more (e.g., 1, 2 or 3) ring atoms are
independently selected from N, O and S. Exemplary six-membered ring
heteroaryls are pyridyl, pyrazinyl, pyrimidinyl, triazinyl and
pyridazinyl.
[0193] The term "cycloalkyl," employed alone or in combination with
other terms, refers to a non-aromatic hydrocarbon ring system
(monocyclic, bicyclic or polycyclic), including cyclized alkyl and
alkenyl groups. The term "C.sub.n-m cycloalkyl" refers to a
cycloalkyl that has n to m ring member carbon atoms. Cycloalkyl
groups can include mono- or polycyclic (e.g., having 2, 3 or 4
fused rings) groups and spirocycles. Cycloalkyl groups can have 3,
4, 5, 6 or 7 ring-forming carbons (C.sub.3-7). In some embodiments,
the cycloalkyl group has 3 to 6 ring members, 3 to 5 ring members,
or 3 to 4 ring members. In some embodiments, the cycloalkyl group
is monocyclic. In some embodiments, the cycloalkyl group is
monocyclic or bicyclic. In some embodiments, the cycloalkyl group
is a C.sub.3-6 monocyclic cycloalkyl group. Ring-forming carbon
atoms of a cycloalkyl group can be optionally oxidized to form an
oxo or sulfido group. Cycloalkyl groups also include
cycloalkylidenes. In some embodiments, cycloalkyl is cyclopropyl,
cyclobutyl, cyclopentyl or cyclohexyl. Also included in the
definition of cycloalkyl are moieties that have one or more
aromatic rings fused (i.e., having a bond in common with) to the
cycloalkyl ring, e.g., benzo or thienyl derivatives of
cyclopentane, cyclohexane and the like. A cycloalkyl group
containing a fused aromatic ring can be attached through any
ring-forming atom including a ring-forming atom of the fused
aromatic ring. Examples of cycloalkyl groups include cyclopropyl,
cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl,
cyclohexenyl, cyclohexadienyl, cycloheptatrienyl, norbornyl,
norpinyl, norcarnyl, bicyclo[1.1.1]pentanyl, bicyclo[2.1.1]hexanyl,
and the like. In some embodiments, the cycloalkyl group is
cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
[0194] The term "heterocycloalkyl," employed alone or in
combination with other terms, refers to a non-aromatic ring or ring
system, which may optionally contain one or more alkenylene groups
as part of the ring structure, which has at least one heteroatom
ring member independently selected from nitrogen, sulfur oxygen and
phosphorus, and which has 4-10 ring members, 4-7 ring members, or
4-6 ring members. Included within the term "heterocycloalkyl" are
monocyclic 4-, 5-, 6- and 7-membered heterocycloalkyl groups.
Heterocycloalkyl groups can include mono- or bicyclic (e.g., having
two fused or bridged rings) ring systems. In some embodiments, the
heterocycloalkyl group is a monocyclic group having 1, 2 or 3
heteroatoms independently selected from nitrogen, sulfur and
oxygen. Ring-forming carbon atoms and heteroatoms of a
heterocycloalkyl group can be optionally oxidized to form an oxo or
sulfido group or other oxidized linkage (e.g., C(O), S(O), C(S) or
S(O).sub.2, N-oxide etc.) or a nitrogen atom can be quaternized.
The heterocycloalkyl group can be attached through a ring-forming
carbon atom or a ring-forming heteroatom. In some embodiments, the
heterocycloalkyl group contains 0 to 3 double bonds. In some
embodiments, the heterocycloalkyl group contains 0 to 2 double
bonds. Also included in the definition of heterocycloalkyl are
moieties that have one or more aromatic rings fused (i.e., having a
bond in common with) to the heterocycloalkyl ring, e.g., benzo or
thienyl derivatives of piperidine, morpholine, azepine, etc. A
heterocycloalkyl group containing a fused aromatic ring can be
attached through any ring-forming atom including a ring-forming
atom of the fused aromatic ring. Examples of heterocycloalkyl
groups include azetidinyl, azepanyl, dihydrobenzofuranyl,
dihydrofuranyl, dihydropyranyl, morpholino,
3-oxa-9-azaspiro[5.5]undecanyl, 1-oxa-8-azaspiro[4.5]decanyl,
piperidinyl, piperazinyl, oxopiperazinyl, pyranyl, pyrrolidinyl,
quinuclidinyl, tetrahydrofuranyl, tetrahydropyranyl,
1,2,3,4-tetrahydroquinolinyl, tropanyl, and thiomorpholino.
[0195] At certain places, the definitions or embodiments refer to
specific rings (e.g., an azetidine ring, a pyridine ring, etc.).
Unless otherwise indicated, these rings can be attached to any ring
member provided that the valency of the atom is not exceeded. For
example, an azetidine ring may be attached at any position of the
ring, whereas an azetidin-3-yl ring is attached at the
3-position.
[0196] The compounds described herein can be asymmetric (e.g.,
having one or more stereocenters). All stereoisomers, such as
enantiomers and diastereomers, are intended unless otherwise
indicated. Compounds of the present invention that contain
asymmetrically substituted carbon atoms can be isolated in
optically active or racemic forms. Methods on how to prepare
optically active forms from optically inactive starting materials
are known in the art, such as by resolution of racemic mixtures or
by stereoselective synthesis. Many geometric isomers of olefins,
C.dbd.N double bonds and the like can also be present in the
compounds described herein, and all such stable isomers are
contemplated in the present invention. Cis and trans geometric
isomers of the compounds of the present invention are described and
may be isolated as a mixture of isomers or as separated isomeric
forms.
[0197] Resolution of racemic mixtures of compounds can be carried
out by any of numerous methods known in the art. One method
includes fractional recrystallization using a chiral resolving acid
which is an optically active, salt-forming organic acid. Suitable
resolving agents for fractional recrystallization methods are,
e.g., optically active acids, such as the D and L forms of tartaric
acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid,
malic acid, lactic acid or the various optically active
camphorsulfonic acids such as (3-camphorsulfonic acid. Other
resolving agents suitable for fractional crystallization methods
include stereoisomerically pure forms of .alpha.-methylbenzylamine
(e.g., S and R forms, or diastereomerically pure forms),
2-phenylglycinol, norephedrine, ephedrine, N-methylephedrine,
cyclohexylethylamine, 1,2-diaminocyclohexane and the like.
[0198] Resolution of racemic mixtures can also be carried out by
elution on a column packed with an optically active resolving agent
(e.g., dinitrobenzoylphenylglycine). Suitable elution solvent
composition can be determined by one skilled in the art.
[0199] In some embodiments, the compounds of the invention have the
(R)-configuration. In other embodiments, the compounds have the
(S)-configuration. In compounds with more than one chiral centers,
each of the chiral centers in the compound may be independently (R)
or (S), unless otherwise indicated.
[0200] Compounds of the invention also include tautomeric forms.
Tautomeric forms result from the swapping of a single bond with an
adjacent double bond together with the concomitant migration of a
proton. Tautomeric forms include prototropic tautomers which are
isomeric protonation states having the same empirical formula and
total charge. Example prototropic tautomers include ketone--enol
pairs, amide--imidic acid pairs, lactam--lactim pairs,
enamine--imine pairs, and annular forms where a proton can occupy
two or more positions of a heterocyclic system, e.g., 1H- and
3H-imidazole, 1H-, 2H- and 4H-1,2,4-triazole, 1H- and 2H-isoindole
and 1H- and 2H-pyrazole. Tautomeric forms can be in equilibrium or
sterically locked into one form by appropriate substitution.
[0201] Compounds of the invention can also include all isotopes of
atoms occurring in the intermediates or final compounds. Isotopes
include those atoms having the same atomic number but different
mass numbers. For example, isotopes of hydrogen include tritium and
deuterium. One or more constituent atoms of the compounds of the
invention can be replaced or substituted with isotopes of the atoms
in natural or non-natural abundance. In some embodiments, the
compound includes at least one deuterium atom. For example, one or
more hydrogen atoms in a compound of the present disclosure can be
replaced or substituted by deuterium. In some embodiments, the
compound includes two or more deuterium atoms. In some embodiments,
the compound includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12
deuterium atoms. Synthetic methods for including isotopes into
organic compounds are known in the art.
[0202] The term, "compound," as used herein is meant to include all
stereoisomers, geometric isomers, tautomers and isotopes of the
structures depicted. The term is also meant to refer to compounds
of the inventions, regardless of how they are prepared, e.g.,
synthetically, through biological process (e.g., metabolism or
enzyme conversion), or a combination thereof.
[0203] All compounds, and pharmaceutically acceptable salts
thereof, can be found together with other substances such as water
and solvents (e.g., hydrates and solvates) or can be isolated. When
in the solid state, the compounds described herein and salts
thereof may occur in various forms and may, e.g., take the form of
solvates, including hydrates. The compounds may be in any solid
state form, such as a polymorph or solvate, so unless clearly
indicated otherwise, reference in the specification to compounds
and salts thereof should be understood as encompassing any solid
state form of the compound.
[0204] In some embodiments, the compounds of the invention, or
salts thereof, are substantially isolated. By "substantially
isolated" is meant that the compound is at least partially or
substantially separated from the environment in which it was formed
or detected. Partial separation can include, e.g., a composition
enriched in the compounds of the invention. Substantial separation
can include compositions containing at least about 50%, at least
about 60%, at least about 70%, at least about 80%, at least about
90%, at least about 95%, at least about 97%, or at least about 99%
by weight of the compounds of the invention, or salt thereof.
[0205] The phrase "pharmaceutically acceptable" is employed herein
to refer to those compounds, materials, compositions and/or dosage
forms which are, within the scope of sound medical judgment,
suitable for use in contact with the tissues of human beings and
animals without excessive toxicity, irritation, allergic response,
or other problem or complication, commensurate with a reasonable
benefit/risk ratio.
[0206] The expressions, "ambient temperature" and "room
temperature," as used herein, are understood in the art, and refer
generally to a temperature, e.g., a reaction temperature, that is
about the temperature of the room in which the reaction is carried
out, e.g., a temperature from about 20.degree. C. to about
30.degree. C.
[0207] The present invention also includes pharmaceutically
acceptable salts of the compounds described herein. The term
"pharmaceutically acceptable salts" refers to derivatives of the
disclosed compounds wherein the parent compound is modified by
converting an existing acid or base moiety to its salt form.
Examples of pharmaceutically acceptable salts include, but are not
limited to, mineral or organic acid salts of basic residues such as
amines; alkali or organic salts of acidic residues such as
carboxylic acids; and the like. The pharmaceutically acceptable
salts of the present invention include the non-toxic salts of the
parent compound formed, e.g., from non-toxic inorganic or organic
acids. The pharmaceutically acceptable salts of the present
invention can be synthesized from the parent compound which
contains a basic or acidic moiety by conventional chemical methods.
Generally, such salts can be prepared by reacting the free acid or
base forms of these compounds with a stoichiometric amount of the
appropriate base or acid in water or in an organic solvent, or in a
mixture of the two; generally, non-aqueous media like ether, ethyl
acetate, alcohols (e.g., methanol, ethanol, iso-propanol or
butanol) or acetonitrile (MeCN) are preferred. Lists of suitable
salts are found in Remington's Pharmaceutical Sciences, 17.sup.th
Ed., (Mack Publishing Company, Easton, 1985), p. 1418, Berge et
al., J. Pharm. Sci., 1977, 66(1), 1-19 and in Stahl et al.,
Handbook of Pharmaceutical Salts: Properties, Selection, and Use,
(Wiley, 2002). In some embodiments, the compounds described herein
include the N-oxide forms.
II. Synthesis
[0208] Compounds of the invention, including salts thereof, can be
prepared using known organic synthesis techniques and can be
synthesized according to any of numerous possible synthetic routes,
such as those in the Schemes below.
[0209] The reactions for preparing compounds of the invention can
be carried out in suitable solvents which can be readily selected
by one of skill in the art of organic synthesis. Suitable solvents
can be substantially non-reactive with the starting materials
(reactants), the intermediates or products at the temperatures at
which the reactions are carried out, e.g., temperatures which can
range from the solvent's freezing temperature to the solvent's
boiling temperature. A given reaction can be carried out in one
solvent or a mixture of more than one solvent. Depending on the
particular reaction step, suitable solvents for a particular
reaction step can be selected by the skilled artisan.
[0210] Preparation of compounds of the invention can involve the
protection and deprotection of various chemical groups. The need
for protection and deprotection, and the selection of appropriate
protecting groups, can be readily determined by one skilled in the
art. The chemistry of protecting groups is described, e.g., in
Kocienski, Protecting Groups, (Thieme, 2007); Robertson, Protecting
Group Chemistry, (Oxford University Press, 2000); Smith et al.,
March's Advanced Organic Chemistry: Reactions, Mechanisms, and
Structure, 6.sup.th Ed. (Wiley, 2007); Peturssion et al.,
"Protecting Groups in Carbohydrate Chemistry," J. Chem. Educ.,
1997, 74(11), 1297; and Wuts et al., Protective Groups in Organic
Synthesis, 4th Ed., (Wiley, 2006).
[0211] Reactions can be monitored according to any suitable method
known in the art. For example, product formation can be monitored
by spectroscopic means, such as nuclear magnetic resonance
spectroscopy (e.g., .sup.1H or .sup.13C), infrared spectroscopy,
spectrophotometry (e.g., UV-visible), mass spectrometry or by
chromatographic methods such as high performance liquid
chromatography (HPLC) or thin layer chromatography (TLC).
[0212] The Schemes below provide general guidance in connection
with preparing the compounds of the invention. One skilled in the
art would understand that the preparations shown in the Schemes can
be modified or optimized using general knowledge of organic
chemistry to prepare various compounds of the invention.
[0213] Compounds of Formula (I'), Formula (I) can be prepared,
e.g., using a process as illustrated in Schemes 1-9.
##STR00024##
[0214] The compounds of Formula 4 can be prepared according to
Scheme 1. The halo group (e.g., Hal.sup.1=Cl, Br or I) of biphenyl
compounds 1 can be converted to the corresponding boronic esters 2
under standard conditions [e.g., bis(pinacolato)diboron in the
presence of a palladium catalyst, such as,
tetrakis(triphenylphosphine) palladium(0), palladium(II) acetate].
Coupling of boronates 2 with the halogenated heterocycles 3
(Hal.sup.2=I, Br or Cl) under standard Suzuki coupling conditions
(e.g., in the presence of a palladium catalyst and a suitable base)
can give the hetero-bicyclic compounds 4.
##STR00025##
[0215] Halogenated bicyclic compounds 3 (Hal.sup.2=I, Br or Cl) can
be prepared according to Scheme 2. Bicyclic compounds 5 (e.g.,
R=SiR'.sub.3, NH.sub.2 etc.) can be treated with appropriate
electrophiles under suitable conditions (e.g., a combination of a
halogen source such as N-iodosuccinimide with a fluoride source
when R is SiR'.sub.3, or a combination of a halogen source such as
iodine with alkyl nitrite when R is NH.sub.2) to give compound
3.
##STR00026##
[0216] The compounds of Formula 9 can be prepared according to
Scheme 3. Methylene hydroxyl group of the substituted biphenyl
compounds 6 can be oxidized to the corresponding aldehyde 7 using
standard oxidation conditions including but not limited to
Dess-Martin oxidation, Swern-type oxidation. Cyclization of the
aldehydes 7 with heterocyclic amines 8 (e.g., X.sup.1=O or S) under
suitable temperature and optionally in the presence of a Lewis acid
(e.g., Zn(OTf).sub.2) to form a cyclized intermediate which can
then be oxidized (e.g., 2,3-dichloro-5,6-dicyanobenzoquinone as
oxidant) to give the aromatic bicyclic compounds 9.
##STR00027##
[0217] The compounds of Formula 12 can be prepared according to
Scheme 4. Aldehyde group of the substituted biphenyl compounds 7
can be converted to the corresponding terminal alkyne 10 under
Seyferth-Gilbert homologation conditions using dimethyl
diazo-2-oxopropylphosphonate (also known as Bestmann-Ohiro reagent)
at basic conditions (e.g., K.sub.2CO.sub.3 in MeOH). Terminal
alkynes 10 can react with heterocyclic halides 11 (e.g.,
Hal.sup.3=Cl, Br, I; X.sup.1=O or S) under standard Sonogashira
coupling condition (e.g., in the presence of a palladium catalyst,
copper(I) salt and a suitable base such as triethylamine or
pyridine) to form an alkyne intermediate followed by an in situ
intramolecular cyclization to give the hetero-bicyclic compounds
12.
##STR00028##
[0218] The aldehydes of Formula 7 can also be prepared according to
Scheme 5. The Hal' group (e.g., Hal.sup.4=I or Br) of substituted
benzenes 13 can selectively couple with substituted phenyl boronic
ester 14 under standard Suzuki coupling (e.g., in the presence of a
palladium catalyst and a suitable base) to produce the biaryl
compounds 1. The biaryl compounds 1 can be converted to vinyl
substituted biaryl compounds 15 under standard Suzuki coupling
condition. The vinyl group in the biaryl compounds 15 can be
cleaved oxidatively to form aldehydes 7 under dihydroxylation then
in situ cleavage conditions (e.g., NaIO.sub.4 in the presence of
catalytic amount of OsO.sub.4). Alternatively, biaryl compounds 1
can be converted to organometallic intermediates by metal-halogen
exchange followed by quenching with dimethylformamide (DMF) at low
temperature to afford the aldehydes 7.
##STR00029##
[0219] The heteroaryl compounds of Formula 18 can be prepared
according to Scheme 6. Heteroaryl esters 16 can be reduced to
aldehydes 17 via a sequence of reduction (e.g., LiAlH4 or LiBH4 as
reducing reagents) then oxidation (e.g., Dess-Martin periodinane as
oxidant). Then the aldehydes 17 react with a variety of amines
under standard reductive amination condition (e.g., sodium
triacetoxyborohydride or sodium cyanoborohydride as reducing
reagents) to generate the compounds of formula 18.
##STR00030##
[0220] Alternatively, aldehydes 17 can also be prepared from
heteroaryl halides 19 (e.g., Hal.sup.5=Cl, Br or I) as outlined in
Scheme 7. The halo group in compounds 19 can be converted to vinyl
groups, forming olefins 20, under standard Suzuki coupling
condition (e.g., vinylboronic acid pinaco ester in the presence of
a palladium catalyst and a suitable base). The vinyl groups in
compounds 20 can be oxidatively cleaved by NaIO4 in the presence of
catalytic amount of 0504 to form aldehydes 17.
##STR00031##
[0221] Compounds of Formula 25 can be prepared using procedures as
outlined in Scheme 8. The halo group (e.g., Hal.sup.2=Cl, Br, I) of
heteroaryl compounds 3 can be converted to the boronic esters 21
under standard conditions [e.g., in the presence of
bis(pinacolato)diboron and a palladium catalyst, such as,
tetrakis(triphenylphosphine) palladium(0), palladium(II) acetate].
Selective coupling of boronates 21 with aryl halides 22 (e.g.,
Hal.sup.6=Cl, Br, I) under suitable Suzuki coupling condition
(e.g., in the presence of a palladium catalyst and a suitable base)
can give the bicyclic compounds 23. The halide (e.g., Hal.sup.7=Cl,
Br, I) in compound 23 can be coupled to compounds of formula 24, in
which M is a boronic acid, boronic ester or an appropriately
substituted metal [e.g., M is B(OR).sub.2, Sn(Alkyl).sub.4, or
Zn-Hal], under Suzuki coupling conditions (e.g., in the presence of
a palladium catalyst and a suitable base) or Stille coupling
conditions (e.g., in the presence of a palladium catalyst), or
Negishi coupling conditions (e.g., in the presence of a palladium
catalyst) to give derivatives of formula 25. Alternatively,
compound 24 can be a cyclic amine (where M is H and attached to an
amine nitrogen in ring Cy) and the coupling of aryl halide 23 with
the cyclic amine 24 can be performed under Buchwald amination
conditions (e.g., in the presence of a palladium catalyst and a
base such as sodium tert-butoxide).
##STR00032##
[0222] Compounds of formula 28 can be prepared using the procedures
as outlined in Scheme 9. Cyclization of the aldehydes 26 with
heterocyclic amines 8 (e.g., X.sup.1=O or S) followed by oxidation
under similar conditions as described in Scheme 3 can give the
aromatic bicyclic compounds 27. Coupling of aryl halides 27 with
compounds 24 can be achieved under similar conditions as described
in Scheme 8 to give compounds of formula 28.
III. Uses of the Compounds
[0223] Compounds of the present disclosure can inhibit the activity
of PD-1/PD-L1 protein/protein interaction and, thus, are useful in
treating diseases and disorders associated with activity of PD-1
and the diseases and disorders associated with PD-L1 including its
interaction with other proteins such as PD-1 and B7-1 (CD80). In
certain embodiments, the compounds of the present disclosure, or
pharmaceutically acceptable salts or stereoisomers thereof, are
useful for therapeutic administration to enhance, stimulate and/or
increase immunity in cancer or chronic infection, including
enhancement of response to vaccination. In some embodiments, the
present disclosure provides a method for inhibiting the PD-1/PD-L1
protein/protein interaction. The method includes administering to
an individual or a patient a compound of Formula (I'), Formula (I)
or of any of the formulas as described herein, or of a compound as
recited in any of the claims and described herein, or a
pharmaceutically acceptable salt or a stereoisomer thereof. The
compounds of the present disclosure can be used alone, in
combination with other agents or therapies or as an adjuvant or
neoadjuvant for the treatment of diseases or disorders, including
cancer or infection diseases. For the uses described herein, any of
the compounds of the disclosure, including any of the embodiments
thereof, may be used.
[0224] The compounds of the present disclosure inhibit the
PD-1/PD-L1 protein/protein interaction, resulting in a PD-1 pathway
blockade. The blockade of PD-1 can enhance the immune response to
cancerous cells and infectious diseases in mammals, including
humans. In some embodiments, the present disclosure provides
treatment of an individual or a patient in vivo using a compound of
Formula (I'), Formula (I) or a salt or stereoisomer thereof such
that growth of cancerous tumors is inhibited. A compound of Formula
(I'), Formula (I) or of any of the formulas as described herein, or
a compound as recited in any of the claims and described herein, or
a salt or stereoisomer thereof, can be used to inhibit the growth
of cancerous tumors.
[0225] Alternatively, a compound of Formula (I'), Formula (I) or of
any of the formulas as described herein, or a compound as recited
in any of the claims and described herein, or a salt or
stereoisomer thereof, can be used in conjunction with other agents
or standard cancer treatments, as described below. In one
embodiment, the present disclosure provides a method for inhibiting
growth of tumor cells in vitro. The method includes contacting the
tumor cells in vitro with a compound of Formula (I'), Formula (I)
or of any of the formulas as described herein, or of a compound as
recited in any of the claims and described herein, or of a salt or
stereoisomer thereof. In another embodiment, the present disclosure
provides a method for inhibiting growth of tumor cells in an
individual or a patient. The method includes administering to the
individual or patient in need thereof a therapeutically effective
amount of a compound of Formula (I'), Formula (I) or of any of the
formulas as described herein, or of a compound as recited in any of
the claims and described herein, or a salt or a stereoisomer
thereof.
[0226] In some embodiments, provided herein is a method for
treating cancer. The method includes administering to a patient in
need thereof, a therapeutically effective amount of a compound of
Formula (I'), Formula (I) or any of the formulas as described
herein, a compound as recited in any of the claims and described
herein, or a salt thereof. Examples of cancers include those whose
growth may be inhibited using compounds of the disclosure and
cancers typically responsive to immunotherapy.
[0227] In some embodiments, the present disclosure provides a
method of enhancing, stimulating and/or increasing the immune
response in a patient. The method includes administering to the
patient in need thereof a therapeutically effective amount of a
compound of Formula (I'), Formula (I) or any of the formulas as
described herein, a compound or composition as recited in any of
the claims and described herein, or a salt thereof.
[0228] Examples of cancers that are treatable using the compounds
of the present disclosure include, but are not limited to, bone
cancer, pancreatic cancer, skin cancer, cancer of the head or neck,
cutaneous or intraocular malignant melanoma, uterine cancer,
ovarian cancer, rectal cancer, cancer of the anal region, stomach
cancer, testicular cancer, uterine cancer, carcinoma of the
fallopian tubes, carcinoma of the endometrium, endometrial cancer,
carcinoma of the cervix, carcinoma of the vagina, carcinoma of the
vulva, Hodgkin's Disease, non-Hodgkin's lymphoma, cancer of the
esophagus, cancer of the small intestine, cancer of the endocrine
system, cancer of the thyroid gland, cancer of the parathyroid
gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer
of the urethra, cancer of the penis, chronic or acute leukemias
including acute myeloid leukemia, chronic myeloid leukemia, acute
lymphoblastic leukemia, chronic lymphocytic leukemia, solid tumors
of childhood, lymphocytic lymphoma, cancer of the bladder, cancer
of the kidney or urethra, carcinoma of the renal pelvis, neoplasm
of the central nervous system (CNS), primary CNS lymphoma, tumor
angiogenesis, spinal axis tumor, brain stem glioma, pituitary
adenoma, Kaposi's sarcoma, epidermoid cancer, squamous cell cancer,
T-cell lymphoma, environmentally induced cancers including those
induced by asbestos, and combinations of said cancers. The
compounds of the present disclosure are also useful for the
treatment of metastatic cancers, especially metastatic cancers that
express PD-L1.
[0229] In some embodiments, cancers treatable with compounds of the
present disclosure include melanoma (e.g., metastatic malignant
melanoma), renal cancer (e.g. clear cell carcinoma), prostate
cancer (e.g. hormone refractory prostate adenocarcinoma), breast
cancer, colon cancer and lung cancer (e.g. non-small cell lung
cancer). Additionally, the disclosure includes refractory or
recurrent malignancies whose growth may be inhibited using the
compounds of the disclosure.
[0230] In some embodiments, cancers that are treatable using the
compounds of the present disclosure include, but are not limited
to, solid tumors (e.g., prostate cancer, colon cancer, esophageal
cancer, endometrial cancer, ovarian cancer, uterine cancer, renal
cancer, hepatic cancer, pancreatic cancer, gastric cancer, breast
cancer, lung cancer, cancers of the head and neck, thyroid cancer,
glioblastoma, sarcoma, bladder cancer, etc.), hematological cancers
(e.g., lymphoma, leukemia such as acute lymphoblastic leukemia
(ALL), acute myelogenous leukemia (AML), chronic lymphocytic
leukemia (CLL), chronic myelogenous leukemia (CML), DLBCL, mantle
cell lymphoma, Non-Hodgkin lymphoma (including relapsed or
refractory NHL and recurrent follicular), Hodgkin lymphoma or
multiple myeloma) and combinations of said cancers.
[0231] PD-1 pathway blockade with compounds of the present
disclosure can also be used for treating infections such as viral,
bacteria, fungus and parasite infections. The present disclosure
provides a method for treating infections such as viral infections.
The method includes administering to a patient in need thereof, a
therapeutically effective amount of a compound of Formula (I'),
Formula (I) or any of the formulas as described herein, a compound
as recited in any of the claims and described herein, a salt
thereof. Examples of viruses causing infections treatable by
methods of the present disclosure include, but are not limit to,
human immunodeficiency virus, human papillomavirus, influenza,
hepatitis A, B, C or D viruses, adenovirus, poxvirus, herpes
simplex viruses, human cytomegalovirus, severe acute respiratory
syndrome virus, ebola virus, and measles virus. In some
embodiments, viruses causing infections treatable by methods of the
present disclosure include, but are not limit to, hepatitis (A, B,
or C), herpes virus (e.g., VZV, HSV-1, HAV-6, HSV-II, and CMV,
Epstein Barr virus), adenovirus, influenza virus, flaviviruses,
echovirus, rhinovirus, coxsackie virus, cornovirus, respiratory
syncytial virus, mumpsvirus, rotavirus, measles virus, rubella
virus, parvovirus, vaccinia virus, HTLV virus, dengue virus,
papillomavirus, molluscum virus, poliovirus, rabies virus, JC virus
and arboviral encephalitis virus.
[0232] The present disclosure provides a method for treating
bacterial infections. The method includes administering to a
patient in need thereof, a therapeutically effective amount of a
compound of Formula (I'), Formula (I) or any of the formulas as
described herein, a compound as recited in any of the claims and
described herein, or a salt thereof. Non-limiting examples of
pathogenic bacteria causing infections treatable by methods of the
disclosure include chlamydia, rickettsial bacteria, mycobacteria,
staphylococci, streptococci, pneumonococci, meningococci and
conococci, klebsiella, proteus, serratia, pseudomonas, legionella,
diphtheria, salmonella, bacilli, cholera, tetanus, botulism,
anthrax, plague, leptospirosis, and Lyme's disease bacteria.
[0233] The present disclosure provides a method for treating fungus
infections. The method includes administering to a patient in need
thereof, a therapeutically effective amount of a compound of
Formula (I'), Formula (I) or any of the formulas as described
herein, a compound as recited in any of the claims and described
herein, or a salt thereof. Non-limiting examples of pathogenic
fungi causing infections treatable by methods of the disclosure
include Candida (albicans, krusei, glabrata, tropicalis, etc.),
Cryptococcus neoformans, Aspergillus (fumigatus, niger, etc.),
Genus Mucorales (mucor, absidia, rhizophus), Sporothrix schenkii,
Blastomyces dermatitidis, Paracoccidioides brasiliensis,
Coccidioides immitis and Histoplasma capsulatum.
[0234] The present disclosure provides a method for treating
parasite infections. The method includes administering to a patient
in need thereof, a therapeutically effective amount of a compound
of Formula (I'), Formula (I) or any of the formulas as described
herein, a compound as recited in any of the claims and described
herein, or a salt thereof. Non-limiting examples of pathogenic
parasites causing infections treatable by methods of the disclosure
include Entamoeba histolytica, Balantidium coli, Naegleriafowleri,
Acanthamoeba sp., Giardia lambia, Cryptosporidium sp., Pneumocystis
carinii, Plasmodium vivax, Babesia microti, Trypanosoma brucei,
Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondi, and
Nippostrongylus brasiliensis.
[0235] The terms "individual" or "patient," used interchangeably,
refer to any animal, including mammals, preferably mice, rats,
other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses,
or primates, and most preferably humans.
[0236] The phrase "therapeutically effective amount" refers to the
amount of active compound or pharmaceutical agent that elicits the
biological or medicinal response in a tissue, system, animal,
individual or human that is being sought by a researcher,
veterinarian, medical doctor or other clinician.
[0237] As used herein, the term "treating" or "treatment" refers to
one or more of (1) inhibiting the disease; e.g., inhibiting a
disease, condition or disorder in an individual who is experiencing
or displaying the pathology or symptomatology of the disease,
condition or disorder (i.e., arresting further development of the
pathology and/or symptomatology); and (2) ameliorating the disease;
e.g., ameliorating a disease, condition or disorder in an
individual who is experiencing or displaying the pathology or
symptomatology of the disease, condition or disorder (i.e.,
reversing the pathology and/or symptomatology) such as decreasing
the severity of disease.
[0238] In some embodiments, the compounds of the invention are
useful in preventing or reducing the risk of developing any of the
diseases referred to herein; e.g., preventing or reducing the risk
of developing a disease, condition or disorder in an individual who
may be predisposed to the disease, condition or disorder but does
not yet experience or display the pathology or symptomatology of
the disease.
Combination Therapies
[0239] Cancer cell growth and survival can be impacted by multiple
signaling pathways. Thus, it is useful to combine different
enzyme/protein/receptor inhibitors, exhibiting different
preferences in the targets which they modulate the activities of,
to treat such conditions. Targeting more than one signaling pathway
(or more than one biological molecule involved in a given signaling
pathway) may reduce the likelihood of drug-resistance arising in a
cell population, and/or reduce the toxicity of treatment.
[0240] The compounds of the present disclosure can be used in
combination with one or more other enzyme/protein/receptor
inhibitors for the treatment of diseases, such as cancer or
infections. Examples of cancers include solid tumors and liquid
tumors, such as blood cancers. Examples of infections include viral
infections, bacterial infections, fungus infections or parasite
infections. For example, the compounds of the present disclosure
can be combined with one or more inhibitors of the following
kinases for the treatment of cancer: Akt1, Akt2, Akt3, TGF-.beta.R,
PKA, PKG, PKC, CaM-kinase, phosphorylase kinase, MEKK, ERK, MAPK,
mTOR, EGFR, HER2, HER3, HER4, INS-R, IGF-1R, IR-R, PDGF.alpha.R,
PDGF.beta.R, CSFIR, KIT, FLK-II, KDR/FLK-1, FLK-4, flt-1, FGFR1,
FGFR2, FGFR3, FGFR4, c-Met, Ron, Sea, TRKA, TRKB, TRKC, FLT3,
VEGFR/Flt2, Flt4, EphA1, EphA2, EphA3, EphB2, EphB4, Tie2, Src,
Fyn, Lck, Fgr, Btk, Fak, SYK, FRK, JAK, ABL, ALK and B-Raf. In some
embodiments, the compounds of the present disclosure can be
combined with one or more of the following inhibitors for the
treatment of cancer or infections. Non-limiting examples of
inhibitors that can be combined with the compounds of the present
disclosure for treatment of cancer and infections include an FGFR
inhibitor (FGFR1, FGFR2, FGFR3 or FGFR4), a JAK inhibitor (JAK1
and/or JAK2, e.g., ruxolitinib, baricitinib or INCB39110), an IDO
inhibitor (e.g., epacadostat and NLG919), a TDO inhibitor, a
PI3K-delta inhibitor, a PI3K-gamma inhibitor, a Pim inhibitor, a
CSF1R inhibitor, a TAM receptor tyrosine kinases (Tyro-3, Axl, and
Mer), an angiogenesis inhibitor, an interleukin receptor inhibitor
and an adenosine receptor antagonist or combinations thereof.
[0241] The compounds of the present disclosure can further be used
in combination with other methods of treating cancers, for example
by chemotherapy, irradiation therapy, tumor-targeted therapy,
adjuvant therapy, immunotherapy or surgery. Examples of
immunotherapy include cytokine treatment (e.g., interferons,
GM-CSF, G-CSF, IL-2), CRS-207 immunotherapy, cancer vaccine,
monoclonal antibody, adoptive T cell transfer, oncolytic
virotherapy and immunomodulating small molecules, including
thalidomide or JAK1/2 inhibitor and the like. The compounds can be
administered in combination with one or more anti-cancer drugs,
such as a chemotherapeutics. Example chemotherapeutics include any
of: abarelix, aldesleukin, alemtuzumab, alitretinoin, allopurinol,
altretamine, anastrozole, arsenic trioxide, asparaginase,
azacitidine, bevacizumab, bexarotene, baricitinib, bleomycin,
bortezombi, bortezomib, busulfan intravenous, busulfan oral,
calusterone, capecitabine, carboplatin, carmustine, cetuximab,
chlorambucil, cisplatin, cladribine, clofarabine, cyclophosphamide,
cytarabine, dacarbazine, dactinomycin, dalteparin sodium,
dasatinib, daunorubicin, decitabine, denileukin, denileukin
diftitox, dexrazoxane, docetaxel, doxorubicin, dromostanolone
propionate, eculizumab, epirubicin, erlotinib, estramustine,
etoposide phosphate, etoposide, exemestane, fentanyl citrate,
filgrastim, floxuridine, fludarabine, fluorouracil, fulvestrant,
gefitinib, gemcitabine, gemtuzumab ozogamicin, goserelin acetate,
histrelin acetate, ibritumomab tiuxetan, idarubicin, ifosfamide,
imatinib mesylate, interferon alfa 2a, irinotecan, lapatinib
ditosylate, lenalidomide, letrozole, leucovorin, leuprolide
acetate, levamisole, lomustine, meclorethamine, megestrol acetate,
melphalan, mercaptopurine, methotrexate, methoxsalen, mitomycin C,
mitotane, mitoxantrone, nandrolone phenpropionate, nelarabine,
nofetumomab, oxaliplatin, paclitaxel, pamidronate, panitumumab,
pegaspargase, pegfilgrastim, pemetrexed disodium, pentostatin,
pipobroman, plicamycin, procarbazine, quinacrine, rasburicase,
rituximab, ruxolitinib, sorafenib, streptozocin, sunitinib,
sunitinib maleate, tamoxifen, temozolomide, teniposide,
testolactone, thalidomide, thioguanine, thiotepa, topotecan,
toremifene, tositumomab, trastuzumab, tretinoin, uracil mustard,
valrubicin, vinblastine, vincristine, vinorelbine, vorinostat and
zoledronate.
[0242] Other anti-cancer agent(s) include antibody therapeutics
such as trastuzumab (Herceptin), antibodies to costimulatory
molecules such as CTLA-4 (e.g., ipilimumab), 4-1BB, antibodies to
PD-1 and PD-L1, or antibodies to cytokines (IL-10, TGF-(3, etc.).
Examples of antibodies to PD-1 and/or PD-L1 that can be combined
with compounds of the present disclosure for the treatment of
cancer or infections such as viral, bacteria, fungus and parasite
infections include, but are not limited to, nivolumab,
pembrolizumab, MPDL3280A, MEDI-4736 and SHR-1210.
[0243] Compounds of the present disclosure can be used in
combination with one or more immune checkpoint inhibitors for the
treatment of diseases, such as cancer or infections. Exemplary
immune checkpoint inhibitors include inhibitors against immune
checkpoint molecules such as CD27, CD28, CD40, CD122, CD96, CD73,
CD47, OX40, GITR, CSF1R, JAK, PI3K delta, PI3K gamma, TAM,
arginase, CD137 (also known as 4-1BB), ICOS, A2AR, B7-H3, B7-H4,
BTLA, CTLA-4, LAG3, TIM3, VISTA, PD-1, PD-L1 and PD-L2. In some
embodiments, the immune checkpoint molecule is a stimulatory
checkpoint molecule selected from CD27, CD28, CD40, ICOS, OX40,
GITR and CD137. In some embodiments, the immune checkpoint molecule
is an inhibitory checkpoint molecule selected from A2AR, B7-H3,
B7-H4, BTLA, CTLA-4, IDO, KIR, LAG3, PD-1, TIM3, and VISTA. In some
embodiments, the compounds provided herein can be used in
combination with one or more agents selected from KIR inhibitors,
TIGIT inhibitors, LAIR1 inhibitors, CD160 inhibitors, 2B4
inhibitors and TGFR beta inhibitors.
[0244] In some embodiments, the inhibitor of an immune checkpoint
molecule is anti-PD1 antibody, anti-PD-L1 antibody, or anti-CTLA-4
antibody.
[0245] In some embodiments, the inhibitor of an immune checkpoint
molecule is an inhibitor of PD-1, e.g., an anti-PD-1 monoclonal
antibody. In some embodiments, the anti-PD-1 monoclonal antibody is
nivolumab, pembrolizumab (also known as MK-3475), pidilizumab,
SHR-1210, PDR001, or AMP-224. In some embodiments, the anti-PD-1
monoclonal antibody is nivolumab or pembrolizumab. In some
embodiments, the anti-PD1 antibody is pembrolizumab.
[0246] In some embodiments, the inhibitor of an immune checkpoint
molecule is an inhibitor of PD-L1, e.g., an anti-PD-L1 monoclonal
antibody. In some embodiments, the anti-PD-L1 monoclonal antibody
is BMS-935559, MEDI4736, MPDL3280A (also known as RG7446), or
MSB0010718C. In some embodiments, the anti-PD-L1 monoclonal
antibody is MPDL3280A or MEDI4736.
[0247] In some embodiments, the inhibitor of an immune checkpoint
molecule is an inhibitor of CTLA-4, e.g., an anti-CTLA-4 antibody.
In some embodiments, the anti-CTLA-4 antibody is ipilimumab.
[0248] In some embodiments, the inhibitor of an immune checkpoint
molecule is an inhibitor of LAG3, e.g., an anti-LAG3 antibody. In
some embodiments, the anti-LAG3 antibody is BMS-986016 or
LAG525.
[0249] The compounds of the present disclosure can further be used
in combination with one or more anti-inflammatory agents, steroids,
immunosuppressants or therapeutic antibodies.
[0250] The compounds of Formula (I'), Formula (I) or any of the
formulas as described herein, a compound as recited in any of the
claims and described herein, or salts thereof can be combined with
another immunogenic agent, such as cancerous cells, purified tumor
antigens (including recombinant proteins, peptides, and
carbohydrate molecules), cells, and cells transfected with genes
encoding immune stimulating cytokines. Non-limiting examples of
tumor vaccines that can be used include peptides of melanoma
antigens, such as peptides of gp100, MAGE antigens, Trp-2, MARTI
and/or tyrosinase, or tumor cells transfected to express the
cytokine GM-CSF.
[0251] The compounds of Formula (I'), Formula (I) or any of the
formulas as described herein, a compound as recited in any of the
claims and described herein, or salts thereof can be used in
combination with a vaccination protocol for the treatment of
cancer. In some embodiments, the tumor cells are transduced to
express GM-CSF. In some embodiments, tumor vaccines include the
proteins from viruses implicated in human cancers such as Human
Papilloma Viruses (HPV), Hepatitis Viruses (HBV and HCV) and
Kaposi's Herpes Sarcoma Virus (KHSV). In some embodiments, the
compounds of the present disclosure can be used in combination with
tumor specific antigen such as heat shock proteins isolated from
tumor tissue itself. In some embodiments, the compounds of Formula
(I'), Formula (I) or any of the formulas as described herein, a
compound as recited in any of the claims and described herein, or
salts thereof can be combined with dendritic cells immunization to
activate potent anti-tumor responses.
[0252] The compounds of the present disclosure can be used in
combination with bispecific macrocyclic peptides that target Fe
alpha or Fe gamma receptor-expressing effectors cells to tumor
cells. The compounds of the present disclosure can also be combined
with macrocyclic peptides that activate host immune
responsiveness.
[0253] The compounds of the present disclosure can be used in
combination with bone marrow transplant for the treatment of a
variety of tumors of hematopoietic origin.
[0254] The compounds of Formula (I'), Formula (I) or any of the
formulas as described herein, a compound as recited in any of the
claims and described herein, or salts thereof can be used in
combination with vaccines, to stimulate the immune response to
pathogens, toxins, and self antigens. Examples of pathogens for
which this therapeutic approach may be particularly useful, include
pathogens for which there is currently no effective vaccine, or
pathogens for which conventional vaccines are less than completely
effective. These include, but are not limited to, HIV, Hepatitis
(A, B, & C), Influenza, Herpes, Giardia, Malaria, Leishmania,
Staphylococcus aureus, Pseudomonas Aeruginosa.
[0255] Viruses causing infections treatable by methods of the
present disclosure include, but are not limit to human
papillomavirus, influenza, hepatitis A, B, C or D viruses,
adenovirus, poxvirus, herpes simplex viruses, human
cytomegalovirtis, severe acute respiratory syndrome virus, ebola
virus, measles virus, herpes virus (e.g., VZV, HSV-1, HAV-6,
HSV-II, and CMV, Epstein Barr virus), flaviviruses, echovirus,
rhinovirus, coxsackie virus, cornovirus, respiratory syncytial
virus, mumpsvirus, rotavirus, measles virus, rubella virus,
parvovirus, vaccinia virus, HTLV virus, dengue virus,
papillomavirus, molluscum virus, poliovirus, rabies virus, JC virus
and arboviral encephalitis virus.
[0256] Pathogenic bacteria causing infections treatable by methods
of the disclosure include, but are not limited to, chlamydia,
rickettsial bacteria, mycobacteria, staphylococci, streptococci,
pneumonococci, meningococci and conococci, klebsiella, proteus,
serratia, pseudomonas, legionella, diphtheria, salmonella, bacilli,
cholera, tetanus, botulism, anthrax, plague, leptospirosis, and
Lyme's disease bacteria.
[0257] Pathogenic fungi causing infections treatable by methods of
the disclosure include, but are not limited to, Candida (albicans,
krusei, glabrata, tropicalis, etc.), Cryptococcus neoformans,
Aspergillus (fumigatus, niger, etc.), Genus Mucorales (mucor,
absidia, rhizophus), Sporothrix schenkii, Blastomyces dermatitidis,
Paracoccidioides brasiliensis, Coccidioides immitis and Histoplasma
capsulatum.
[0258] Pathogenic parasites causing infections treatable by methods
of the disclosure include, but are not limited to, Entamoeba
histolytica, Balantidium coli, Naegleriafowleri, Acanthamoeba sp.,
Giardia lambia, Cryptosporidium sp., Pneumocystis carinii,
Plasmodium vivax, Babesia microti, Trypanosoma brucei, Trypanosoma
cruzi, Leishmania donovani, Toxoplasma gondi, and Nippostrongylus
brasiliensis.
[0259] When more than one pharmaceutical agent is administered to a
patient, they can be administered simultaneously, separately,
sequentially, or in combination (e.g., for more than two
agents).
IV. Formulation, Dosage Forms and Administration
[0260] When employed as pharmaceuticals, the compounds of the
present disclosure can be administered in the form of
pharmaceutical compositions. Thus the present disclosure provides a
composition comprising a compound of Formula (I'), Formula (I) or
any of the formulas as described herein, a compound as recited in
any of the claims and described herein, or a pharmaceutically
acceptable salt thereof, or any of the embodiments thereof, and at
least one pharmaceutically acceptable carrier or excipient. These
compositions can be prepared in a manner well known in the
pharmaceutical art, and can be administered by a variety of routes,
depending upon whether local or systemic treatment is indicated and
upon the area to be treated. Administration may be topical
(including transdermal, epidermal, ophthalmic and to mucous
membranes including intranasal, vaginal and rectal delivery),
pulmonary (e.g., by inhalation or insufflation of powders or
aerosols, including by nebulizer; intratracheal or intranasal),
oral or parenteral. Parenteral administration includes intravenous,
intraarterial, subcutaneous, intraperitoneal intramuscular or
injection or infusion; or intracranial, e.g., intrathecal or
intraventricular, administration. Parenteral administration can be
in the form of a single bolus dose, or may be, e.g., by a
continuous perfusion pump. Pharmaceutical compositions and
formulations for topical administration may include transdermal
patches, ointments, lotions, creams, gels, drops, suppositories,
sprays, liquids and powders. Conventional pharmaceutical carriers,
aqueous, powder or oily bases, thickeners and the like may be
necessary or desirable.
[0261] This invention also includes pharmaceutical compositions
which contain, as the active ingredient, the compound of the
present disclosure or a pharmaceutically acceptable salt thereof,
in combination with one or more pharmaceutically acceptable
carriers or excipients. In some embodiments, the composition is
suitable for topical administration. In making the compositions of
the invention, the active ingredient is typically mixed with an
excipient, diluted by an excipient or enclosed within such a
carrier in the form of, e.g., a capsule, sachet, paper, or other
container. When the excipient serves as a diluent, it can be a
solid, semi-solid, or liquid material, which acts as a vehicle,
carrier or medium for the active ingredient. Thus, the compositions
can be in the form of tablets, pills, powders, lozenges, sachets,
cachets, elixirs, suspensions, emulsions, solutions, syrups,
aerosols (as a solid or in a liquid medium), ointments containing,
e.g., up to 10% by weight of the active compound, soft and hard
gelatin capsules, suppositories, sterile injectable solutions and
sterile packaged powders.
[0262] In preparing a formulation, the active compound can be
milled to provide the appropriate particle size prior to combining
with the other ingredients. If the active compound is substantially
insoluble, it can be milled to a particle size of less than 200
mesh. If the active compound is substantially water soluble, the
particle size can be adjusted by milling to provide a substantially
uniform distribution in the formulation, e.g., about 40 mesh.
[0263] The compounds of the invention may be milled using known
milling procedures such as wet milling to obtain a particle size
appropriate for tablet formation and for other formulation types.
Finely divided (nanoparticulate) preparations of the compounds of
the invention can be prepared by processes known in the art see,
e.g., WO 2002/000196.
[0264] Some examples of suitable excipients include lactose,
dextrose, sucrose, sorbitol, mannitol, starches, gum acacia,
calcium phosphate, alginates, tragacanth, gelatin, calcium
silicate, microcrystalline cellulose, polyvinylpyrrolidone,
cellulose, water, syrup and methyl cellulose. The formulations can
additionally include: lubricating agents such as talc, magnesium
stearate and mineral oil; wetting agents; emulsifying and
suspending agents; preserving agents such as methyl- and
propylhydroxy-benzoates; sweetening agents; and flavoring agents.
The compositions of the invention can be formulated so as to
provide quick, sustained or delayed release of the active
ingredient after administration to the patient by employing
procedures known in the art.
[0265] In some embodiments, the pharmaceutical composition
comprises silicified microcrystalline cellulose (SMCC) and at least
one compound described herein, or a pharmaceutically acceptable
salt thereof. In some embodiments, the silicified microcrystalline
cellulose comprises about 98% microcrystalline cellulose and about
2% silicon dioxide w/w.
[0266] In some embodiments, the composition is a sustained release
composition comprising at least one compound described herein, or a
pharmaceutically acceptable salt thereof, and at least one
pharmaceutically acceptable carrier or excipient. In some
embodiments, the composition comprises at least one compound
described herein, or a pharmaceutically acceptable salt thereof,
and at least one component selected from microcrystalline
cellulose, lactose monohydrate, hydroxypropyl methylcellulose and
polyethylene oxide. In some embodiments, the composition comprises
at least one compound described herein, or a pharmaceutically
acceptable salt thereof, and microcrystalline cellulose, lactose
monohydrate and hydroxypropyl methylcellulose. In some embodiments,
the composition comprises at least one compound described herein,
or a pharmaceutically acceptable salt thereof, and microcrystalline
cellulose, lactose monohydrate and polyethylene oxide. In some
embodiments, the composition further comprises magnesium stearate
or silicon dioxide. In some embodiments, the microcrystalline
cellulose is Avicel PH102.TM.. In some embodiments, the lactose
monohydrate is Fast-flo316.TM.. In some embodiments, the
hydroxypropyl methylcellulose is hydroxypropyl methylcellulose 2208
K4M (e.g., Methocel K4 M Premier.TM.) and/or hydroxypropyl
methylcellulose 2208 K100LV (e.g., Methocel K00LV.TM.). In some
embodiments, the polyethylene oxide is polyethylene oxide WSR 1105
(e.g., Polyox WSR 1105.TM.).
[0267] In some embodiments, a wet granulation process is used to
produce the composition. In some embodiments, a dry granulation
process is used to produce the composition.
[0268] The compositions can be formulated in a unit dosage form,
each dosage containing from about 5 to about 1,000 mg (1 g), more
usually about 100 mg to about 500 mg, of the active ingredient. In
some embodiments, each dosage contains about 10 mg of the active
ingredient. In some embodiments, each dosage contains about 50 mg
of the active ingredient. In some embodiments, each dosage contains
about 25 mg of the active ingredient. The term "unit dosage forms"
refers to physically discrete units suitable as unitary dosages for
human subjects and other mammals, each unit containing a
predetermined quantity of active material calculated to produce the
desired therapeutic effect, in association with a suitable
pharmaceutical excipient.
[0269] The components used to formulate the pharmaceutical
compositions are of high purity and are substantially free of
potentially harmful contaminants (e.g., at least National Food
grade, generally at least analytical grade, and more typically at
least pharmaceutical grade). Particularly for human consumption,
the composition is preferably manufactured or formulated under Good
Manufacturing Practice standards as defined in the applicable
regulations of the U.S. Food and Drug Administration. For example,
suitable formulations may be sterile and/or substantially isotonic
and/or in full compliance with all Good Manufacturing Practice
regulations of the U.S. Food and Drug Administration.
[0270] The active compound may be effective over a wide dosage
range and is generally administered in a therapeutically effective
amount. It will be understood, however, that the amount of the
compound actually administered will usually be determined by a
physician, according to the relevant circumstances, including the
condition to be treated, the chosen route of administration, the
actual compound administered, the age, weight, and response of the
individual patient, the severity of the patient's symptoms and the
like.
[0271] The therapeutic dosage of a compound of the present
invention can vary according to, e.g., the particular use for which
the treatment is made, the manner of administration of the
compound, the health and condition of the patient, and the judgment
of the prescribing physician. The proportion or concentration of a
compound of the invention in a pharmaceutical composition can vary
depending upon a number of factors including dosage, chemical
characteristics (e.g., hydrophobicity), and the route of
administration. For example, the compounds of the invention can be
provided in an aqueous physiological buffer solution containing
about 0.1 to about 10% w/v of the compound for parenteral
administration. Some typical dose ranges are from about 1 .mu.g/kg
to about 1 g/kg of body weight per day. In some embodiments, the
dose range is from about 0.01 mg/kg to about 100 mg/kg of body
weight per day. The dosage is likely to depend on such variables as
the type and extent of progression of the disease or disorder, the
overall health status of the particular patient, the relative
biological efficacy of the compound selected, formulation of the
excipient, and its route of administration. Effective doses can be
extrapolated from dose-response curves derived from in vitro or
animal model test systems.
[0272] For preparing solid compositions such as tablets, the
principal active ingredient is mixed with a pharmaceutical
excipient to form a solid preformulation composition containing a
homogeneous mixture of a compound of the present invention. When
referring to these preformulation compositions as homogeneous, the
active ingredient is typically dispersed evenly throughout the
composition so that the composition can be readily subdivided into
equally effective unit dosage forms such as tablets, pills and
capsules. This solid preformulation is then subdivided into unit
dosage forms of the type described above containing from, e.g.,
about 0.1 to about 1000 mg of the active ingredient of the present
invention.
[0273] The tablets or pills of the present invention can be coated
or otherwise compounded to provide a dosage form affording the
advantage of prolonged action. For example, the tablet or pill can
comprise an inner dosage and an outer dosage component, the latter
being in the form of an envelope over the former. The two
components can be separated by an enteric layer which serves to
resist disintegration in the stomach and permit the inner component
to pass intact into the duodenum or to be delayed in release. A
variety of materials can be used for such enteric layers or
coatings, such materials including a number of polymeric acids and
mixtures of polymeric acids with such materials as shellac, cetyl
alcohol and cellulose acetate.
[0274] The liquid forms in which the compounds and compositions of
the present invention can be incorporated for administration orally
or by injection include aqueous solutions, suitably flavored
syrups, aqueous or oil suspensions, and flavored emulsions with
edible oils such as cottonseed oil, sesame oil, coconut oil, or
peanut oil, as well as elixirs and similar pharmaceutical
vehicles.
[0275] Compositions for inhalation or insufflation include
solutions and suspensions in pharmaceutically acceptable, aqueous
or organic solvents, or mixtures thereof, and powders. The liquid
or solid compositions may contain suitable pharmaceutically
acceptable excipients as described supra. In some embodiments, the
compositions are administered by the oral or nasal respiratory
route for local or systemic effect. Compositions can be nebulized
by use of inert gases. Nebulized solutions may be breathed directly
from the nebulizing device or the nebulizing device can be attached
to a face mask, tert, or intermittent positive pressure breathing
machine. Solution, suspension, or powder compositions can be
administered orally or nasally from devices which deliver the
formulation in an appropriate manner.
[0276] Topical formulations can contain one or more conventional
carriers. In some embodiments, ointments can contain water and one
or more hydrophobic carriers selected from, e.g., liquid paraffin,
polyoxyethylene alkyl ether, propylene glycol, white Vaseline, and
the like. Carrier compositions of creams can be based on water in
combination with glycerol and one or more other components, e.g.,
glycerinemonostearate, PEG-glycerinemonostearate and cetylstearyl
alcohol. Gels can be formulated using isopropyl alcohol and water,
suitably in combination with other components such as, e.g.,
glycerol, hydroxyethyl cellulose, and the like. In some
embodiments, topical formulations contain at least about 0.1, at
least about 0.25, at least about 0.5, at least about 1, at least
about 2 or at least about 5 wt % of the compound of the invention.
The topical formulations can be suitably packaged in tubes of,
e.g., 100 g which are optionally associated with instructions for
the treatment of the select indication, e.g., psoriasis or other
skin condition.
[0277] The amount of compound or composition administered to a
patient will vary depending upon what is being administered, the
purpose of the administration, such as prophylaxis or therapy, the
state of the patient, the manner of administration and the like. In
therapeutic applications, compositions can be administered to a
patient already suffering from a disease in an amount sufficient to
cure or at least partially arrest the symptoms of the disease and
its complications. Effective doses will depend on the disease
condition being treated as well as by the judgment of the attending
clinician depending upon factors such as the severity of the
disease, the age, weight and general condition of the patient and
the like.
[0278] The compositions administered to a patient can be in the
form of pharmaceutical compositions described above. These
compositions can be sterilized by conventional sterilization
techniques, or may be sterile filtered. Aqueous solutions can be
packaged for use as is, or lyophilized, the lyophilized preparation
being combined with a sterile aqueous carrier prior to
administration. The pH of the compound preparations typically will
be between 3 and 11, more preferably from 5 to 9 and most
preferably from 7 to 8. It will be understood that use of certain
of the foregoing excipients, carriers or stabilizers will result in
the formation of pharmaceutical salts.
[0279] The therapeutic dosage of a compound of the present
invention can vary according to, e.g., the particular use for which
the treatment is made, the manner of administration of the
compound, the health and condition of the patient, and the judgment
of the prescribing physician. The proportion or concentration of a
compound of the invention in a pharmaceutical composition can vary
depending upon a number of factors including dosage, chemical
characteristics (e.g., hydrophobicity), and the route of
administration. For example, the compounds of the invention can be
provided in an aqueous physiological buffer solution containing
about 0.1 to about 10% w/v of the compound for parenteral
administration. Some typical dose ranges are from about 1 .mu.g/kg
to about 1 g/kg of body weight per day. In some embodiments, the
dose range is from about 0.01 mg/kg to about 100 mg/kg of body
weight per day. The dosage is likely to depend on such variables as
the type and extent of progression of the disease or disorder, the
overall health status of the particular patient, the relative
biological efficacy of the compound selected, formulation of the
excipient, and its route of administration. Effective doses can be
extrapolated from dose-response curves derived from in vitro or
animal model test systems.
V. Labeled Compounds and Assay Methods
[0280] The compounds of the present disclosure can further be
useful in investigations of biological processes in normal and
abnormal tissues. Thus, another aspect of the present invention
relates to labeled compounds of the invention (radio-labeled,
fluorescent-labeled, etc.) that would be useful not only in imaging
techniques but also in assays, both in vitro and in vivo, for
localizing and quantitating PD-1 or PD-L1 protein in tissue
samples, including human, and for identifying PD-L1 ligands by
inhibition binding of a labeled compound. Accordingly, the present
invention includes PD-1/PD-L1 binding assays that contain such
labeled compounds.
[0281] The present invention further includes
isotopically-substituted compounds of the disclosure. An
"isotopically-substituted" compound is a compound of the invention
where one or more atoms are replaced or substituted by an atom
having an atomic mass or mass number different from the atomic mass
or mass number typically found in nature (i.e., naturally
occurring). It is to be understood that a "radio-labeled" compound
is a compound that has incorporated at least one isotope that is
radioactive (e.g., radionuclide). Suitable radionuclides that may
be incorporated in compounds of the present invention include but
are not limited to .sup.3H (also written as T for tritium),
.sup.11C, .sup.13C, .sup.14C, .sup.13N, .sup.15N, .sup.15O,
.sup.17O, .sup.18O, .sup.18F, .sup.35S, .sup.36Cl, .sup.82Br,
.sup.75Br, .sup.76Br, .sup.77Br, .sup.123I, .sup.124I, .sup.125I
and .sup.131I. The radionuclide that is incorporated in the instant
radio-labeled compounds will depend on the specific application of
that radio-labeled compound. For example, for in vitro PD-L1
protein labeling and competition assays, compounds that incorporate
.sup.3H, .sup.14C, .sup.82Br, .sup.125I, .sup.131I, .sup.35S or
will generally be most useful. For radio-imaging applications
.sup.11C, .sup.18F, .sup.125I, .sup.123I, .sup.124I, .sup.131I,
.sup.75Br, .sup.76Br or .sup.77Br will generally be most
useful.
[0282] In some embodiments the radionuclide is selected from the
group consisting of .sup.3H, .sup.14C, .sup.125I, .sup.35S and
.sup.82Br. Synthetic methods for incorporating radio-isotopes into
organic compounds are known in the art.
[0283] Specifically, a labeled compound of the invention can be
used in a screening assay to identify and/or evaluate compounds.
For example, a newly synthesized or identified compound (i.e., test
compound) which is labeled can be evaluated for its ability to bind
a PD-L1 protein by monitoring its concentration variation when
contacting with the PD-L1 protein, through tracking of the
labeling. For example, a test compound (labeled) can be evaluated
for its ability to reduce binding of another compound which is
known to bind to a PD-L1 protein (i.e., standard compound).
Accordingly, the ability of a test compound to compete with the
standard compound for binding to the PD-L1 protein directly
correlates to its binding affinity. Conversely, in some other
screening assays, the standard compound is labeled and test
compounds are unlabeled. Accordingly, the concentration of the
labeled standard compound is monitored in order to evaluate the
competition between the standard compound and the test compound,
and the relative binding affinity of the test compound is thus
ascertained.
VI. Kits
[0284] The present disclosure also includes pharmaceutical kits
useful, e.g., in the treatment or prevention of diseases or
disorders associated with the activity of PD-L1 including its
interaction with other proteins such as PD-1 and B7-1 (CD80), such
as cancer or infections, which include one or more containers
containing a pharmaceutical composition comprising a
therapeutically effective amount of a compound of Formula (I'),
Formula (I), or any of the embodiments thereof. Such kits can
further include one or more of various conventional pharmaceutical
kit components, such as, e.g., containers with one or more
pharmaceutically acceptable carriers, additional containers, etc.,
as will be readily apparent to those skilled in the art.
Instructions, either as inserts or as labels, indicating quantities
of the components to be administered, guidelines for
administration, and/or guidelines for mixing the components, can
also be included in the kit.
[0285] The invention will be described in greater detail by way of
specific examples. The following examples are offered for
illustrative purposes, and are not intended to limit the invention
in any manner. Those of skill in the art will readily recognize a
variety of non-critical parameters which can be changed or modified
to yield essentially the same results. The compounds of the
Examples have been found to inhibit the activity of PD-1/PD-L1
protein/protein interaction according to at least one assay
described herein.
EXAMPLES
[0286] Experimental procedures for compounds of the invention are
provided below. Open Access Preparative LCMS Purification of some
of the compounds prepared was performed on Waters mass directed
fractionation systems. The basic equipment setup, protocols and
control software for the operation of these systems have been
described in detail in literature. See, e.g., Blom, "Two-Pump At
Column Dilution Configuration for Preparative LC-MS", K. Blom, J.
Combi. Chem., 2002, 4, 295-301; Blom et al., "Optimizing
Preparative LC-MS Configurations and Methods for Parallel Synthesis
Purification", J. Combi. Chem., 2003, 5, 670-83; and Blom et al.,
"Preparative LC-MS Purification: Improved Compound Specific Method
Optimization", J. Combi. Chem., 2004, 6, 874-883.
Example 1
2-({[2-(2-methylbiphenyl-3-yl)furo[2,3-b]pyridin-6-yl]methyl}amino)ethanol
##STR00033##
[0287] Step 1: 2-methylbiphenyl-3-carbaldehyde
##STR00034##
[0289] To a solution of (2-methylbiphenyl-3-yl)methanol (TCI,
cat#H0777: 1.45 g, 7.31 mmol) in methylene chloride (15 mL) was
added Dess-Martin periodinane (3.26 g, 7.68 mmol) portion-wise at
room temperature. The resulting mixture was stirred at room
temperature for 30 min then quenched by NaHCO.sub.3 solution and
Na.sub.2S.sub.2O.sub.3 solution. The mixture was extracted with
methylene chloride and the combined extracts were dried over
MgSO.sub.4 and concentrated. The residue was purified by column
chromatography (0-5% EtOAc in hexanes) to give the desired product.
LC-MS calculated for C.sub.14H.sub.13O (M+H).sup.+: m/z=197.1.
found 197.1.
Step 2: 3-ethynyl-2-methylbiphenyl
##STR00035##
[0291] To a solution of 2-methylbiphenyl-3-carbaldehyde (589 mg,
3.00 mmol) and dimethyl (1-diazo-2-oxopropyl)phosphonate (650 mg,
4.00 mmol) in methanol (10 mL) was added potassium carbonate (830
mg, 6.00 mmol) at room temperature. The reaction mixture was
stirred at room temperature for 2 h then quenched by water. The
mixture was extracted with diethyl ether. The organic phase was
combined, dried over MgSO.sub.4 and concentrated. The residue was
purified by column chromatography (100% hexanes) to give the
desired product.
Step 3: methyl
2-(2-methylbiphenyl-3-yl)furo[2,3-b]pyridine-6-carboxylate
##STR00036##
[0293] To a solution of methyl
5-bromo-6-hydroxypyridine-2-carboxylate (Ark Pharm, cat#AK100454:
99 mg, 0.42 mmol) in dry 1, 4-dioxane (1 mL) were added
3-ethynyl-2-methylbiphenyl (90 mg, 0.47 mmol),
dichloro[bis(triphenylphosphoranyl)]palladium (10 mg, 0.02 mmol),
copper(I) iodide (4 mg, 0.02 mmol) and triethylamine (200 .mu.L).
The mixture was purged with N.sub.2, then refluxed for 7 h. The
reaction mixture was cooled to room temperature, diluted with EtOAc
then filtered through a pad of Celite. The filtrate was washed with
water and brine. The organic phase was dried over MgSO.sub.4,
filtered and concentrated. The residue was purified by flash
chromatography on a silica gel column eluting with 0 to 10%
EtOAc/Hexanes to give the desired product. LC-MS calculated for
C.sub.22H.sub.18NO.sub.3 (M+H).sup.+: m/z=344.1. found 344.1.
Step 4:
2-(2-methylbiphenyl-3-yl)furo[2,3-b]pyridine-6-carbaldehyde
##STR00037##
[0295] To a solution of methyl
2-(2-methylbiphenyl-3-yl)furo[2,3-b]pyridine-6-carboxylate (144 mg,
0.42 mmol) in tetrahydrofuran (3 mL) was added lithium
tetrahydroaluminate in THF (1.0 M, 300 .mu.L, 0.3 mmol) dropwise at
0.degree. C. The mixture was slowly warmed up to room temperature.
Then the mixture was quenched with ethyl acetate followed by water
and sodium hydroxide solution. The mixture was extracted with ethyl
acetate three times. The organic phase was combined, dried over
MgSO.sub.4 and concentrated. The residue was used in the next step
without further purification. LC-MS calculated for
C.sub.21H.sub.18NO.sub.2 (M+H).sup.+: m/z=316.1. found 316.0.
[0296] The above residue was dissolved in methylene chloride (1 mL)
then Dess-Martin periodinane (180 mg, 0.42 mmol) was added at room
temperature. The resulting mixture was stirred for 10 min and then
quenched with NaHCO.sub.3 solution and Na.sub.2S.sub.2O.sub.3
solution. The mixture was extracted with methylene chloride. The
organic phase was combined, dried over MgSO.sub.4 and concentrated.
The residue was purified by flash chromatography on a silica gel
column eluting with 0 to 25% EtOAc/Hexanes to give the desired
product. LC-MS calculated for C.sub.21H.sub.16NO.sub.2 (M+H).sup.+:
m/z=314.1. found 314.1.
Step 5:
2-({[2-(2-methylbiphenyl-3-yl)furo[2,3-b]pyridin-6-yl]methyl}amino-
)ethanol
[0297] A solution of
2-(2-methylbiphenyl-3-yl)furo[2,3-b]pyridine-6-carbaldehyde (10 mg,
0.03 mmol) and ethanolamine (5.5 .mu.L, 0.092 mmol) in methylene
chloride (0.4 mL) was stirred at room temperature for 2 h. Then
sodium triacetoxyborohydride (19 mg, 0.092 mmol) and acetic acid
(3.5 .mu.L, 0.061 mmol) were added and the mixture was stirred
overnight. The reaction mixture was diluted with MeOH and then
purified by prep-HPLC (pH=2, acetonitrile/water+TFA) to give the
desired product as the TFA salt. LC-MS calculated for
C.sub.23H.sub.23N.sub.2O.sub.2 (M+H).sup.+: m/z=359.2. found
359.2.
Example 2
(2S)-1-{[2-(2-methylbiphenyl-3-yl)furo[2,3-b]pyridin-6-yl]methyl}piperidin-
e-2-carboxylic acid
##STR00038##
[0299] This compound was prepared using similar procedures as
described for Example 1 with (S)-piperidine-2-carboxylic acid
replacing ethanolamine in Step 5. The reaction mixture was diluted
with MeOH then purified by prep-HPLC (pH=10,
acetonitrile/water+NH.sub.4OH) to give the desired product. LC-MS
calculated for C.sub.27H.sub.27N.sub.2O.sub.3 (M+H).sup.+:
m/z=427.2. found 427.2.
Example 3
2-({[7-methyl-2-(2-methylbiphenyl-3-yl)furo[3,2-b]pyridin-5-yl]methyl}amin-
o)ethanol
##STR00039##
[0300] Step 1: 6-chloro-2-iodo-4-methylpyridin-3-ol
##STR00040##
[0302] To a solution of 6-chloro-4-methylpyridin-3-ol (AstaTech,
cat#BL009435: 200. mg, 1.39 mmol) and sodium carbonate (440 mg, 4.2
mmol) in water (5 mL) and tetrahydrofuran (5 mL) was added iodine
(530 mg, 2.1 mmol). The mixture was stirred at room temperature
overnight then diluted with water and extracted with EtOAc. The
combined extracts were dried over MgSO.sub.4 and concentrated. The
residue was purified by column chromatography (0-50% EtOAc in
hexanes) to give the desired product. LC-MS calculated for
C.sub.6H.sub.6ClINO (M+H).sup.+: m/z=269.9. found 269.9.
Step 2:
5-chloro-7-methyl-2-(2-methylbiphenyl-3-yl)furo[3,2-b]pyridine
##STR00041##
[0304] This compound was prepared using similar procedures as
described for Example 1, Step 3 with
6-chloro-2-iodo-4-methylpyridin-3-ol replacing
5-bromo-6-hydroxypyridine-2-carboxylate. The crude material was
used directly in the next step without further purification. LC-MS
calculated for C.sub.21H.sub.17ClNO (M+H).sup.+: m/z=334.1. found
334.1.
Step 3:
7-methyl-2-(2-methylbiphenyl-3-yl)-5-vinylfuro[3,2-b]pyridine
##STR00042##
[0306] A mixture of 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane
(89 .mu.L, 0.52 mmol),
5-chloro-7-methyl-2-(2-methylbiphenyl-3-yl)furo[3,2-b]pyridine (120
mg, 0.35 mmol), potassium phosphate (186 mg, 0.875 mmol) and
dichloro[1,1'-bis(dicyclohexylphosphino)ferrocene]palladium(II) (10
mg, 0.02 mmol) in 1,4-dioxane (3 mL) and water (0.6 mL) was purged
with N.sub.2 and then stirred at 100.degree. C. overnight. The
reaction mixture was cooled to room temperature and then diluted
with EtOAc and water. The aqueous phase was extracted with EtOAc
and the combined organic phase was dried over MgSO.sub.4 and then
concentrated. The residue was used directly for the next step
without further purification. LC-MS calculated for
C.sub.23H.sub.20NO (M+H).sup.+: m/z=326.2. found 326.2.
Step 4:
7-methyl-2-(2-methylbiphenyl-3-yl)furo[3,2-b]pyridine-5-carbaldehy-
de
##STR00043##
[0308] To a mixture of
7-methyl-2-(2-methylbiphenyl-3-yl)-5-vinylfuro[3,2-b]pyridine (110
mg, 0.34 mmol), sodium metaperiodate (400 mg, 2 mmol) in
tetrahydrofuran (3 mL) and water (0.4 mL) was added osmium
tetraoxide in water (0.16 M, 200 .mu.L, 0.03 mmol). The resulting
mixture was stirred at room temperature for 0.5 h, then diluted
with methylene chloride, washed with saturated NaHCO.sub.3
solution, water and brine. The organic layer was dried over
Na.sub.2SO.sub.4, filtered and concentrated. The residue was
purified by column chromatography (0-10% EtOAc in hexanes) to give
the desired product. LC-MS calculated for C.sub.22H.sub.18NO.sub.2
(M+H).sup.+: m/z=328.1. found 328.1.
Step 5:
2-({[7-methyl-2-(2-methylbiphenyl-3-yl)furo[3,2-b]pyridin-5-yl]met-
hyl}amino)ethanol
[0309] This compound was prepared using similar procedures as
described for Example 1, Step 5 with
7-methyl-2-(2-methylbiphenyl-3-yl)furo[3,2-b]pyridine-5-carbaldehyde
(product from Step 4) replacing
2-(2-methylbiphenyl-3-yl)furo[2,3-b]pyridine-6-carbaldehyde. The
reaction mixture was diluted with MeOH then purified by prep-HPLC
(pH=2, acetonitrile/water+TFA) to give the desired product as the
TFA salt. LC-MS calculated for C.sub.24H.sub.25N.sub.2O.sub.2
(M+H).sup.+: m/z=373.2. found 373.2.
Example 4
(2S)-1-{[7-methyl-2-(2-methylbiphenyl-3-yl)furo[3,2-b]pyridin-5-yl]methyl}-
piperidine-2-carboxylic acid
##STR00044##
[0311] This compound was prepared using similar procedures as
described for Example 3 with (S)-piperidine-2-carboxylic acid
replacing ethanolamine in Step 5. The reaction mixture was diluted
with MeOH then purified by prep-HPLC (pH=10,
acetonitrile/water+NH.sub.4OH) to give the desired product. LC-MS
calculated for C.sub.28H.sub.29N.sub.2O.sub.3 (M+H).sup.+:
m/z=441.2. found 441.1.
Example 5
2-({[7-methyl-2-(2-methylbiphenyl-3-yl)furo[2,3-c]pyridin-5-yl]methyl}amin-
o)ethanol
##STR00045##
[0312] Step 1: methyl 5-hydroxy-6-methylpyridine-2-carboxylate
##STR00046##
[0314] A mixture of methyl 6-bromo-5-hydroxypyridine-2-carboxylate
(Ark Pharm, cat#AK25486: 205 mg, 0.884 mmol), potassium carbonate
(300 mg, 2.2 mmol),
dichloro[1,1'-bis(dicyclohexylphosphino)ferrocene]palladium(II) (67
mg, 0.088 mmol) and trimethylboroxine (140 .mu.L, 0.97 mmol) in
1,4-dioxane (8 mL) was purged with N.sub.2 then stirred at
100.degree. C. for 2 h. The reaction mixture was cooled to room
temperature then diluted with EtOAc and washed with water. The
organic phase was dried over MgSO.sub.4 and concentrated. The
residue was purified by column chromatography (0-15% EtOAc in
hexanes gradient) to give the desired product. LC-MS calculated for
C.sub.8H.sub.10NO.sub.3 (M+H).sup.+: m/z=168.1. found 168.1.
Step 2: methyl 4-bromo-5-hydroxy-6-methylpyridine-2-carboxylate
##STR00047##
[0316] To a solution of methyl
5-hydroxy-6-methylpyridine-2-carboxylate (35.0 mg, 0.209 mmol) in
methanol (550 .mu.L) was added sodium methoxide in methanol (4.89
M, 43 .mu.L, 0.21 mmol) at 0.degree. C. After stirring at room
temperature for 30 min, N-bromosuccinimide (37.3 mg, 0.209 mmol)
was added into the mixture. The resulting mixture was stirred at
room temperature for 2 h then quenched by acetic acid and
concentrated. The residue was purified by column chromatography
(0-25% EtOAc in hexanes gradient) to give the desired product.
LC-MS calculated for C.sub.8H.sub.9BrNO.sub.3 (M+H).sup.+:
m/z=246.0. found 246.0.
Step 3: methyl
7-methyl-2-(2-methylbiphenyl-3-yl)furo[2,3-c]pyridine-5-carboxylate
##STR00048##
[0318] This compound was prepared using similar procedure as
described for Example 1, Step 3 with methyl
4-bromo-5-hydroxy-6-methylpyridine-2-carboxylate replacing
5-bromo-6-hydroxypyridine-2-carboxylate. The reaction mixture was
cooled to room temperature, diluted with EtOAc then filtered
through Celite. The filtrate was concentrated. The residue was
purified by column chromatograph (0-10% EtOAc) to give the desired
product. LC-MS calculated for C.sub.23H.sub.20NO.sub.3 (M+H).sup.+:
m/z=358.1. found 358.1.
Step 4:
7-methyl-2-(2-methylbiphenyl-3-yl)furo[2,3-e]pyridine-5-carbaldehy-
de
##STR00049##
[0320] This compound was prepared using similar procedures as
described for Example 1, Step 4 with methyl
7-methyl-2-(2-methylbiphenyl-3-yl)furo[2,3-c]pyridine-5-carboxylate
(product from Step 3) replacing methyl
2-(2-methylbiphenyl-3-yl)furo[2,3-b]pyridine-6-carboxylate. The
crude product was purified by column chromatography on silica gel
eluting with 0 to 35% EtOAc/Hexanes. LC-MS calculated for
C.sub.22H.sub.18NO.sub.2 (M+H).sup.+: m/z=328.1. found 328.1.
Step 5:
2-({[7-methyl-2-(2-methylbiphenyl-3-yl)furo[2,3-c]pyridin-5-yl]met-
hyl}amino)ethanol
[0321] This compound was prepared using similar procedures as
described for Example 1, Step 5 with
7-methyl-2-(2-methylbiphenyl-3-yl)furo[2,3-c]pyridine-5-carbaldehyde
(product from Step 4) replacing
2-(2-methylbiphenyl-3-yl)furo[2,3-b]pyridine-6-carbaldehyde. The
crude material was diluted with methanol and purified by prep-HPLC
(pH=10, acetonitrile/water+NH.sub.4OH) to give the desired product.
LC-MS calculated for C.sub.24H.sub.25N.sub.2O.sub.2 (M+H).sup.+:
m/z=373.2. found 373.2.
Example 6
(2S)-1-{[7-methyl-2-(2-methylbiphenyl-3-yl)furo[2,3-c]pyridin-5-yl]methyl}-
piperidine-2-carboxylic acid
##STR00050##
[0323] This compound was prepared using similar procedures as
described for Example 5 with (S)-piperidine-2-carboxylic acid
replacing ethanolamine in Step 5. The resulting mixture was
purified by prep-HPLC (pH=10, acetonitrile/water+NH.sub.4OH) to
give the desired product. LC-MS calculated for
C.sub.28H.sub.29N.sub.2O.sub.3 (M+H).sup.+: m/z=441.2. found
441.1.
Example 7
(2S)-1-{[2-(2-methylbiphenyl-3-yl)-1,3-benzoxazol-5-yl]methyl}piperidine-2-
-carboxylic acid
##STR00051##
[0324] Step 1: methyl
2-(2-methylbiphenyl-3-yl)-1,3-benzoxazole-5-carboxylate
##STR00052##
[0326] A mixture of methyl 3-amino-4-hydroxybenzoate (Ark Pharm,
cat#AK-76584: 49 mg, 0.29 mmol), 2-methylbiphenyl-3-carbaldehyde
(69 mg, 0.35 mmol) and zinc triflate (10 mg, 0.03 mmol) in ethanol
(1.5 mL) was refluxed overnight. The reaction mixture was cooled to
room temperature then concentrated. The residue was dissolved in
methylene chloride (1.5 mL) then dichlorodicyanoquinone (100 mg,
0.6 mmol) was added. The mixture was stirred at room temperature
for 0.5 h then diluted with ethyl acetate and washed with
NaHCO.sub.3 solution, Na.sub.2S.sub.2O.sub.3 solution, water and
brine. The organic layer was dried over Na.sub.2SO.sub.4 and
concentrated. The residue was purified by column chromatography to
give the desired product. LC-MS calculated for
C.sub.22H.sub.18NO.sub.3 (M+H).sup.+: m/z=344.1. found 344.1.
Step 2:
2-(2-methylbiphenyl-3-yl)-1,3-benzoxazole-5-carbaldehyde
##STR00053##
[0328] This compound was prepared using similar procedures as
described for Example 1, Step 4 with methyl
2-(2-methylbiphenyl-3-yl)-1,3-benzoxazole-5-carboxylate (product
from Step 1) replacing methyl
2-(2-methylbiphenyl-3-yl)furo[2,3-b]pyridine-6-carboxylate. The
crude material was purified by flash chromatography on a silica gel
column eluting with 0 to 50% EtOAc/Hexanes to give the desired
product. LC-MS calculated for C.sub.21H.sub.16NO.sub.2 (M+H).sup.+:
m/z=314.1. found 314.1.
Step 3:
(2S)-1-{[2-(2-methylbiphenyl-3-yl)-1,3-benzoxazol-5-yl]methyl}pipe-
ridine-2-carboxylic acid
[0329] This compound was prepared using similar procedures as
described for Example 1, Step 5 with
2-(2-methylbiphenyl-3-yl)-1,3-benzoxazole-5-carbaldehyde (product
from Step 2) replacing
2-(2-methylbiphenyl-3-yl)furo[2,3-b]pyridine-6-carbaldehyde and
(S)-piperidine-2-carboxylic acid replacing ethanolamine. The
reaction mixture was diluted with methanol then purified by
prep-HPLC (pH=2, acetonitrile/water+TFA) to give the desired
product as the TFA salt. LC-MS calculated for
C.sub.27H.sub.27N.sub.2O.sub.3 (M+H).sup.+: m/z=427.2. found
427.2.
Example 8
2-({[2-(2-methylbiphenyl-3-yl)-1,3-benzoxazol-5-yl]methyl}amino)ethanol
##STR00054##
[0331] This compound was prepared using similar procedures as
described for Example 1, Step 5 with
2-(2-methylbiphenyl-3-yl)-1,3-benzoxazole-5-carbaldehyde (Example
7, Step 2) replacing
2-(2-methylbiphenyl-3-yl)furo[2,3-b]pyridine-6-carbaldehyde. The
reaction mixture was diluted with MeOH then purified by prep-HPLC
(pH=2, acetonitrile/water+TFA) to give the desired product as the
TFA salt. LC-MS calculated for C.sub.23H.sub.23N.sub.2O.sub.2
(M+H).sup.+: m/z=359.2. found 359.2.
Example 9
(2S)-1-{[2-(2-methylbiphenyl-3-yl)furo[2,3-b]pyridin-5-yl]methyl}piperidin-
e-2-carboxylic acid
##STR00055##
[0332] Step 1: methyl
2-(2-methylbiphenyl-3-yl)furo[2,3-b]pyridine-5-carboxylate
##STR00056##
[0334] This compound was prepared using a similar procedure as
described for Example 1, Step 3 with methyl
5-bromo-6-hydroxynicotinate (Ark Pharm, cat#AK-25063) replacing
5-bromo-6-hydroxypyridine-2-carboxylate. The crude product was
purified by column chromatography on a silica gel column to give
the desired product. LC-MS calculated for C.sub.22H.sub.18NO.sub.3
(M+H).sup.+: m/z=344.1. found 344.1.
Step 2:
2-(2-methylbiphenyl-3-yl)furo[2,3-b]pyridine-5-carbaldehyde
##STR00057##
[0336] This compound was prepared using similar procedures as
described for Example 1, Step 4 with methyl
2-(2-methylbiphenyl-3-yl)-1,3-benzoxazole-5-carboxylate (product
from Step 1) replacing methyl
2-(2-methylbiphenyl-3-yl)furo[2,3-b]pyridine-6-carboxylate. The
crude material was purified by flash chromatography on a silica gel
column eluting with 0 to 30% EtOAc/Hexanes to give the desired
product. LC-MS calculated for C.sub.21H.sub.16NO.sub.2 (M+H).sup.+:
m/z=314.1. found 314.1.
Step 3:
(2S)-1-{[2-(2-methylbiphenyl-3-yl)furo[2,3-b]pyridin-5-yl]methyl}p-
iperidine-2-carboxylic acid
[0337] This compound was prepared using similar procedures as
described for Example 1, Step 5 with
2-(2-methylbiphenyl-3-yl)furo[2,3-b]pyridine-5-carbaldehyde
(product from Step 2) replacing
2-(2-methylbiphenyl-3-yl)furo[2,3-b]pyridine-6-carbaldehyde and
(5)-piperidine-2-carboxylic acid replacing ethanolamine. The
reaction mixture was diluted with methanol then purified by
prep-HPLC (pH=2, acetonitrile/water+TFA) to give the desired
product as the TFA salt. LC-MS calculated for
C.sub.27H.sub.27N.sub.2O.sub.3 (M+H).sup.+: m/z=427.2. found
427.2.
Example 10
2-({[2-(2-methylbiphenyl-3-yl)furo[2,3-b]pyridin-5-yl]methyl}amino)ethanol
##STR00058##
[0339] This compound was prepared using similar procedures as
described for Example 1, Step 5 with
2-(2-methylbiphenyl-3-yl)furo[2,3-b]pyridine-5-carbaldehyde
(Example 9, Step 2) replacing
2-(2-methylbiphenyl-3-yl)furo[2,3-b]pyridine-6-carbaldehyde. The
reaction mixture was diluted with MeOH then purified by prep-HPLC
(pH=2, acetonitrile/water+TFA) to give the desired product as the
TFA salt. LC-MS calculated for C.sub.23H.sub.23N.sub.2O.sub.2
(M+H).sup.+: m/z=359.2. found 359.2.
Example 11
(2S)-1-{[7-methyl-2-(2-methylbiphenyl-3-yl)-1,3-benzoxazol-5-yl]methyl}pip-
eridine-2-carboxylic acid
##STR00059##
[0340] Step 1:
5-bromo-7-methyl-2-(2-methylbiphenyl-3-yl)-1,3-benzoxazole
##STR00060##
[0342] This compound was prepared using similar procedures as
described for Example 7, Step 1 with 2-amino-4-bromo-6-methylphenol
(Combi-Blocks, cat#AN-2889) replacing methyl
3-amino-4-hydroxybenzoate (Ark Pharm, cat#AK-76584). The organic
phase was dried over MgSO.sub.4 and concentrated. The residue was
used directly for next step without further purification. LC-MS
calculated for C.sub.21H.sub.17BrNO (M+H).sup.+: m/z=378.0. found
378.0.
Step 2:
7-methyl-2-(2-methylbiphenyl-3-yl)-5-vinyl-1,3-benzoxazole
##STR00061##
[0344] This compound was prepared using similar procedures as
described for Example 3, Step 3 with
5-bromo-7-methyl-2-(2-methylbiphenyl-3-yl)-1,3-benzoxazole (product
from Step 1) replacing
5-chloro-7-methyl-2-(2-methylbiphenyl-3-yl)furo[3,2-k]pyridine. The
crude product was used directly for next step without further
purification. LC-MS calculated for C.sub.23H.sub.20NO (M+H).sup.+:
m/z=326.2. found 326.2.
Step 3:
7-methyl-2-(2-methylbiphenyl-3-yl)-1,3-benzoxazole-5-carbaldehyde
##STR00062##
[0346] This compound was prepared using similar procedures as
described for Example 3, Step 4 with
7-methyl-2-(2-methylbiphenyl-3-yl)-5-vinyl-1,3-benzoxazole (product
from Step 2) replacing
7-methyl-2-(2-methylbiphenyl-3-yl)-5-vinylfuro[3,2-b]pyridine. The
residue was purified by column chromatography on silica gel
(gradient, 0-10% EtOAc in hexanes) to give the desired product.
LC-MS calculated for C.sub.22H.sub.18NO.sub.2 (M+H).sup.+:
m/z=328.1. found 328.1.
Step 4:
(2S)-1-{[7-methyl-2-(2-methylbiphenyl-3-yl)-1,3-benzoxazol-5-yl]me-
thyl}piperidine-2-carboxylic acid
[0347] This compound was prepared using similar procedures as
described for Example 1, Step 5 with
7-methyl-2-(2-methylbiphenyl-3-yl)-1,3-benzoxazole-5-carbaldehyde
(product from Step 3) replacing
2-(2-methylbiphenyl-3-yl)furo[2,3-b]pyridine-6-carbaldehyde and
(5)-piperidine-2-carboxylic acid replacing ethanolamine. The crude
material was purified via prep-HPLC (pH=10,
acetonitrile/water+NH.sub.4OH) to give the desired product. LC-MS
calculated for C.sub.28H.sub.29N.sub.2O.sub.3 (M+H).sup.+:
m/z=441.2. found 441.2.
Example 12
2-({[7-methyl-2-(2-methylbiphenyl-3-yl)-1,3-benzoxazol-5-yl]methyl}amino)e-
thanol
##STR00063##
[0349] This compound was prepared using similar procedures as
described for Example 1, Step 5 with
7-methyl-2-(2-methylbiphenyl-3-yl)-1,3-benzoxazole-5-carbaldehyde
(Example 11, Step 3) replacing
2-(2-methylbiphenyl-3-yl)furo[2,3-b]pyridine-6-carbaldehyde. The
reaction mixture was diluted with MeOH then purified by prep-HPLC
(pH=2, acetonitrile/water+TFA) to give the desired product as the
TFA salt. LC-MS calculated for C.sub.24H.sub.25N.sub.2O.sub.2
(M+H).sup.+: m/z=373.2. found 373.2.
Example 13
(2S)-1-{[2-(2-cyano
biphenyl-3-yl)-7-methyl-1,3-benzoxazol-5-yl]methyl}piperidine-2-carboxyli-
c acid
##STR00064##
[0350] Step 1: 3-bromobiphenyl-2-carbonitrile
##STR00065##
[0352] A mixture of 2-bromo-6-iodobenzonitrile (Combi-Blocks,
cat#QA-5802: 1.51 g, 4.90 mmol), phenylboronic acid (0.627 g, 5.14
mmol), dichloro[1,1'-bis(dicyclo
hexylphosphino)ferrocene]palladium(II) (0.2 g, 0.05 mmol) and
potassium phosphate (2.6 g, 12 mmol) in 1,4-dioxane (10 mL) and
water (3 mL) was purged with N.sub.2 then stirred at 80.degree. C.
for 2 h. The reaction mixture was cooled to room temperature then
diluted with EtOAc and water. The mixture was extracted with EtOAc
and the organic phase was dried over MgSO.sub.4, and concentrated.
The residue was purified by column chromatography on silica gel
(gradient, 0-20% EtOAc in hexanes) to give the desired product.
LC-MS calculated for C.sub.13H.sub.9BrN (M+H).sup.+: m/z=258.0.
found 257.9.
Step 2: 3-formylbiphenyl-2-carbonitrile
##STR00066##
[0354] To a solution of 3-bromobiphenyl-2-carbonitrile (222 mg,
0.86 mmol) in tetrahydrofuran (1 mL) was added isopropylmagnesium
chloride in tetrahydrofuran (2.0 M, 520 .mu.L, 1.0 mmol) at
-30.degree. C. The mixture was stirred at -30.degree. C. for 3 h
then N,N-dimethylformamide (200 .mu.L, 2.6 mmol) was added. The
reaction mixture was warmed up slowly to room temperature and
stirred for 30 min. The reaction mixture was quenched with aqueous
solution of sodium dihydrogen phosphate then extracted with EtOAc.
The combined organic phase was dried over MgSO.sub.4, filtered and
concentrated. The residue was purified by column chromatography
(gradient, 0-40% EtOAc in hexanes) to give the desired product.
LC-MS calculated for C.sub.14H.sub.10NO (M+H).sup.+: m/z=208.1.
found 208.0.
Step 3:
(2S)-1-{[2-(2-cyanobiphenyl-3-yl)-7-methyl-1,3-benzoxazol-5-yl]met-
hyl}piperidine-2-carboxylic acid
[0355] This compound was prepared using similar procedures as
described for Example 11 with 3-formylbiphenyl-2-carbonitrile
(product from Step 2) replacing 2-methylbiphenyl-3-carbaldehyde in
Steps 1. The reaction mixture was purified by prep-HPLC (pH=10,
acetonitrile/water+NH.sub.4OH) to give the desired product. LC-MS
calculated for C.sub.28H.sub.26N.sub.3O.sub.3 (M+H).sup.+:
m/z=452.2. found 452.2.
Example 14
3-(5-{[(2-hydroxyethyl)amino]methyl}-7-methyl-1,3-benzoxazol-2-yl)biphenyl-
-2-carbonitrile
##STR00067##
[0357] This compound was prepared using similar procedures as
described for Example 13 with ethanolamine replacing
(S)-piperidine-2-carboxylic acid in the last step. The reaction
mixture was diluted with methanol then purified by prep-HPLC
(pH=10, acetonitrile/water+NH.sub.4OH) to give the desired product.
LC-MS calculated for C.sub.24H.sub.22N.sub.3O.sub.2 (M+H).sup.+:
m/z=384.2. found 384.2.
Example 15
(2S)-1-({2-[3-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-methylphenyl]-7-methyl--
1,3-benzoxazol-5-yl}methyl)piperidine-2-carboxylic acid
##STR00068##
[0358] Step 1:
[3-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-methylphenyl]methanol
##STR00069##
[0360] A mixture of (3-bromo-2-methylphenyl)methanol (139 mg, 0.69
mmol), potassium phosphate (360 mg, 1.7 mmol),
2,3-dihydro-1,4-benzodioxin-6-ylboronic acid (0.130 g, 0.724 mmol)
and dichloro[1,1'-bis(dicyclohexylphosphino)ferrocene]palladium(II)
(0.03 g, 0.03 mmol) in 1,4-dioxane (2 mL) and water (0.5 mL) was
purged with N.sub.2 then stirred at 90.degree. C. for 1 h. The
reaction mixture was cooled to room temperature then quenched water
and extracted with ethyl acetate. The combined organic phase was
dried over MgSO.sub.4 and concentrated. The residue was used
directly in the next step without further purification. LC-MS
calculated for C.sub.16H.sub.15O.sub.2 (M+H-H.sub.2O).sup.+:
m/z=239.1. found 239.1.
Step 2:
3-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-methylbenzaldehyde
##STR00070##
[0362] To a solution of
[3-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-methylphenyl]methanol (171
mg, 0.667 mmol) in methylene chloride (3.4 mL) was added
Dess-Martin periodinane (280 mg, 0.67 mmol) at room temperature.
The mixture was stirred at room temperature for 30 min then
quenched by a mixture of NaHCO.sub.3 solution and
Na.sub.2S.sub.2O.sub.3 solution and extracted with methylene
chloride. The combined organic phase was dried over MgSO.sub.4 and
concentrated. The residue was purified by column chromatography
(0-40% EtOAc in hexanes) to give the desired product. LC-MS
calculated for C.sub.16H.sub.15O.sub.3 (M+H).sup.+: m/z=255.1.
found 255.1.
Step 3:
(2S)-1-({2-[3-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-methylphenyl]-7-
-methyl-1,3-benzoxazol-5-yl}methyl)piperidine-2-carboxylic acid
[0363] This compound was prepared using similar procedures as
described for Example 11 with
3-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-methylbenzaldehyde (product
from Step 2) replacing 2-methylbiphenyl-3-carbaldehyde in Step 1.
The resulting mixture was purified by prep-HPLC (pH=10,
acetonitrile/water+NH.sub.4OH) to give the desired product. LC-MS
calculated for C.sub.30H.sub.31N.sub.2O.sub.5 (M+H).sup.+:
m/z=499.2. found 499.2.
Example 16
2-[({2-[3-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-methylphenyl]-7-methyl-1,3--
benzoxazol-5-yl}methyl)amino]ethanol
##STR00071##
[0365] This compound was prepared using similar procedures as
described for Example 15 with ethanolamine replacing
(S)-piperidine-2-carboxylic acid in last step. The reaction mixture
was diluted with methanol then purified by prep-HPLC (pH=10,
acetonitrile/water+NH.sub.4OH) to give the desired product. LC-MS
calculated for C.sub.26H.sub.27N.sub.2O.sub.4 (M+H).sup.+:
m/z=431.2. found 431.2.
Example 17
(2S)-1-({2-[2-cyano-3-(2,3-dihydro-1,4-benzodioxin-6-yl)phenyl]-7-methyl-1-
,3-benzoxazol-5-yl}methyl)piperidine-2-carboxylic acid
##STR00072##
[0366] Step 1:
2-bromo-6-(2,3-dihydro-1,4-benzodioxin-6-yl)benzonitrile
##STR00073##
[0368] A mixture of 2-bromo-6-iodobenzonitrile (Combi-Blocks,
cat#QA-5802: 198 mg, 0.64 mmol),
2,3-dihydro-1,4-benzodioxin-6-ylboronic acid (110 mg, 0.61 mmol),
dichloro[1,1'-bis(dicyclohexylphosphino)ferrocene]palladium(II)
(0.02 g, 0.03 mmol) and potassium phosphate (340 mg, 1.6 mmol) in
1,4-dioxane (2 mL) and water (0.4 mL) was purged with N.sub.2 then
stirred at 80.degree. C. for 2 h. The reaction mixture was cooled
to room temperature then diluted water and extracted with EtOAc.
The combined extract was dried over MgSO.sub.4, filtered and
concentrated. The residue was purified by column chromatography
(gradient, 0-30% EtOAc in hexanes) to give the desired product.
LC-MS calculated for C.sub.15H.sub.11BrNO.sub.2 (M+H).sup.+:
m/z=316.0. found 316.0.
Step 2:
2-(2,3-dihydro-1,4-benzodioxin-6-yl)-6-vinylbenzonitrile
##STR00074##
[0370] A mixture of 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane
(110 .mu.L, 0.66 mmol),
2-bromo-6-(2,3-dihydro-1,4-benzodioxin-6-yl)benzonitrile (140 mg,
0.44 mmol), potassium phosphate (235 mg, 1.11 mmol) and
dichloro[1,1'-bis(dicyclohexylphosphino)ferrocene]palladium(II) (20
mg, 0.02 mmol) in 1,4-dioxane (3 mL) and water (0.8 mL) was purged
with N.sub.2 then stirred at 100.degree. C. overnight. The reaction
mixture was cooled to room temperature and then diluted with water
and extracted with EtOAc. The combined organic phase was dried over
MgSO.sub.4 then concentrated. The residue was used directly for
next step without further purification. LC-MS calculated for
C.sub.17H.sub.14NO.sub.2 (M+H).sup.+: m/z=264.1. found 264.1.
Step 3:
2-(2,3-dihydro-1,4-benzodioxin-6-yl)-6-formylbenzonitrile
##STR00075##
[0372] To a mixture of
2-(2,3-dihydro-1,4-benzodioxin-6-yl)-6-vinylbenzonitrile (100 mg,
0.40 mmol), sodium metaperiodate (400 mg, 2 mmol) in
tetrahydrofuran (3 mL) and water (0.5 mL) was added osmium
tetraoxide in water (0.16 M, 200 .mu.L, 0.04 mmol). The resulting
mixture was stirred at room temperature for 0.5 h then diluted with
methylene chloride, washed with saturated NaHCO.sub.3 solution,
water and brine. The organic layer was dried over Na.sub.2SO.sub.4,
filtered and concentrated. The residue was purified by column
chromatography (0-30% EtOAc in hexanes) to give the desired
product. LC-MS calculated for C.sub.16H.sub.12NO.sub.3 (M+H).sup.+:
m/z 266.1. found 266.1.
Step 4:
(2S)-1-({2-[2-cyano-3-(2,3-dihydro-1,4-benzodioxin-6-yl)phenyl]-7--
methyl-1,3-benzoxazol-5-yl}methyl)piperidine-2-carboxylic acid
[0373] This compound was prepared using similar procedures as
described for Example 11 with
3-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-methylbenzaldehyde (product
from Step 3) replacing 2-methylbiphenyl-3-carbaldehyde in Step 1.
The reaction mixture was purified by prep-HPLC (pH=10,
acetonitrile/water+NH.sub.4OH) to give the desired product. LC-MS
calculated for C.sub.30H.sub.28N.sub.3O.sub.5 (M+H).sup.+:
m/z=510.2. found 510.2.
Example 18
2-(2,3-dihydro-1,4-benzodioxin-6-yl)-6-(5-{[(2-hydroxyethyl)amino]methyl}--
7-methyl-1,3-benzoxazol-2-yl)benzonitrile
##STR00076##
[0375] This compound was prepared using similar procedures as
described for Example 17 with ethanolamine replacing
(S)-piperidine-2-carboxylic acid in the last step. The reaction
mixture was diluted with methanol then purified by prep-HPLC
(pH=10, acetonitrile/water+NH.sub.4OH) to give the desired product.
LC-MS calculated for C.sub.26H.sub.24N.sub.3O.sub.4 (M+H).sup.+:
m/z=442.2. found 442.2.
Example 19
(2S)-1-{[2-(2-methylbiphenyl-3-yl)-1,3-benzothiazol-5-yl]methyl}piperidine-
-2-carboxylic acid
##STR00077##
[0376] Step 1: 2-chloro-1,3-benzothiazole-5-carbaldehyde
##STR00078##
[0378] To a solution of 2-chloro-1,3-benzothiazole-5-carbonitrile
(Ark Pharm, cat#AK-80680: 48 mg, 0.25 mmol) in a mixture of toluene
(1 mL) and methylene chloride (1 mL) was slowly added 1.0 M
diisobutyl aluminum hydride in THF (100 .mu.L, 0.10 mmol) at
-78.degree. C. The reaction mixture was stirred at -78.degree. C.
for 2 h then slowly warmed up to -10.degree. C. and quenched with
Rochells' salt solution. The mixture was stirred vigorously for 1
h. The organic phase was separated, dried over MgSO.sub.4 then
concentrated. The residue was purified by column chromatography
(gradient, 0-30% EtOAc in hexanes) to give the desired product.
LC-MS calculated for C.sub.8H.sub.5ClNOS (M+H).sup.+: m/z=198.0.
found 198.0.
Step 2: methyl
(2S)-1-[(2-chloro-1,3-benzothiazol-5-yl)methyl]piperidine-2-carboxylate
##STR00079##
[0380] To a solution of 2-chloro-1,3-benzothiazole-5-carbaldehyde
(18 mg, 0.091 mmol), methyl (2S)-piperidine-2-carboxylate hydrogen
chloride (30 mg, 0.2 mmol) and diisopropylethylamine (30 .mu.L, 0.2
mmol) in methylene chloride (0.4 mL) was added acetic acid (5 pt).
The mixture was stirred at room temperature for 2 h then sodium
triacetoxyborohydride (80 mg, 0.4 mmol) was added. The resulting
mixture was stirred at 45.degree. C. for 1 h then cooled to room
temperature, quenched by ammonium hydroxide solution and extracted
with methylene chloride. The combined organic phase was dried over
MgSO.sub.4 and concentrated. The residue was purified by column
chromatography (0-30% EtOAc in hexanes) to give the desired
product. LC-MS calculated for C.sub.15H.sub.18ClN.sub.2O.sub.2S
(M+H).sup.+: m/z=325.1. found 325.1.
Step 3:
4,4,5,5-tetramethyl-2-(2-methylbiphenyl-3-yl)-1,3,2-dioxaborolane
##STR00080##
[0382] A mixture of 3-chloro-2-methylbiphenyl (0.440 mL, 2.47 mmol)
(Aldrich, cat#361623),
4,4,5,5,4',4',5',5'-octamethyl-[2,2']bi[[1,3,2]dioxaborolanyl]
(1.88 g, 7.40 mmol), palladium acetate (22.2 mg, 0.0987 mmol),
K.sub.3PO.sub.4 (1.57 g, 7.40 mmol) and
2-(dicyclohexylphosphino)-2',6'-dimethoxy-1,1'-biphenyl (101 mg,
0.247 mmol) in 1,4-dioxane (10 mL) was purged with nitrogen then
stirred at room temperature for 48 h. The reaction mixture was
diluted with dichloromethane (DCM), then washed over water and
brine. The organic layer was dried over Na.sub.2SO.sub.4, filtered
and concentrated. The residue was purified by flash chromatography
on a silica gel column eluting with 0 to 5% EtOAc/DCM to give the
desired product (656 mg, 90%). LC-MS calculated for
C.sub.19H.sub.24BO.sub.2 (M+H).sup.+: m/z=295.2. found 295.2.
Step 4: Methyl
(2S)-1-{[2-(2-methylbiphenyl-3-yl)-1,3-benzothiazol-5-yl]methyl}piperidin-
e-2-carboxylate
##STR00081##
[0384] A mixture of
4,4,5,5-tetramethyl-2-(2-methylbiphenyl-3-yl)-1,3,2-dioxaborolane
(17 mg, 0.058 mmol), potassium phosphate (18.0 mg, 0.0847 mmol),
dichloro[1,1'-bis(dicyclo hexylphosphino)ferrocene]palladium(II)
(2.6 mg, 0.0034 mmol) and methyl
(2S)-1-[(2-chloro-1,3-benzothiazol-5-yl)methyl]piperidine-2-carboxylate
(11 mg, 0.034 mmol) in 1,4-Dioxane (0.5 mL) and water (0.1 mL) was
purged with N.sub.2 and then stirred at 90.degree. C. for 2 h. The
reaction mixture was cooled to room temperature and extracted with
EtOAc. The organic phase was dried over MgSO.sub.4 and
concentrated. The residue was purified by column chromatography
(gradient, 0-30% EtOAc in Hexanes) to give the desired product.
LC-MS calculated for C.sub.28H.sub.29N.sub.2O.sub.2S (M+H).sup.+:
m/z=457.2. found 457.2.
Step 5:
(2S)-1-{[2-(2-methylbiphenyl-3-yl)-1,3-benzothiazol-5-yl]methyl}pi-
peridine-2-carboxylic acid
[0385] To a mixture of methyl
(2S)-1-{[2-(2-methylbiphenyl-3-yl)-1,3-benzothiazol-5-yl]methyl}piperidin-
e-2-carboxylate (7.0 mg, 0.015 mmol) in tetrahydrofuran (0.1 mL)
and methanol (0.1 mL) was added lithium hydroxide hydrate (8 mg,
0.2 mmol) and water(0.1 mL). The resulting mixture was stirred at
room temperature overnight. The reaction mixture was diluted with
methanol then purified by prep-HPLC (pH=2, acetonitrile/water+TFA)
to give the desired product as the TFA salt. LC-MS calculated for
C.sub.27H.sub.27N.sub.2O.sub.2S (M+H).sup.+: m/z=443.2. found
443.2.
Example 20
(2S)-1-{[2-(2-methylbiphenyl-3-yl)furo[3,2-b]pyridin-5-yl]methyl}piperidin-
e-2-carboxylic acid
##STR00082##
[0386] Step 1:
[2-(2-methylbiphenyl-3-yl)furo[3,2-b]pyridin-5-yl]methanol
##STR00083##
[0388] This compound was prepared using similar procedure as
described for Example 1, Step 3 with
2-bromo-6-(hydroxymethyl)pyridin-3-ol (Oakwood, cat#047047)
replacing 5-bromo-6-hydroxypyridine-2-carboxylate. The crude
material was used directly for next step without further
purification. LC-MS calculated for C.sub.21H.sub.18NO.sub.2
(M+H).sup.+: m/z=316.1. found 316.1.
Step 2:
2-(2-methylbiphenyl-3-yl)furo[3,2-b]pyridine-5-carbaldehyde
##STR00084##
[0390] To a solution of
[2-(2-methylbiphenyl-3-yl)furo[3,2-b]pyridin-5-yl]methanol (87 mg,
0.28 mmol) in methylene chloride (1.4 mL) was added Dess-Martin
periodinane (120 mg, 0.28 mmol). The reaction mixture was stirred
at room temperature for 10 min then quenched with NaHCO.sub.3
solution and Na.sub.2S.sub.2O.sub.3 solution. The mixture was
extracted with methylene chloride. The organic phase was combined,
dried over MgSO.sub.4 and concentrated. The residue was purified by
flash chromatography on a silica gel column eluting with 0 to 30%
EtOAc/Hexanes to give the desired product. LC-MS calculated for
C.sub.21H.sub.16NO.sub.2 (M+H).sup.+: m/z=314.1. found 314.1.
Step 3:
(2S)-1-{[2-(2-methylbiphenyl-3-yl)furo[3,2-b]pyridin-5-yl]methyl}p-
iperidine-2-carboxylic acid
[0391] This compound was prepared using similar procedures as
described for Example 1, Step 5 with
2-(2-methylbiphenyl-3-yl)furo[3,2-b]pyridine-5-carbaldehyde
(product from Step 2) replacing 2-(2-methylbiphenyl-3-yl)furo[2,
3-b]pyridine-6-carbaldehyde, and (S)-piperidine-2-carboxylic acid
replacing ethanolamine. The reaction mixture was diluted with MeOH
then purified by prep-HPLC (pH=2, acetonitrile/water+TFA) to give
the desired product as the TFA salt. LC-MS calculated for
C.sub.27H.sub.27N.sub.2O.sub.3 (M+H).sup.+: m/z=427.2. found
427.2.
Example 21
2-({[2-(2-methylbiphenyl-3-yl)furo[3,2-b]pyridin-5-yl]methyl}amino)ethanol
##STR00085##
[0393] This compound was prepared using similar procedures as
described for Example 1, Step 5 with
2-(2-methylbiphenyl-3-yl)furo[3,2-b]pyridine-5-carbaldehyde
(Example 20, Step 2) replacing
2-(2-methylbiphenyl-3-yl)furo[2,3-b]pyridine-6-carbaldehyde. The
reaction mixture was diluted with methanol then purified by
prep-HPLC (pH=2, acetonitrile/water+TFA) to give the desired
product as the TFA salt. LC-MS calculated for
C.sub.23H.sub.23N.sub.2O.sub.2 (M+H).sup.+: m/z=359.2. found
359.2.
Example 22
(2S)-1-{[4-methyl-2-(2-methylbiphenyl-3-yl)-1,3-benzothiazol-6-yl]methyl}p-
iperidine-2-carboxylic acid
##STR00086##
[0394] Step 1: 6-bromo-2-iodo-4-methyl-1,3-benzothiazole
##STR00087##
[0396] To a suspension of 6-bromo-4-methyl-1,3-benzothiazol-2-amine
(ChemBridge, cat#4029174: 284 mg, 1.17 mmol) and iodine (590 mg,
2.3 mmol) in acetonitrile (11.3 mL) was added tert-butyl nitrite
(0.33 mL, 2.8 mmol) at 0.degree. C. The mixture was stirred at room
temperature for 10 min then stirred at 80.degree. C. for 1 h. After
cooling to room temperature, the reaction mixture was diluted with
DCM and washed with water. The organic phase was dried over
MgSO.sub.4 and concentrated. The residue was used directly in the
next step without further purification. LC-MS calculated for
C.sub.8H.sub.6BrINS (M+H).sup.+: m/z=353.8. found 353.8.
Step 2:
4-methyl-2-(2-methylbiphenyl-3-yl)-6-vinyl-1,3-benzothiazole
##STR00088##
[0398] A mixture of
4,4,5,5-tetramethyl-2-(2-methylbiphenyl-3-yl)-1,3,2-dioxaborolane
(Example 19, Step 3: 88 mg, 0.30 mmol), potassium phosphate (159
mg, 0.748 mmol), dichloro[1,1'-bis(dicyclo
hexylphosphino)ferrocene]palladium(II) (10 mg, 0.01 mmol) and
6-bromo-2-iodo-4-methyl-1,3-benzothiazole (60 mg, 0.2 mmol) in
1,4-dioxane (2 mL) and water (0.5 mL) was purged with N.sub.2 then
stirred at 100.degree. C. overnight. The reaction mixture was
cooled to room temperature then dichloro[1,1'-bis(dicyclo
hexylphosphino)ferrocene]palladium(II) (10 mg, 0.01 mmol),
4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane (76 .mu.L, 0.45
mmol) and potassium phosphate (159 mg, 0.748 mmol) were added. The
resulting mixture was purged with N.sub.2 then stirred at
100.degree. C. for 3 h. The reaction mixture was cooled to room
temperature, diluted with water and extracted with EtOAc. The
organic phase was dried over MgSO.sub.4 then concentrated. The
residue was used directly in the next step without further
purification. LC-MS calculated for C.sub.23H.sub.20NS (M+H).sup.+:
m/z=342.1. found 342.1.
Step 3:
4-methyl-2-(2-methylbiphenyl-3-yl)-1,3-benzothiazole-6-carbaldehyd-
e
##STR00089##
[0400] This compound was prepared using similar procedures as
described for Example 3, Step 4 with
4-methyl-2-(2-methylbiphenyl-3-yl)-6-vinyl-1,3-benzothiazole
(product from Step 2) replacing
7-methyl-2-(2-methylbiphenyl-3-yl)-5-vinylfuro[3,2-b]pyridine. The
crude material was purified by column chromatography (0-10% EtOAc
in hexanes) to give the desired product. LC-MS calculated for
C.sub.22H.sub.18NOS (M+H).sup.+: m/z=344.1. found 344.1.
Step 4:
(2S)-1-{[4-methyl-2-(2-methylbiphenyl-3-yl)-1,3-benzothiazol-6-yl]-
methyl}piperidine-2-carboxylic acid
[0401] This compound was prepared using similar procedures as
described for Example 1, Step 5 with
4-methyl-2-(2-methylbiphenyl-3-yl)-1,3-benzothiazole-6-carbaldehyde
(product from Step 3) replacing
2-(2-methylbiphenyl-3-yl)furo[2,3-h]pyridine-6-carbaldehyde, and
(S)-piperidine-2-carboxylic acid replacing ethanolamine. The
reaction mixture was diluted with methanol then purified by
prep-HPLC (pH=10, acetonitrile/water+NH.sub.4OH) to give the
desired product. LC-MS calculated for
C.sub.28H.sub.29N.sub.2O.sub.2S (M+H).sup.+: m/z=457.2. found
457.2.
Example 23
2-({[4-methyl-2-(2-methylbiphenyl-3-yl)-1,3-benzothiazol-6-yl]methyl}amino-
)ethanol
##STR00090##
[0403] This compound was prepared using similar procedures as
described for Example 1, Step 5 with
4-methyl-2-(2-methylbiphenyl-3-yl)-1,3-benzothiazole-6-carbaldehyde
(Example 22, Step 3) replacing
2-(2-methylbiphenyl-3-yl)furo[2,3-b]pyridine-6-carbaldehyde. The
reaction mixture was diluted with methanol then purified by
prep-HPLC (pH=10, acetonitrile/water+NH.sub.4OH) to give the
desired product. LC-MS calculated for C.sub.24H.sub.25N.sub.2OS
(M+H).sup.+: m/z=389.2. found 389.2.
Example 24
2-({[6-(2-methylbiphenyl-3-yl)furo[2,3-b]pyrazin-2-yl]methyl}amino)ethanol
##STR00091##
[0404] Step 1: methyl 6-bromo-5-hydroxypyrazine-2-carboxylate
##STR00092##
[0406] To a solution of methyl 5-hydroxypyrazine-2 carboxylate (Ark
Pharm, cat#24812: 145 mg, 0.94 mmol) in N, N-dimethylformamide (4
mL) was added N-bromo succinimide (200 mg, 1.13 mmol) at 0.degree.
C. The resulting mixture was stirred at room temperature for 5 h
then quenched by NaHCO.sub.3 solution. The mixture was concentrated
and the residue was purified by column chromatography (gradient,
0-80% MeOH in DCM) to give the desired product. LC-MS calculated
for C.sub.6H.sub.6BrN.sub.2O.sub.3 (M+H).sup.+: m/z=233.0. found
232.9.
Step 2: methyl
6-(2-methylbiphenyl-3-yl)furo[2,3-b]pyrazine-2-carboxylate
##STR00093##
[0408] This compound was prepared using similar procedure as
described for Example 1, Step 3 with methyl
6-bromo-5-hydroxypyrazine-2-carboxylate (product from Step 1)
replacing 5-bromo-6-hydroxypyridine-2-carboxylate. The crude
material was purified by column chromatograph (0-40% EtOAc in
hexanes) to give the desired product. LC-MS calculated for
C.sub.21H.sub.17N.sub.2O.sub.3 (M+H).sup.+: m/z=345.1. found
345.1.
Step 3:
6-(2-methylbiphenyl-3-yl)furo[2,3-b]pyrazine-2-carbaldehyde
##STR00094##
[0410] This compound was prepared using similar procedures as
described for Example 1, Step 4 with methyl
6-(2-methylbiphenyl-3-yl)furo[2,3-b]pyrazine-2-carboxylate (product
from Step 2) replacing methyl
2-(2-methylbiphenyl-3-yl)furo[2,3-b]pyridine-6-carboxylate. The
crude material was purified by column chromatography (gradient,
0-25% EtOAc in hexanes) to give the desired product. LC-MS
calculated for C.sub.20H.sub.15N.sub.2O.sub.2 (M+H).sup.+:
m/z=315.1. found 315.1.
Step 4:
2-({[6-(2-methylbiphenyl-3-yl)furo[2,3-b]pyrazin-2-yl]methyl}amino-
)ethanol
[0411] This compound was prepared using similar procedures as
described for Example 1, Step 5 with
6-(2-methylbiphenyl-3-yl)furo[2,3-b]pyrazine-2-carbaldehyde
(product from Step 3) replacing 2-(2-methylbiphenyl-3-yl)furo[2,
3-b]pyridine-6-carbaldehyde. The reaction mixture was diluted with
methanol then purified by prep-HPLC (pH=10,
acetonitrile/water+NH.sub.4OH) to give the desired product. LC-MS
calculated for C.sub.22H.sub.22N.sub.3O.sub.2 (M+H).sup.+:
m/z=360.2. found 360.2.
Example 25
(2S)-1-{[6-(2-methylbiphenyl-3-yl)furo[2,3-b]pyrazin-2-yl]methyl}piperidin-
e-2-carboxylic acid
##STR00095##
[0413] This compound was prepared using similar procedures as
described for Example 1, Step 5 with
6-(2-methylbiphenyl-3-yl)furo[2,3-b]pyrazine-2-carbaldehyde
(Example 24, Step 3) replacing
2-(2-methylbiphenyl-3-yl)furo[2,3-b]pyridine-6-carbaldehyde, and
(S)-piperidine-2-carboxylic acid replacing ethanolamine. The
reaction mixture was diluted with methanol then purified by
prep-HPLC (pH=10, acetonitrile/water+NH.sub.4OH) to give the
desired product. LC-MS calculated for
C.sub.26H.sub.26N.sub.3O.sub.3 (M+H).sup.+: m/z=428.2. found
428.2.
Example 26
(2S)-1-{[6-(cyanomethoxy)-2-(2-methylbiphenyl-3-yl)-1,
3-benzoxazol-5-yl]methyl}piperidine-2-carboxylic acid
##STR00096##
[0414] Step 1: methyl 2,4-dihydroxy-5-nitrobenzoate
##STR00097##
[0416] To a solution of methyl 2,4-dihydroxybenzoate (Aldrich,
cat#M42505: 9.15 g, 54.4 mmol) in acetic anhydride (34 mL) and
acetic acid (66 mL) was slowly added a mixture of nitric acid (3.82
mL, 63.8 mmol) in acetic acid (30 mL) at 0.degree. C. After
addition, a light brown solution was formed. Then the mixture was
stirred at room temperature for 30 min, after which a suspension
had formed. Water (130 mL) was added, whereupon the mixture was
aged for another 30 min without stirring. The precipitate was
filtered, rinsed with small amount of water, and dried under vacuum
to give crude product, which was used directly in the next step
without further purification. LC-MS calculated for
C.sub.8H.sub.8NO.sub.6 (M+H).sup.+: m/z=214.0. found 214.0.
Step 2: methyl 5-amino-2,4-dihydroxybenzoate
##STR00098##
[0418] Methyl 2,4-dihydroxy-5-nitrobenzoate (592 mg, 2.78 mmol) was
hydrogenated under ambient pressure of hydrogen using palladium on
carbon (10 wt %, 300 mg, 0.28 mmol) in ethyl acetate (30 mL) for 3
h. The resulting suspension was filtered through a pad of Celite,
washed with ethyl acetate and the solvent was removed under reduced
pressure to give crude product, which was used directly without
further purification. LC-MS calculated for C.sub.8H.sub.10NO.sub.4
(M+H).sup.+: m/z=184.1. found 184.0.
Step 3: methyl
6-hydroxy-2-(2-methylbiphenyl-3-yl)-1,3-benzoxazole-5-carboxylate
##STR00099##
[0420] A mixture of methyl 5-amino-2, 4-dihydroxybenzoate (660 mg,
3.60 mmol), 2-methylbiphenyl-3-carbaldehyde (777.8 mg, 3.96 mmol)
in ethanol (23 mL) was placed in a vial and stirred at room
temperature overnight. LC-MS calculated for
C.sub.22H.sub.20NO.sub.4 (M+H).sup.+: m/z=362.1. found 362.1. The
mixture was then concentrated. The residue was redissolved in
methylene chloride (20 mL) and dichlorodicyanoquinone (981 mg, 4.32
mmol) was added. The mixture was stirred at room temperature for 30
min. The reaction was diluted with methylene chloride and washed
with a Na.sub.2S.sub.2O.sub.3 solution and NaHCO.sub.3 solution.
The organic phase was dried over MgSO.sub.4 and concentrated. The
crude residue was purified by flash chromatography on a silica gel
column eluting with 0 to 50% EtOAc/Hexanes. LC-MS calculated for
C.sub.22H.sub.18NO.sub.4 (M+H).sup.+: m/z=360.1. found 360.1.
Step 4:
5-(hydroxymethyl)-2-(2-methylbiphenyl-3-yl)-1,3-benzoxazol-6-ol
##STR00100##
[0422] To a solution of methyl
6-hydroxy-2-(2-methylbiphenyl-3-yl)-1,3-benzoxazole-5-carboxylate
(845.3 mg, 2.35 mmol) in tetrahydrofuran (20 mL) was added lithium
tetrahydroaluminate in THF (1.0 M, 1600 .mu.L) dropwise at
0.degree. C. The mixture was slowly warmed up to room temperature.
Then the mixture was quenched with ethyl acetate followed by water
and sodium hydroxide solution. The mixture was extracted with ethyl
acetate three times. The organic phase was combined, dried over
MgSO.sub.4 and concentrated. The residue was used in the next step
without further purification. LC-MS calculated for
C.sub.21H.sub.18NO.sub.3 (M+H).sup.+: m/z=332.1. found 332.1.
Step 5:
{[5-(hydroxymethyl)-2-(2-methylbiphenyl-3-yl)-1,3-benzoxazol-6-yl]-
oxy}acetonitrile
##STR00101##
[0424] To
5-(hydroxymethyl)-2-(2-methylbiphenyl-3-yl)-1,3-benzoxazol-6-ol in
N,N-dimethylformamide (0.64 mL) was added potassium carbonate (34.1
mg, 0.247 mmol) and bromoacetonitrile (17.2 .mu.L, 0.247 mmol). The
mixture was stirred at 50.degree. C. for 40 min. The reaction was
then cooled to room temperature and diluted with EtOAc, quenched
with water. After extraction, the organic phase was dried over
MgSO.sub.4 and concentrated. The residue was used directly without
further purification. LC-MS calculated for
C.sub.23H.sub.19N.sub.2O.sub.3 (M+H).sup.+: m/z=371.1. found
371.1.
Step 6:
{[5-formyl-2-(2-methylbiphenyl-3-yl)-1,3-benzoxazol-6-yl]oxy}aceto-
nitrile
##STR00102##
[0426]
{[5-(hydroxymethyl)-2-(2-methylbiphenyl-3-yl)-1,3-benzoxazol-6-yl]o-
xy}acetonitrile (52 mg, 0.14 mmol) was dissolved in methylene
chloride (0.4 mL) and treated with Dess-Martin periodinane (60.1
mg, 0.142 mmol) at room temperature. The reaction was stirred at
room temperature for 10 min. and then was quenched with a
NaHCO.sub.3 solution and Na.sub.2S.sub.2O.sub.3 solution. The
mixture was extracted with methylene chloride. The organic phase
was combined, dried over MgSO.sub.4 and concentrated. The residue
was purified by flash chromatography on a silica gel column eluting
with 0 to 45% EtOAc/Hexanes. LC-MS calculated for
C.sub.23H.sub.17N.sub.2O.sub.3 (M+H).sup.+: m/z=369.1. found
369.2.
Step 7:
(2S)-1-{[6-(cyanomethoxy)-2-(2-methylbiphenyl-3-yl)-1,3-benzoxazol-
-5-yl]methyl}piperidine-2-carboxylic acid
[0427] This compound was prepared using similar procedures as
described for Example 1 with
{[5-formyl-2-(2-methylbiphenyl-3-yl)-1,3-benzoxazol-6-yl]oxy}acetonitrile
(product from Step 6) replacing
2-(2-methylbiphenyl-3-yl)furo[2,3-b]pyridine-6-carbaldehyde and
(S)-piperidine-2-carboxylic acid replacing ethanolamine in Step 5.
The reaction mixture was diluted with methanol then purified by
prep-HPLC (pH=10, acetonitrile/water+NH.sub.4OH) to give the
desired product. LC-MS calculated for
C.sub.29H.sub.28N.sub.3O.sub.4 (M+H).sup.+: m/z=482.2. found
482.2.
Example 27
{[5-{[(2-hydroxyethyl)amino]methyl}-2-(2-methylbiphenyl-3-yl)-1,3-benzoxaz-
ol-6-yl]oxy}acetonitrile
##STR00103##
[0429] This compound was prepared using similar procedures as
described for Example 26 with ethanolamine replacing
(S)-piperidine-2-carboxylic acid in Step 7. The reaction mixture
was diluted with methanol and then purified by prep-HPLC (pH=10,
acetonitrile/water+NH.sub.4OH) to give the desired product. LC-MS
calculated for C.sub.25H.sub.24N.sub.3O.sub.3 (M+H).sup.+:
m/z=414.2. found 414.2.
Example 28
(2S)-1-{[6-(3-cyanopropoxy)-2-(2-methylbiphenyl-3-yl)-1,3-benzoxazol-5-yl]-
methyl}piperidine-2-carboxylic acid
##STR00104##
[0431] This compound was prepared using similar procedures as
described for Example 26 with 4-bromobutanenitrile (Aldrich,
cat#B59802) replacing bromoacetonitrile in Step 5. The reaction
mixture was diluted with methanol and then purified by prep-HPLC
(pH=10, acetonitrile/water+NH.sub.4OH) to give the desired product.
LC-MS calculated for C.sub.31H.sub.32N.sub.3O.sub.4 (M+H).sup.+:
m/z=510.2. found 510.3.
Example 29
3-({[5-{[(2-hydroxyethyl)amino]methyl}-2-(2-methylbiphenyl-3-yl)-1,3-benzo-
xazol-6-yl]oxy}methyl)benzonitrile
##STR00105##
[0433] This compound was prepared using similar procedures as
described for Example 26 with m-cyanobenzyl bromide (Aldrich,
cat#145610) replacing bromoacetonitrile in Step 5 and ethanolamine
replacing (S)-piperidine-2-carboxylic acid in Step 7. The reaction
mixture was diluted with methanol and then purified by prep-HPLC
(pH=10, acetonitrile/water+NH.sub.4OH) to give the desired product.
LC-MS calculated for C.sub.31H.sub.28N.sub.3O.sub.3 (M+H).sup.+:
m/z=490.2. found 490.2.
Example 30
2-({[2-(2-methylbiphenyl-3-yl)-6-(pyridin-2-ylmethoxy)-1,3-benzoxazol-5-yl-
]methyl}amino)ethanol
##STR00106##
[0435] This compound was prepared using similar procedures as
described for Example 26 with 2-(bromomethyl)pyridine replacing
bromoacetonitrile in Step 5 and ethanolamine replacing
(S)-piperidine-2-carboxylic acid in Step 7. The reaction mixture
was diluted with methanol then purified by prep-HPLC (pH=2,
acetonitrile/water+TFA) to give the desired product as TFA salt.
LC-MS calculated for C.sub.29H.sub.28N.sub.3O.sub.3 (M+H).sup.+:
m/z=466.2. found 466.3.
Example 31
2-({[6-methoxy-2-(2-methylbiphenyl-3-yl)-1,3-benzoxazol-5-yl]methyl}amino)-
ethanol
##STR00107##
[0437] This compound was prepared using similar procedures as
described for Example 26 with methyl iodide replacing
bromoacetonitrile in Step 5 and ethanolamine replacing
(S)-piperidine-2-carboxylic acid in Step 7. The reaction mixture
was diluted with methanol and then purified by prep-HPLC (pH=10,
acetonitrile/water+NH.sub.4OH) to give the desired product. LC-MS
calculated for C.sub.24H.sub.25N.sub.2O.sub.3 (M+H).sup.+:
m/z=389.2. found 389.2.
Example 32
2-({[2-(2-methylbiphenyl-3-yl)-6-(2-morpholin-4-ylethoxy)-1,3-benzoxazol-5-
-yl]methyl}amino)ethanol
##STR00108##
[0439] This compound was prepared using similar procedures as
described for Example 26 with 4-(2-bromoethyl)morpholine hydrogen
chloridere placing bromoacetonitrile in Step 5 and ethanolamine
replacing (S)-piperidine-2-carboxylic acid in Step 7. The reaction
mixture was diluted with methanol and then purified by prep-HPLC
(pH=10, acetonitrile/water+NH.sub.4OH) to give the desired product.
LC-MS calculated for C.sub.29H.sub.34N.sub.3O.sub.4 (M+H).sup.+:
m/z=488.2. found 488.2.
Example 33
2-({[2-(2-methylbiphenyl-3-yl)[1,3]oxazolo[5,4-c]pyridin-6-yl]methyl}amino-
)ethanol
##STR00109##
[0440] Step 1:
6-chloro-2-(2-methylbiphenyl-3-yl)[1,3]oxazolo[5,4-c]pyridine
##STR00110##
[0442] This compound was prepared using similar procedures as
described for Example 7 with 4-amino-6-chloropyridin-3-ol
hydrochloride (Anichem, cat#K10684) replacing methyl
2-(2-methylbiphenyl-3-yl)furo[2,3-b]pyridine-6-carboxylate in Step
1. The crude material was purified by flash chromatography on a
silica gel column eluting with 0 to 30% EtOAc/Hexanes. LC-MS
calculated for C.sub.19H.sub.14ClN.sub.2O (M+H).sup.+: m/z=321.1.
found 321.1.
Step 2:
2-(2-methylbiphenyl-3-yl)-6-vinyl[1,3]oxazolo[5,4-c]pyridine
##STR00111##
[0444] This compound was prepared using similar procedures as
described for Example 3 with
6-chloro-2-(2-methylbiphenyl-3-yl)[1,3]oxazolo[5,4-c]pyridine
replacing
5-chloro-7-methyl-2-(2-methylbiphenyl-3-yl)furo[3,2-b]pyridine in
Step 3. The residue was used directly for next step. LC-MS
calculated for C.sub.21H.sub.17N.sub.2O (M+H).sup.+: m/z=313.1.
found 313.1.
Step 3:
2-(2-methylbiphenyl-3-yl)[1,3]oxazolo[5,4-c]pyridine-6-carbaldehyd-
e
##STR00112##
[0446] This compound was prepared using similar procedures as
described for Example 7 with
2-(2-methylbiphenyl-3-yl)-6-vinyl[1,3]oxazolo[5,4-c]pyridine
replacing
7-methyl-2-(2-methylbiphenyl-3-yl)-5-vinylfuro[3,2-b]pyridine in
Step 4. The crude material was purified by flash chromatography on
a silica gel column eluting with 0 to 40% EtOAc/Hexanes. LC-MS
calculated for C.sub.20H.sub.15N.sub.2O.sub.2 (M+H).sup.+:
m/z=315.1. found 315.0.
Step 4:
2-({[2-(2-methylbiphenyl-3-yl)[1,3]oxazolo[5,4-c]pyridin-6-yl]meth-
yl}amino)ethanol
[0447] This compound was prepared using similar procedures as
described for Example 1 with
2-(2-methylbiphenyl-3-yl)[1,3]oxazolo[5,4-c]pyridine-6-carbaldehyde
(product from Step 3) replacing
2-(2-methylbiphenyl-3-yl)furo[2,3-b]pyridine-6-carbaldehyde in Step
5. The reaction mixture was diluted with MeOH and then purified by
prep-HPLC (pH=2, acetonitrile/water+TFA) to give the desired
product as the TFA salt. LC-MS calculated for
C.sub.22H.sub.22N.sub.3O.sub.2 (M+H).sup.+: m/z=360.2. found
360.1.
Example 34
4-{[5-{[(2-hydroxyethyl)amino]methyl}-7-methyl-2-(2-methylbiphenyl-3-yl)-1-
,3-benzoxazol-6-yl]oxy}butanenitrile
##STR00113##
[0448] Step 1: methyl
7-bromo-6-hydroxy-2-(2-methylbiphenyl-3-yl)-1,3-benzoxazole-5-carboxylate
##STR00114##
[0450] To a solution of methyl
6-hydroxy-2-(2-methylbiphenyl-3-yl)-1,3-benzoxazole-5-carboxylate
(product of Step 3 in Example 26: 223.1 mg, 0.621 mmol) in
acetonitrile (4 mL) and N,N-dimethylformamide (1 mL) was slowly
added N-bromosuccinimide (122 mg, 0.683 mmol). The mixture was
stirred at room temperature for 30 min and then refluxed for 1 h.
The reaction mixture was stirred at room temperature overnight.
Another batch of N-bromosuccinimide (122 mg, 0.683 mmol) was added
and the resulting mixture was stirred at 50.degree. C. for 30 min.
The reaction was diluted with EtOAc and quenched with water. The
mixture was extracted with EtOAc and the organic phase was dried
over MgSO.sub.4, and then concentrated to give a residue, which was
used directly without further purification. LC-MS calculated for
C.sub.22H.sub.17BrNO.sub.4 (M+H).sup.+: m/z=438.0, 440.0. found
438.0, 440.0.
Step 2: methyl
6-hydroxy-7-methyl-2-(2-methylbiphenyl-3-yl)-1,3-benzoxazole-5-carboxylat-
e
##STR00115##
[0452] This compound was prepared using similar procedures as
described for Example 5 with methyl
7-bromo-6-hydroxy-2-(2-methylbiphenyl-3-yl)-1,3-benzoxazole-5-carboxylate
(product from Step 1) replacing methyl
6-bromo-5-hydroxypyridine-2-carboxylate in Step 1. The crude
material was purified by flash chromatography on a silica gel
column eluting with 0 to 20% EtOAc/Hexanes. LC-MS calculated for
C.sub.23H.sub.20NO.sub.4 (M+H).sup.+: m/z=374.1. found 374.1.
Step 3:
4-{[5-formyl-7-methyl-2-(2-methylbiphenyl-3-yl)-1,3-benzoxazol-6-y-
l]oxy}butanenitrile
##STR00116##
[0454] This compound was prepared using similar procedures as
described for Example 26 with methyl
6-hydroxy-7-methyl-2-(2-methylbiphenyl-3-yl)-1,3-benzoxazole-5-carboxylat-
e (product from Step 2) replacing methyl
6-hydroxy-2-(2-methylbiphenyl-3-yl)-1,3-benzoxazole-5-carboxylate
in Step 4-6. The crude material was purified by flash
chromatography on a silica gel column eluting with 0 to 60%
EtOAc/Hexanes. LC-MS calculated for C.sub.26H.sub.23N.sub.2O.sub.3
(M+H).sup.+: m/z=411.2. found 411.1.
Step 4:
4-{[5-{[(2-hydroxyethyl)amino]methyl}-7-methyl-2-(2-methylbiphenyl-
-3-yl)-1,3-benzoxazol-6-yl]oxy}butanenitrile
[0455] This compound was prepared using similar procedures as
described for Example 1 with
4-{[5-formyl-7-methyl-2-(2-methylbiphenyl-3-yl)-1,3-benzoxazol-6-yl]oxy}b-
utanenitrile (product from Step 3) replacing
2-(2-methylbiphenyl-3-yl)furo[2,3-b]pyridine-6-carbaldehyde in Step
5. The reaction mixture was diluted with MeOH then purified by
prep-HPLC (pH=10, acetonitrile/water+NH.sub.4OH) to give the
desired product. LC-MS calculated for
C.sub.28H.sub.30N.sub.3O.sub.3 (M+H).sup.+: m/z=456.2. found
456.2.
Example 35
(2S)-1-({6-(cyanomethoxy)-2-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-methyl-
pyridin-2-yl]-1,3-benzoxazol-5-yl}methyl)piperidine-2-carboxylic
acid
##STR00117##
[0456] Step 1:
4-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-methylpyridine-2-carbaldehyde
##STR00118##
[0458] This compound was prepared using similar procedures as
described for Example 17 with 2-chloro-4-iodo-3-methylpyridine
(Aldrich, cat#724092) replacing 2-bromo-6-iodobenzonitrile in Step
1-3. The crude material was purified by flash chromatography on a
silica gel column eluting with 0 to 50% EtOAc/Hexanes. LC-MS
calculated for C.sub.15H.sub.14NO.sub.3 (M+H).sup.+: m/z=256.1.
found 256.1.
Step 2:
({2-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-methylpyridin-2-yl]-5--
formyl-1,3-benzoxazol-6-yl}oxy)acetonitrile
##STR00119##
[0460] This compound was prepared using similar procedures as
described for Example 26 with
4-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-methylpyridine-2-carbaldehyde
(product from Step 1) replacing 2-methylbiphenyl-3-carbaldehyde in
Step 3-6. The crude material was purified by flash chromatography
on a silica gel column eluting with 0 to 50% EtOAc/Hexanes. LC-MS
calculated for C.sub.24H.sub.18N.sub.3O.sub.5 (M+H).sup.+:
m/z=428.1. found 428.1.
Step 3:
(2S)-1-({6-(cyanomethoxy)-2-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)--
3-methylpyridin-2-yl]-1,3-benzoxazol-5-yl}methyl)piperidine-2-carboxylic
acid
[0461] This compound was prepared using similar procedures as
described for Example 2 with
({2-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-methylpyridin-2-yl]-5-formyl--
1,3-benzoxazol-6-yl}oxy)acetonitrile (product from Step 2)
replacing
2-(2-methylbiphenyl-3-yl)furo[2,3-b]pyridine-6-carbaldehyde in last
step. The reaction mixture was diluted with MeOH and then purified
by prep-HPLC (pH=2, acetonitrile/water+TFA) to give the desired
product as the TFA salt. LC-MS calculated for
C.sub.30H.sub.29N.sub.4O.sub.6 (M+H).sup.+: m/z=541.2. found
541.3.
Example 36
(2S)-1-({6-(cyanomethoxy)-2-[3-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-methyl-
phenyl]-1,3-benzoxazol-5-yl}methyl)piperidine-2-carboxylic acid
##STR00120##
[0463] This compound was prepared using similar procedures as
described for Example 26 with
3-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-methylbenzaldehyde (product
from Step 2 in Example 15) replacing
2-methylbiphenyl-3-carbaldehyde in Step 3. The reaction mixture was
diluted with MeOH and then purified by prep-HPLC (pH=10,
acetonitrile/water+NH.sub.4OH) to give the desired product. LC-MS
calculated for C.sub.31H.sub.30N.sub.3O.sub.6 (M+H).sup.+:
m/z=540.2. found 540.2.
Example 37
(2S)-1-{[2-[2-cyano-3-(2,3-dihydro-1,4-benzodioxin-6-yl)phenyl]-6-(cyanome-
thoxy)-1,3-benzoxazol-5-yl]methyl}piperidine-2-carboxylic acid
##STR00121##
[0464] Step 1: 1,5-bis(benzyloxy)-2-chloro-4-nitrobenzene
##STR00122##
[0466] To a solution of 5-bromo-4-chloro-2-nitrophenol
(Combi-Blocks, cat#LD-1305: 1603 mg, 6.352 mmol) and benzyl bromide
(831 .mu.L, 7.00 mmol) in N,N-dimethylformamide (3 mL) and
acetonitrile (6 mL) was added potassium carbonate (1050 mg, 7.62
mmol). The mixture was stirred at 50.degree. C. for 30 min. After
filtration, the solution was concentrated and used directly for
next step.
[0467] To a solution of benzyl alcohol (3200 .mu.L, 31 mmol) in
N,N-dimethylformamide (12 mL) was added sodium hydride (60%
dispersion in mineral oil, 324 mg, 8.10 mmol) at 0.degree. C. The
mixture was stirred at room temperature for 5 min. The mixture was
added dropwisely to a solution of crude
1-(benzyloxy)-5-bromo-4-chloro-2-nitrobenzene in
N,N-dimethylformamide (6 mL). The resulting mixture was stirred at
50.degree. C. for 1 h. The reaction was quenched with water and
extracted with EtOAc. The organic phase was dried over MgSO.sub.4,
filtered and then concentrated to yield a crude product. LC-MS
calculated for C.sub.20H.sub.17ClNaNO.sub.4 (M+Na).sup.+:
m/z=392.1. found 392.1.
Step 2: 4-amino-6-chlorobenzene-1,3-diol
##STR00123##
[0469] To a mixture of crude
1,5-bis(benzyloxy)-2-chloro-4-nitrobenzene (319.1 mg, 0.8629 mmol)
and palladium on carbon (10 wt %, 63 mg, 0.059 mmol) in methanol
(3.0 mL) was added triethylsilane (1380 .mu.L, 8.63 mmol) at
0.degree. C. The resulting mixture was stirred at room temperature
for 10 min. Upon completion, the mixture was filtered; the filtrate
was concentrated and used directly. LC-MS calculated for
C.sub.6H.sub.7ClNO.sub.2 (M+H).sup.+: m/z=160.0. found 160.0.
Step 3:
2-(5-chloro-6-hydroxy-1,3-benzoxazol-2-yl)-6-(2,3-dihydro-1,4-benz-
odioxin-6-yl)benzonitrile
##STR00124##
[0471] This compound was prepared using similar procedures as
described for Example 26 with 4-amino-6-chlorobenzene-1,3-diol
(product from Step 2) replacing methyl
5-amino-2,4-dihydroxybenzoate and
2-(2,3-dihydro-1,4-benzodioxin-6-yl)-6-formylbenzonitrile replacing
2-methylbiphenyl-3-carbaldehyde in Step 3. The crude material was
purified by flash chromatography on a silica gel column eluting
with 0 to 60% EtOAc/Hexanes. LC-MS calculated for
C.sub.22H.sub.14ClN.sub.2O.sub.4 (M+H).sup.+: m/z=405.1. found
405.0.
Step 4:
2-[6-(cyanomethoxy)-5-vinyl-1,3-benzoxazol-2-yl]-6-(2,3-dihydro-1,-
4-benzodioxin-6-yl)benzonitrile
##STR00125##
[0473] A mixture of potassium trifluoro(vinyl)borate (22.7 mg,
0.169 mmol),
2-[5-chloro-6-(cyanomethoxy)-1,3-benzoxazol-2-yl]-6-(2,3-dihydro-1-
,4-benzodioxin-6-yl)benzonitrile (50.1 mg, 0.113 mmol), potassium
phosphate (71.9 mg, 0.339 mmol) and
dichloro[1,1'-bis(dicyclohexylphosphino)ferrocene]palladium(II) (10
mg, 0.02 mmol) in a mixed solvent of water (0.5 mL) and
tert-butanol (0.5 mL) was purged with N.sub.2 and then stirred at
100.degree. C. overnight. The reaction was cooled to room
temperature and then diluted with EtOAc and water. The aqeuous
phase was extracted with EtOAc. The organic phase was dried over
MgSO.sub.4 and then concentrated under vacuum. The crude material
was used directly without further purification. LC-MS calculated
for C.sub.26H.sub.18N.sub.3O.sub.4 (M+H).sup.+: m/z=436.1. found
436.1.
Step 5:
2-[6-(cyanomethoxy)-5-formyl-1,3-benzoxazol-2-yl]-6-(2,3-dihydro-1-
,4-benzodioxin-6-yl)benzonitrile
##STR00126##
[0475] This compound was prepared using similar procedures as
described for Example 3 with
2-[6-(cyanomethoxy)-5-vinyl-1,3-benzoxazol-2-yl]-6-(2,3-dihydro-1,4-benzo-
dioxin-6-yl)benzonitrile (product from Step 4) replacing
7-methyl-2-(2-methylbiphenyl-3-yl)-5-vinylfuro[3,2-b]pyridine in
Step 4. The crude material was purified by flash chromatography on
a silica gel column eluting with 0 to 50% EtOAc/Hexanes. LC-MS
calculated for C.sub.25H.sub.16N.sub.3O.sub.5 (M+H).sup.+:
m/z=438.1. found 438.1.
Step 6:
(2S)-1-{[2-[2-cyano-3-(2,3-dihydro-1,4-benzodioxin-6-yl)phenyl]-6--
(cyanomethoxy)-1,3-benzoxazol-5-yl]methyl}piperidine-2-carboxylic
acid
[0476] This compound was prepared using similar procedures as
described for Example 26 with
2-[6-(cyanomethoxy)-5-formyl-1,3-benzoxazol-2-yl]-6-(2,3-dihydro-1,4-benz-
odioxin-6-yl)benzonitrile (product from Step 5) replacing
{[5-formyl-2-(2-methylbiphenyl-3-yl)-1,3-benzoxazol-6-yl]oxy}acetonitrile
in last step. The reaction mixture was diluted with MeOH and then
purified by prep-HPLC (pH=10, acetonitrile/water+NH.sub.4OH) to
give the desired product. LC-MS calculated for
C.sub.31H.sub.27N.sub.4O.sub.6 (M+H).sup.+: m/z=551.2. found
551.2.
Example 38
(2S)-1-{[2-(2-methylbiphenyl-3-yl)-1,3-benzoxazol-6-yl]methyl}piperidine-2-
-carboxylic acid
##STR00127##
[0477] Step 1:
6-bromo-2-(2-methylbiphenyl-3-yl)-1,3-benzoxazole
##STR00128##
[0479] This compound was prepared using similar procedures as
described for Example 26 with 2-amino-5-bromophenol (Combi-Blocks,
cat#SS-6172) replacing methyl 5-amino-2,4-dihydroxybenzoate in Step
3. The crude material was used directly without further
purification. LC-MS calculated for C.sub.20H.sub.15BrNO
(M+H).sup.+: m/z=364.0. found 364.0.
Step 2:
2-(2-methylbiphenyl-3-yl)-1,3-benzoxazole-6-carbaldehyde
##STR00129##
[0481] This compound was prepared using similar procedures as
described for Example 3 with
6-bromo-2-(2-methylbiphenyl-3-yl)-1,3-benzoxazole replacing
5-chloro-7-methyl-2-(2-methylbiphenyl-3-yl)furo[3,2-b]pyridine in
Step 3-4. The crude material was purified by flash chromatography
on a silica gel column eluting with 0 to 30% EtOAc/Hexanes. LC-MS
calculated for C.sub.21H.sub.16NO.sub.2 (M+H).sup.+: m/z=314.1.
found 314.1.
Step 3:
(2S)-1-{[2-(2-methylbiphenyl-3-yl)-1,3-benzoxazol-6-yl]methyl}pipe-
ridine-2-carboxylic acid
[0482] This compound was prepared using similar procedures as
described for Example 2 with
2-(2-methylbiphenyl-3-yl)-1,3-benzoxazole-6-carbaldehyde (product
from Step 2) replacing
2-(2-methylbiphenyl-3-yl)furo[2,3-b]pyridine-6-carbaldehyde in Step
5. The reaction mixture was diluted with MeOH and then purified by
prep-HPLC (pH=10, acetonitrile/water+NH.sub.4OH) to give the
desired product. LC-MS calculated for
C.sub.27H.sub.27N.sub.2O.sub.3 (M+H).sup.+: m/z=427.2. found
427.1.
Example 39
[(2-(2'-fluoro-2-methylbiphenyl-3-yl)-5-{[(2-hydroxyethyl)amino]methyl}-1,-
3-benzoxazol-6-yl)oxy]acetonitrile
##STR00130##
[0483] Step 1: 3-bromo-2-methylbenzaldehyde
##STR00131##
[0485] This compound was prepared using similar procedures as
described for Example 1 with (3-bromo-2-methylphenyl)methanol
(Aurum Pharmtech, cat#q-7366) replacing
(2-methylbiphenyl-3-yl)methanol in Step 1. TLC monitored the
completion of reaction. The crude material was purified by flash
chromatography on a silica gel column eluting with 0 to 50%
EtOAc/Hexanes.
Step 2:
{[2-(3-bromo-2-methylphenyl)-5-formyl-1,3-benzoxazol-6-yl]oxy}acet-
onitrile
##STR00132##
[0487] This compound was prepared using similar procedures as
described for Example 26 with 3-bromo-2-methylbenzaldehyde
replacing 2-methylbiphenyl-3-carbaldehyde in Step 3-6. The crude
material was purified by flash chromatography on a silica gel
column eluting with 0 to 50% EtOAc/Hexanes. LC-MS calculated for
C.sub.17H.sub.12BrN.sub.2O.sub.3 (M+H).sup.+: m/z=371.0, 373.0.
found 371.0, 373.0.
Step 3:
[(2-(3-bromo-2-methylphenyl)-5-{[(2-hydroxyethyl)amino]methyl}-1,3-
-benzoxazol-6-yl)oxy]acetonitrile
##STR00133##
[0489] This compound was prepared using similar procedures as
described for Example 27 with
{[2-(3-bromo-2-methylphenyl)-5-formyl-1,3-benzoxazol-6-yl]oxy}acetonitril-
e replacing
{[5-formyl-2-(2-methylbiphenyl-3-yl)-1,3-benzoxazol-6-yl]oxy}acetonitrile
in last step. The crude material was purified by flash
chromatography on a silica gel column eluting with 0 to 70%
EtOAc/Hexanes. LC-MS calculated for
C.sub.19H.sub.19BrN.sub.3O.sub.3 (M+H).sup.+: m/z=416.1, 418.1.
found 416.1, 418.1.
Step 4:
[(2-(2'-fluoro-2-methylbiphenyl-3-yl)-5-{[(2-hydroxyethyl)amino]me-
thyl}-1,3-benzoxazol-6-yl)oxy]acetonitrile
[0490] A N.sub.2 degassed solution of
[(2-(3-bromo-2-methylphenyl)-5-{[(2-hydroxyethyl)amino]methyl}-1,3-benzox-
azol-6-yl)oxy]acetonitrile (10.7 mg, 0.0257 mmol), (2-fluorophenyl)
boronic acid (4.32 mg, 0.0308 mmol),
dichloro[1,1'-bis(dicyclohexylphosphino)ferrocene]palladium(II)
(0.97 mg, 0.0013 mmol) and sodium carbonate (6.81 mg, 0.0643 mmol)
in a mixed solvent of tert-butyl alcohol (0.1 mL) and water (0.05
mL) was heated to 100.degree. C. for 3 h. The reaction was cooled
to room temperature. The reaction mixture was diluted with MeOH and
then purified by prep-HPLC (pH=2, acetonitrile/water+TFA) to give
the desired product as TFA salt. LC-MS calculated for
C.sub.25H.sub.23FN.sub.3O.sub.3 (M+H).sup.+: m/z=432.2. found
432.2.
Example 40
[(2-(3-cyclohex-1-en-1-yl-2-methylphenyl)-5-{[(2-hydroxyethyl)amino]methyl-
}-1,3-benzoxazol-6-yl)oxy]acetonitrile
##STR00134##
[0492] This compound was prepared using similar procedures as
described for Example 39 with
2-cyclohex-1-en-1-yl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
(Aldrich, cat#650277) replacing (2-fluorophenyl)boronic acid in
Step 4. The reaction mixture was diluted with MeOH and then
purified by prep-HPLC (pH=2, acetonitrile/water+TFA) to give the
desired product as TFA salt. LC-MS calculated for
C.sub.25H.sub.28N.sub.3O.sub.3 (M+H).sup.+: m/z=418.2. found
418.2.
Example A. PD-1/PD-L1 Homogeneous Time-Resolved Fluorescence (HTRF)
Binding Assay
[0493] The assays were conducted in a standard black 384-well
polystyrene plate with a final volume of 20 .mu.L. Inhibitors were
first serially diluted in DMSO and then added to the plate wells
before the addition of other reaction components. The final
concentration of DMSO in the assay was 1%. The assays were carried
out at 25.degree. C. in the PBS buffer (pH 7.4) with 0.05% Tween-20
and 0.1% BSA. Recombinant human PD-L1 protein (19-238) with a
His-tag at the C-terminus was purchased from AcroBiosystems
(PD1-H5229). Recombinant human PD-1 protein (25-167) with Fc tag at
the C-terminus was also purchased from AcroBiosystems (PD1-H5257).
PD-L1 and PD-1 proteins were diluted in the assay buffer and 10
.mu.L was added to the plate well. Plates were centrifuged and
proteins were preincubated with inhibitors for 40 minutes. The
incubation was followed by the addition of 10 .mu.L of HTRF
detection buffer supplemented with Europium cryptate-labeled
anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His
antibody conjugated to SureLight.RTM.-Allophycocyanin (APC,
PerkinElmer-AD0059H). After centrifugation, the plate was incubated
at 25.degree. C. for 60 min. before reading on a PHERAstar FS plate
reader (665 nm/620 nm ratio). Final concentrations in the assay
were -3 nM PD1, 10 nM PD-L1, 1 nM europium anti-human IgG and 20 nM
anti-His-Allophycocyanin. IC.sub.50 determination was performed by
fitting the curve of percent control activity versus the log of the
inhibitor concentration using the GraphPad Prism 5.0 software.
[0494] Compounds of the present disclosure, as exemplified in
Examples 1-40, showed IC.sub.50 values in the following ranges:
+=IC.sub.50.ltoreq.10 nM; ++=10 nM<IC.sub.50<100 nM; +++=100
nM<IC.sub.50.ltoreq.1000 nM
[0495] Data obtained for the Example compounds using the PD-1/PD-L1
homogenous time-resolved fluorescence (HTRF) binding assay
described in Example A is provided in Table 1.
TABLE-US-00001 TABLE 1 PD-1/PD-L1 HTRF Example IC.sub.50 (nM) 1 ++
2 +++ 3 ++ 4 ++ 5 ++ 6 ++ 7 ++ 8 + 9 +++ 10 ++ 11 + 12 + 13 ++ 14 +
15 ++ 16 + 17 ++ 18 + 19 +++ 20 +++ 21 ++ 22 ++ 23 ++ 24 ++ 25 +++
26 + 27 + 28 + 29 ++ 30 + 31 + 32 + 33 ++ 34 ++ 35 ++ 36 + 37 ++ 38
++ 39 + 40 ++
[0496] Various modifications of the invention, in addition to those
described herein, will be apparent to those skilled in the art from
the foregoing description. Such modifications are also intended to
fall within the scope of the appended claims. Each reference,
including without limitation all patent, patent applications, and
publications, cited in the present application is incorporated
herein by reference in its entirety.
* * * * *